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Melanoma is a highly aggressive tumour with a poor prognosis for patients with 
advanced disease because it is resistant to current therapies. Therefore, the 
development of novel strategies for melanoma treatment is important. The 
characterization of the molecular mechanisms underlying melanoma proliferation, 
progression, and survival could help the development of novel targeted melanoma 
treatments. The MAPK and PI3K pathways both play important roles in melanoma 
progression. In the MAPK pathway, DUSP6, which acts as a phosphatase to 
negatively control the activation of ERK1/2, is involved in the development of 
human cancers. The MAPK pathway also regulates expression of the DNA repair 
gene ERCC1 following EGF treatment. ERCC1 is essential for nucleotide excision 
repair, which is one of the major systems for removal of cisplatin induced DNA 
lesions. The aims of this project were: 1, to investigate the molecular changes in our 
immortal mouse melanocyte cell lines that were needed for them to form tumours in 
a xenograft model; 2, to investigate whether the MAPK pathway regulates ERCC1 
following cisplatin treatment and protects melanoma cells from death.  
 
 
Through comparison of the RAS/RAF/MEK/ERK (MAPK) and the PI3K/AKT 
(AKT) signalling pathways between our immortal mouse melanocyte cell lines and 
their tumour derivatives in our xenograft model, we identified a molecularly distinct 
subtype of mouse melanoma characterized by reduced ERK and AKT activity and 
increased expression of DUSP6.  Functional analyses employing ectopic 
overexpression indicated that increased expression of DUSP6 enhanced anchorage 
independent growth ability and invasive ability in our mouse melanocytes, 
suggesting that increased DUSP6 expression may contribute to melanoma formation 
in the xenograft assay. We also demonstrated that higher expression of p-ERK 
suppressed invasion, but not anchorage independent growth, in our subtype of mouse 
melanoma by enforced expression of constitutively active MEK1 and MEK2. In 
addition, the role of DUSP6 in classical human melanoma was investigated in this 
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study. Inhibition of anchorage independent growth and invasion were observed after 
exogenous expression of DUSP6 in human melanoma cells. This suggested that 
DUSP6 played different roles in classic human melanoma than in our distinct 
subtype of mouse melanoma. Our study also investigated the phosphorylation level 
of ERK1/2 and the mRNA and protein level of ERCC1 and its partner XPF in the 
human melanoma cell line following cisplatin treatment. Significant increases in 
expression of p-ERK, ERCC1 and XPF were found in cisplatin treated cells. 
Moreover, a MEK inhibitor inhibited ERCC1 induction by cisplatin, but did not 
significantly affect XPF induction. This suggested that the MAPK pathway was 
involved in regulation of ERCC1 but not XPF. Furthermore, the DUSP6 level 
decreased after cisplatin treatment and overexpression of DUSP6 inhibited ERCC1 
and XPF induction and reduced resistance to cisplatin. DUSP6 seems to play a 
crucial role in resistance of melanoma to cisplatin. In addition, a novel larger ERCC1 
transcript was identified in human cell lines and was found to be upregulated by 
cisplatin. The ratio of larger ERCC1 transcript relative to the normal ERCC1 
transcript increased following cisplatin treatment. The functions of this larger 
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1.1 Melanoma  
 
 
1.1.1 General introduction to melanoma 
 
 
Melanoma is an aggressive, therapy-resistant malignancy of melanocytes. The 
incidence of melanoma has risen at an astonishing rate worldwide. Cutaneous 
melanoma is the sixth most common cancer in the UK and the second commonest in 
young people (Gandini et al. 2005). Approximately 85 percent of patients with 
primary cutaneous melanoma who are diagnosed at an early stage enjoy long- term 
survival and a high cure rate (Tsao and Sober 2005). However, average survival 
durations in patients with metastatic melanoma range from 6 to 9 months, because of 




Melanocytic transformation is generally believed to occur by sequential 
accumulation of genetic and molecular changes (Miller and Mihm 2006). Although 
the molecular basis of human malignant melanoma progression has remained largely 
unknown, several genes and metabolic pathways have been shown to carry molecular 
alterations during this process. Mutations of BRAF, CDKN2A and PTEN have been 
proposed to contribute to melanoma progression. Both the RAS/RAF/MEK/ERK 
(MAPK) and the PI3K/AKT (AKT) signaling pathways are reported to be involved 
in melanomagenesis (Takata and Saida 2006).The characterization of the molecular 
mechanisms involved in melanoma proliferation, progression, and survival could 
help to identify the molecular profiles underlying aggressiveness, clinical behaviour, 
and create many opportunities for targets, drugs and new therapeutic approaches for 
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1.1.2 Introduction to melanocytes 
 
 
Melanocytes are specialist pigment cells that are located in the lower layers of the 
skin, the middle layer of the eye, the inner ear, heart, bones and meninges. Cutaneous 
melanocytes originate in the neural crest and migrate to the basal layer of the 
epidermis and the hair follicles during embryonic development. Melanocytes 
produce melanin which is responsible for skin and hair colour (Lin and Fisher 2007).  
 
 
There are two main types of melanin-eumelanin and pheomelanin. Eumelanin is 
brown to black and is the main type in dark skin and hair, while pheomelanin is red 
to yellow and is the main type in red hair and freckled individuals. Both types of 
melanin are regulated by a common tyrosinase-dependent pathway with the same 
precursor, tyrosine. Production of eumelanin or pheomelanin depends on the 
interaction of the melanocortin 1 receptor (MC1R) on the surface of the melanocyte 
with melanocyte stimulating hormone (MSH) or with the agouti signaling protein 
(ASP). The binding of MSH to MC1R leads to the production of eumelanin while the 
binding of ASP to MC1R results in the formation of pheomelanin (Jimbow et al. 
1979, Prota et al. 1976). MSH is a ligand of the receptor MC1R, and activation 
results in an increase in cellular cAMP. ASP antagonizes the effects of MSH at 
MC1R. Overexpression of ASP in mice results in yellow coat colour. The role of 
ASP in humans is still unclear. It seems that the MC1R receptor has some degree of 
constitutive (ligand-independent) activity. The increased cAMP leads to activation of 
protein kinase A (PKA), which results in an increase in microphthalmia transcription 
factor (MITF). MITF seems to play an important role in control of melanogenesis 
that leads to increased transcription of many genes (including genes encoding 
tyrosinase and tyrosinase-related protein 1 and 2). These genes are involved in the 
control of the relative and absolute amounts of eumelanin and pheomelanin (Rees 
2004). 
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Melanin production takes place in unique organelles known as melanosomes. 
Melanosomes usually cluster together near the centre of the cell but can rapidly 
redistribute themselves to the ends of dendritic processes projecting from cells. Two 
types of transport are responsible for melanosome redistribution: long-range 
transport from the center along microtubules and along the periphery; short range 
capture and transport. External stimuli such as UV radiation or mutations in the 
transport system can affect melanosome distribution (Hirobe 1995, Sulaimon and 
Kitchell 2003).  
 
 
The function of melanocytes is best studied and defined in skin. In the basal layer of 
the epidermis, each melanocyte can distribute melanin to about 30 surrounding 
keratinocytes through melanocytic dendritic processes. The melanin granules orient 
in an umbrella-like fashion over the keratinocyte nucleus parallel to the skin surface. 
It is generally believed that melanin absorbs ultraviolet radiation (UVR) and 
possesses antioxidant properties which can neutralize UVR-induced free radicals. 
When the skin is exposed to UVR, melanocytes synthesize more melanin and 
transfer it to keratinocytes to dissipate ultraviolet energy and protect cells (Agar and 
Young 2005). Eumelanin is more protective against UVR exposure than 
pheomelanin. Tanning of the skin due to UV exposure represents an increase in the 




1.1.3 Melanoma epidemiology, risk factors and prevention  
 
 
The latest statistics show that 11,767 new malignant melanoma cases were diagnosed 
in the UK during 2008 and there were 2,067 deaths at the same year. Among these 
cases, 6,183 cases were diagnosed in women and 5,584 cases diagnosed in men. It 
was the sixth most common cancer in females and the ninth in males in the UK. The 
commonest site of melanoma is on the legs in female; while over a third of male 
cases arise on the trunk of the body. Melanoma is notorious for affecting young 
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people, unlike other solid tumours, which mainly affect older adults. The age specific 
rates of malignant melanoma in UK show that about 30% of all cases occur in people 
aged less than 50 years and malignant melanoma is the second most common cancer 




The incidence rates vary 100 fold among different populations. The highest rates 
occur in Queensland, Australia where fair skinned individuals have high UV 
radiation exposure, the cumulative incidence in the population older than 50 years is 
1 in 19 for men and 1 in 25 for women (Goldstein and Tucker 1993). Scotland has 
the highest rate of melanoma compared to other countries in the UK. The incidence 
of malignant melanoma is dramatically increasing in most white populations. The 
increase is occurring at a faster rate than any other common cancer in Scotland: the 
rate has increased from only 633 cases in 1998 to 1,164 cases in 2008 (NHS National 
Services Scotland, 2009, http://www.isdscotland.org/isd/1048.html). 
 
 
Several factors have been reported to be responsible for the world wide increase in 
the incidence of melanomas. A large number of studies have shown an increased 
melanoma risk in individuals who have sunburn history in childhood, and a lower 
melanoma risk for sunburn with older age. Higher incidences of melanoma occur in 
the population who live in low latitudes or close to the coast during childhood. In 
contrast, people living in high latitudes or who never lived near the coast have lower 
incidences of melanoma (Oliveria et al. 2006). Some studies also showed that 
intermittent sun exposure from recreational and vacation activities during childhood 
increased melanoma risk (Elwood 1992, Nelemans et al. 1995)  
 
 
The risk of melanoma has been directly related to the presence of multiple naevi on 
the body. The risk is approximately 1.5 times higher in people with 11 to 25 naevi 
and seems to be doubled with every 25 naevi increase (Bevona et al. 2003, Garbe et 
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al. 1994). Dysplastic nevi are strongly associated with the risk of melanoma. Patients 
with dysplastic nevus syndrome have almost a 100-times increased risk of 
developing melanoma, and approximately 50% of these patients would have 
melanoma by the age of 50 years (Tucker et al. 1993).    
 
 
A family history of melanoma is another risk factor for developing melanoma. 
Patients with a family history of melanoma have double the risk of developing 
melanoma than patients without a family history. About 10% of all melanoma is 
familial melanoma (Meyer and Zone 1994). Mutations in CDKN2A and CDK4 have 
been reported to occur in the patients with a family history of melanoma (Tsao and 
Niendorf 2004). The roles of the CDKN2A mutations will be discussed in 
Introduction 1.2.3. Variation in melanocortin-1 receptor has been found to predispose 
to the development of melanoma. Red hair, fair skin, presence of freckles, and sun 
sensitivity are associated with variation in the melanocortin-1 receptor and may be 
related to the increasing risk for melanoma in these phenotypes (Titus-Ernstoff et al. 
2005, Veierod et al. 2003).  
 
 
Primary prevention of melanoma is by reduction of risk factors. Reducing intense, 
intermittent sun exposure and avoiding sunburn in childhood are the most important 
behaviours to prevent development of melanoma (Kaskel et al. 2001). However, 
there has been some concern that reduction of sun exposure will disturb the synthesis 
of vitamin D which may have a negative impact on health (Weinstock et al. 1992). 
Research on how much UVR exposure is required to synthesize the optimal vitamin 
D levels is ongoing. Early diagnosis and treatment of melanoma are the secondary 
steps to prevent metastatic melanoma. People with high risk for development of 
melanoma such as xeroderma pigmentosum and familial multiple mole syndrome 
patients and people with a family history of melanoma and men older than 50 years 
should be identified and receive skin screening by a dermatologist (Geller et al. 
2003a, Geller et al. 2002, Geller et al. 2003b). 
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1.1.4 Melanoma stages and diagnosis 
 
 
The “ABCDE” mnemonic is used to examine and interpret pigmented lesions of 
melanoma. These include: asymmetric moles, border irregularity of moles, colour 
variability in a lesion, diameter greater than 6mm and evolving (or changing). 
Evolving is defined as any significant change in shape, surface, colour, or symptoms 
(Goldstein and Goldstein 2001).  
 
 
Melanomas are histologically classified into five distinct stages according to their 
location and progression: benign nevus; dysplastic nevus; radial-growth phase (RGP) 
melanoma; vertical-growth phase (VGP) melanoma; and metastatic melanoma (Fig. 
1.1). Both benign nevus and dysplastic nevus are characterized by increased numbers 
of melanocytes and disruption of the epidermal melanin unit. During the radial-
growth phase, cells grow laterally and remain largely confined to the epidermis. In 
addition, the cells can penetrate the papillary dermis singly or in small nests but fail 
to form colonies in soft agar. When lesions progress to the vertical-growth phase, 
cells aquire ability to invade the upper layer of the epidermis, and penetrate into the 
underlying dermis and subcutaneous tissue through the basement membrane, forming 
expansile nodules. The cells are capable of growth in soft agar. The final step is 
metastatic melanoma: cells are spread to other areas of the skin and other ogans, 
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Cutaneous melanomas are classified as superficial spreading, acral lentiginous, 
nodular, and lentigo maligna. Superficial spreading is the most common type of 
melanoma, accounting for 70% of cases. It tends to be found on the back of the legs 
of women and on the backs of men (Newell et al. 1988). These tumours are usually 
composed of epithelioid melanoma cells and are linked with intermittent sun 
exposure (Markovic et al. 2007). Acral lentiginous melanomas account for 5% of 
melanomas in white people. However, it is the most common type of melanoma in 
the non-caucasian population, accounting for 50% of cases (MacKie 1985). Acral 
lentiginous melanomas are usually found on glabrous skin, the palms of hands and 
the soles of feet (Cascinelli et al. 1994). Nodular melanoma often occurs on the trunk 
and limbs of patients, accounting for 5% of melanoma cases. It only has a vertical 
growth phase without a radial growth phase (Markovic et al. 2007). Lentigo maligna 
generally occurs on sun-exposed regions in the elderly, accounting for 4% to 15% of 
cutaneous melanoma. It correlates with long-term sun exposure and increasing age 
(Clark and Mihm 1969, Flotte and Mihm 1999).    
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Several clinical and histological parameters that influence the prognosis of cutaneous 
melanoma have been identified (Balch et al. 2000). Three clinical parameters are 
considered: anatomical site, gender, and age. Patients with melanoma on the trunk, 
head or neck have poorer prognosis than patients with melanoma on the extremities. 
As the histological parameters, depth of invasion and ulceration are considered for 
melanoma prognosis. There is a linear correlation between patient survival and 
tumour thickness. Female and young people have higher survival rate compared to 
male and older people. Tumour thickness (Breslow) and Depth of invasion (Clark) 
are the most important melanoma prognostic factors. 20-25% of all melanomas 
harbour ulceration. Based on these clinical and histological parameters, melanoma 
can be staged (Table 1.1). 
 
 
Stage I and II melanomas are characterized by tumour thickness and ulceration 
status. There is no evidence of regional lymph node or distant metastasis. Stage III 
melanoma is characterized by the level of lymph node metastasis without distant 
metastasis. Stage IV melanoma patients have distant metastatic spread of melanoma 
(Goldstein and Goldstein 2001). Although staging patients is helpful for clinical 
treatment, sometimes the parameters are not reliable. Some thin lesions may become 
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Stage TNM classification  Histological/Clinical Features  5 Year 
Survival  
0            Tis0 N0 M0                  intraepithelial/in-situ melanoma 100% 
IA   T1a N0 M0     <1mm without ulceration and level II/III    >95% 
IB T1b N0 M0     
T2a N0 M0     
<1mm with ulceration and level III/IV 
1.01-2cm without ulceration    
 
89-91% 
IIA T2b N0 M0      
T3a N0 M0 
1.01-2cm with ulceration    
2.01-4cm without ulceration   
 
77-79% 
IIB  T3b N0 M0   
T4a N0 M0 
2.01-4cm with ulceration 
>4cm without ulceration   
 
63-67% 
IIC T4b N0 M0 >4cm with ulceration   45% 
IIIA T1-4a N1a M0 
T1-4a N2a M0 
1 nodal micrometastases, nonulcerated 1 
2-3 microscopic nodes, nonulcerated 1 
 
63-69% 
IIIB T1-4b N1a M0 
T1-4b N2a M0 
T1-4a N1b M0 
T1-4a N2b M0 
T1-4a/b N2c M0 
1 nodal micrometastases, ulcerated 1 
2-3 microscopic nodes, ulcerated 1 
1 nodal micrometastases, nonulcerated 1 
2-3 macroscopic nodes, nonulcerated 1 






IIIC T1-4b N2b M0 
T1-4a/b N2a M0 
Any T N3 M0 
1 macroscopic region node, ulcerated 1  
2-3 metastatic nodes, ulcerated 1  




IV  Any T any N M1a  
Any T any N M1a 
Any T any N M1a 
Skin, or nodal mets with normal LDH  
Lung mets with normal LDH 





Table 1.1 AJCC 2002 Revised Melanoma Staging. The table shows 5 year survival for patients 
with different stages of melanoma determined by Breslow thickness, presence of ulceration, 
nodal involvement or presence of metastatic disease. TNM means tumour, nodes and metastases. 
LDH means lactate dehydrogenase.  
 
 
1.1.5 Melanoma therapy  
 
 
Surgery is the standard treatment for melanoma in situ, Stage I, Stage II, and Stage 
III melanoma and may be considered for Stage IV melanoma. The aim of surgery is 
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to remove the tumour and its surrounding normal skin. Surgery in early-stage 
melanoma can be curative. The goal of surgery in late-stage melanoma is to remove 
the tumours or lymph nodes from spread to other areas of the body. Adjuvant therapy 
including chemotherapy, radiation, and immunotherapy can be applied to late-stage 
patients after surgery (McMasters and Swetter 2003)  
 
 
Melanoma is not so sensitive to chemotherapy as other types of cancers. However, 
application of chemotherapy can relieve the symptoms of some late-stage patients. 
The most common single agents used for melanoma therapy are dacarbazine (DTIC), 
temozolomide (TMZ), and cisplatin (CDDP). Dacarbazine is approved by the U.S. 
Food and Drug Administration (FDA) for treatment of melanoma. Studies indicate 
that dacarbazine results in melanoma shrinkage in 15% to 20% patients for an 
average of six months before the melanomas resume growth. Dacarbazine does not 
significantly prolong the overall survival (Kirkwood and Agarwala 1993). 
Temozolomide is another agent used in treatment of advanced metastatic malignant 
melanoma. It can be given as outpatient treatment which is easier to administer with 
fewer side effects. Temozolomide is as effective as DTIC according to a phase III 
trial. Median overall survival times were 7.7 months with TMZ vs 6.4 months with 
DTIC (Middleton et al. 2000). Besides DTIC and TMZ, cisplatin has achieved higher 
response rate in advanced melanoma patients. The functions of cisplatin will be 
discussed in detail in the following section. Cisplatin has been tested as a single 
agent at doses of up 200mg/m3, with response rate in the range of 0-53% (Al-Sarraf 
et al. 1982, Glover et al. 1987, Schilcher et al. 1984). However, high dose cisplatin 
can result in therapy resistance and side effects. Combination of cisplatin, 
dacarbazine and tamoxifen (a hormonal therapy drug used in breast cancer treatment) 
known as the Dartmouth regimen is also applied for treatment of advanced 
melanoma (Chapman et al. 1999). However, the clinical trials have not shown that 
this combination is more effective than dacarbazine alone.  
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Radiation therapy can be applied to advanced melanoma where surgery is not 
possible. It is used to relieve symptoms where the melanoma has metastasized to 
areas such as the brain or bone. Radiation therapy can prevent melanoma recurrence 
after surgery as well (Berk 2008, Guadagnolo and Zagars 2009). Various 
immunotherapeutic strategies are also used for treatment of advanced melanoma. 
These strategies include interferon-alpha and interleukin-2 (IL-2). Interferon-a2b is 
approved for stage III melanoma in the USA, however its efficacy is limited. 
Interferon-a2b has demonstrated a 10-20% improvement in overall survival, but 
without a clear effect on mortality (Fecher and Flaherty 2009). Interleukin-2 is used 
for stage IV melanoma. High-dose Interleukin-2 produces durable responses in 10-
20% patients with metastatic melanoma (Atkins et al. 2000).  
 
 
The improved understanding of molecular changes underlying melanoma initiation 
and progression resulted in the development of novel targeted melanoma therapy. 
Given BRAF V600E mutations occur in up to 70% of human melanoma (Dong et al. 
2003), there has been intense interest in selective BRAF inhibitors. Sorafenib is one 
of the earlier BRAF inhibitors which targets BRAF, CRAF and receptor tyrosine 
kinases (Wilhelm et al. 2004). Although sorafenib showed limited activity against 
melanoma alone, it showed greater activity when combined with other 
chemotherapeutic agents (Amaravadi et al. 2009, Flaherty 2006). PLX4032 is a more 
selective BRAF inhibitor which suppresses BRAF V600E with 30-fold selectivity 
relative to the wild type BRAF kinase. It produced about 70% objective response 
rates in patients with metastatic melanoma harbouring BRAF mutations in the phase 
I trial and has already proceeded to phase II/III trials (Ko and Fisher 2010). However, 
recent study also indicated that patients with melanomas frequently acquire 
resistance to PLX4032 after initial responses. Melanomas escape BRAF(V600E) 
targeting through RTK-mediated activation of alternative survival pathways or 
activated RAS-mediated reactivation of the MAPK pathway, suggesting additional 
therapeutic strategies (Nazarian et al. 2010). The c-KIT RTK has been reported to be 
amplified or mutated in some subtypes of melanoma (Curtin et al. 2006), suggesting 
that c-KIT is another novel drug target. Several phase II trials are ongoing to evaluate 
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KIT-targeted agents, including imatinib, sunitinib, inlotinib and dasatanib, in 
melanoma patients who have KIT amplifications or mutations. Targeted therapies, 
specifically those against BRAF V600E and mutant KIT open a new era in 
melanoma treatment.  
 
 
1.2 Molecular changes in melanoma progression  
 
 
1.2.1 The RAS/RAF/MEK/ERK pathway  
 
 
1.2.1.1 Overview of the RAS/RAF/MEK/ERK pathway 
 
 
The RAS/RAF/MEK/ERK pathway, also known as the MAPK (mitogen-activated 
protein kinase) pathway, is a signaling cascade relaying extracellular signals from 
plasma membrane to nucleus via a series of consecutive phosphorylation events (Fig. 
1.2). A variety of cellular stimuli, such as growth factors, bind to their respective 
receptor tyrosine kinase (RTK), and receptor dimerization results in activation of 
intrinsic tyrosine kinase activity followed by autophosphorylation of specific tyrosine 
residues on the intracellular portion of the receptor. Then the sequence homology 2 
(SH2) domains of adaptor proteins such as GRB2 recognize tyrosine phosphate 
docking sites located on the receptor or on receptor substrate proteins and recruit 
SOS (son of sevenless), a cytosolic protein, to the plasma membrane (Chin 2003). 
The binding of SOS to RAS switches the RAS-family GTPases from the inactive 
GDP-bound state to the active GTP-bound state (Cobb 1999, Kolch 2000). The 
activation of RAS leads to recruitment of RAF, which includes 3 isoforms: ARAF, 
BRAF and CRAF, from the cytosol the cell membrane where it becomes activated 
(Stokoe et al. 1994). Once active, RAF results in phosphorylation and activation of 
MAP kinase extracellular signal regulated kinases 1 and 2 (MEK1 and MEK2), 
which in turn phosphorylate extracellular signal regulated kinases 1 and 2 (ERK1 
and ERK2) (Crews et al. 1992). The activated ERK either phosphorylates a variety of 
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cytoplasmic targets or migrates to the nucleus to phosphorylate several 
transcriptional factors such as Elk-1, Fos, CREB and Myc (Lenormand et al. 1993, 
Treisman 1994). These transcriptional factors bind to the promoters of many genes 
that regulate cell proliferation, differentiation and survival.  
 
 
For many years, RAS signalling has been implicated in initiation and progression of 
melanoma. Approximately 15–20% of human melanomas have mutations in RAS 
genes (Fecher et al. 2007). Knockdown of NRAS by RNA interference results in 
apoptosis in melanoma cells carrying a NRAS mutation, suggesting the important 
role of NRAS in maintaining the growth of melanoma cells (Eskandarpour et al. 
2005). Most of the RAS mutations in melanoma involve a substitution of leucine for 
glutamine at residue 61 of N-RAS, which remains constitutively GTP bound and 
active. K-RAS and H-RAS mutations are relatively rare in melanoma, suggesting 
that RAS activities are dependent on specific isoforms (Whitwam et al. 2007).  
 
 
Although RAS clearly plays a role in human melanoma, BRAF mutations in human 
melanoma have recently received much attention. BRAF mutation occurs in 
approximately 70 percent of melanomas (Dong et al. 2003). The most frequent 
mutation in BRAF is a glutamic acid for valine substitution (V600E), which 
produces a protein that induces constitutive activation of ERK (Wan et al. 2004). 
One possible explanation for the high rates of BRAF mutation in melanoma is that 
the mutation is UV-induced. However, the T>A transversion of this mutation is not a 
typical UV-induced lesion(C>T or CC>TT), which makes this hypothesis unlikely. 
Others have proposed that UVB-induced DNA photoproducts account indirectly for 
BRAF mutation in melanoma (Thomas et al. 2006). According to this hypothesis, the 
BRAF mutations may arise from UV-induced oxidation of melanin, resulting in the 
formation of reactive oxygen species and leading to increased DNA damage. None of 
these hypotheses have been proved; therefore the mechanism of BRAF mutation 
remains unclear. Mutations of ARAF and CRAF are not found in melanoma, which 
may be because BRAF just needs one genetic mutation for oncogenic activation, 
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while ARAF and CRAF both need two mutations to activate, and this is rare (Emuss 
et al. 2005, Lee et al. 2005).    
 
 





Growth factors bind to cell surface receptor RTK to activate RAS though various adaptor 
proteins. Once activated, RAS triggers phosphorylation of a series of kinases: RAF, MEK and 
ERK. Activated ERK transmits signals to the nucleus by activating transcription factors to 
stimulate cell proliferation. RTK genes, NRAS, and BRAF are oncogenes in malignant 
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1.2.1.2 Roles of the RAS/RAF/MEK/ERK pathway in cell 
proliferation and invasion  
 
 
Cell proliferation is regulated at the G1 restriction checkpoint. Progression through  
G1 into S phase of the cell cycle is controlled by CDK4 and CDK6, which interact 
with the cyclin D family of proteins, and by CDK2, which interacts with cyclins A/E 
(Polyak et al. 1994, Sherr 1994, Sherr and Roberts 1995). Sustained ERK activation 
is reported to stimulate cells to pass the G1 restriction (Pages et al. 1993). 
Microinjection of active-RAS resulted in proliferation in fibroblasts (Feramisco et al. 
1984). Mutant BRAF V600E can initiate the formation of papillary thyroid cancer 
(PTC) and maintain the proliferation and tumorigenicity of papillary thyoid cancer 
cells (Liu et al. 2007). However, the MAPK pathway is downregulated in some types 
of tumours. There is a pronounced decrease in p-ERK levels with increasing tumour 
stage in colorectal cancer (Gulmann et al. 2009). The expression of the MAPK 
pathway may  shut off in some prostate cancers isolated from advanced prostate 
cancer patients by the deletion of PTEN gene, which regulates AKT activity (Shelton 
et al. 2005). Moreover, under some circumstances, a constitutively active MAPK 
pathway can lead to cell cycle arrest instead of proliferation. This pre-G1 arrest and 
subsequent senescence are driven by ERK-mediated upregulation of p53 and p16 
(Lin et al. 1998). Recently, it has been demonstrated that BRAF mutation can induce  
isulin-like growth factor-binding protain 7 (IGFBP7) which may take part in arrest of 
the cell cycle (Wajapeyee et al. 2008). 
 
 
In melanoma, the roles of ERK activity in proliferation are still controversial. 
Classical studies have indicated that uncontrolled growth of the majority of 
melanoma cells results from constitutive activation of the MAPK pathway. ERK 
activity controls the proliferation of human and mouse melanoma cell lines, which 
can be blocked by administration of a MEK inhibitor (Kortylewski et al. 2001, 
Smalley and Eisen 2000). Inhibition of the MAPK pathway is associated with G1-
phase cell cycle arrest via the downregulation of pRB phosphorylation and CDK2 
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activity, and the upregulation of p27 activity (Kortylewski et al. 2001). In contrast, 
other studies indicated that there was little correlation between the inhibition of 
phospho-ERK levels and growth of melanoma cells following MEK inhibitor 
treatment (Smalley et al. 2006). It suggests that there are likely other molecular 
changes in the pathways involved in regulation of cell proliferation. Some subtypes 
of melanomas without MAPK activation seem to stimulate cell proliferation by 
reduction of RB activity or overexpression of c-kit (Shields et al. 2007, Smalley et al. 
2008). Furthermore, BRAF mutations also occur in naevi. Mutant BRAF protein 
induces cell senescence by increasing expression levels of p16 protein, which in turn, 
could limit the hyperplastic growth of melanocytes by BRAF mutation. (Michaloglou 
et al. 2005) 
 
 
In normal skin, melanocytes interact with keratinocytes through the adhesion 
molecule E-cadherin. Downregulation of E-cadherin and upregulation of N-cadherin 
were reported during melanoma development (Kuphal and Bosserhoff 2006). The 
switch of cadherin subtypes frees melanoma cells from keratinocyte-mediated 
control and allows tumour cell invasion and migration. The decrease of E-cadherin is 
regulated by autocrine hepatocyte growth factor (HGF) which is expressed in 
melanoma cells. Inhibition of the MAPK pathway by the MEK inhibitor can partially 
block the downregulation of E-cadherin. It suggests that the MAPK pathway is 
involved in this process (Meier et al. 2005). The MAPK pathway is also involved in 
the upregulation of integrins which promote survival and invasive growth of 
melanoma cells in the extracellular matrix (ECM) (Schwartz et al. 1995). The 
expression of αVβ3 integrin is involved in transition from radial to vertical growth of 
melanoma (Albelda et al. 1990). Introducing αVβ3 integrin into a benign melanoma 
can induce invasion and metastasis in mouse xenograft models (Li et al. 1998b). The 
expression of α6 is also involved in melanoma invasion: human melanoma cells 
injected into nude mice were diminished in their metastatic potential by anti-α6 
antibodies (Ruiz et al. 1993). The sustained activation of MAPK is associated with 
the expression of β3 and α6 in melanoma cell lines. The expression of β3 and α6 
integrin in WM793, WM9, WM164 and WM1205 melanoma cell lines was 
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completely inhibited by the MEK1 inhibitor U1026 (Woods et al. 2001). Another 
important factor contributing to the metastatic spread of melanoma is the proteolytic 
enzymes which break down the surrounding matrix and facilitate cell migration 
though the basement membrane. Matrix metalloproteinases (MMPs) and the 
urokinase plasminogen activator (uPA), two families of proteases, are involved in 
matrix remodelling. With regard to melanoma, the expression of MMP-9 is linked 
with highly invasive melanoma and the expression of MMP-2 is a prognostic factor 
for survival of melanoma patients (MacDougall et al. 1999, Vaisanen et al. 1999). 
The expression of the MMP family is regulated by the MAPK pathway. Treatment of 
melanoma cells with MEK inhibitor reduced invasion of human melanoma A375 
cells. This reduced invasion is due to downregulation of uPA and MMP-9 (Ge et al. 
2002). However, in MeWo melanoma cells, MEK inhibitor had no affect on invasion 
(Denkert et al. 2002b). The functions of the MAPK pathway in the regulation of 
melanoma invasion still need further investigation. 
 
 




For the past 14 years, a large number of studies have revealed that the DNA cross-
linking agent diamminedichloroplatinum (II) (cisplatin; CDDP) could activate the 
MAPK pathway. It is generally believed that MAPK activation is a major component 
in deciding the cell fate in response to cisplatin. However, the role of the MAPK 
pathway in response to cisplatin is complex because this pathway, in some cases, is 
able to induce apoptosis, but in other cases, has no roles in this process, or even 
suppresses apoptosis. The final outcome depends on the cell type, proliferation and 
differentiation status of tumour cells (Brozovic and Osmak 2007).  
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In Hela cells, activation of ERK is important for the induction of cisplatin-induced 
apoptosis. Downregulation of ERK results in an inhibition of CDDP-induced 
apoptosis, while enhanced activation of ERK contributes to cell death. Activation of 
ERK by cisplatin could release cytochrome c which is involved in mediating CDDP 
induced apoptosis. The influence of the ERK pathway on CDDP-induced apoptosis 
is not limited to Hela cells, but also occurs in lung cancer cell line A549 cells (Wang 
et al. 2000). In contrast to the foregoing results, there are also reports which indicate 
that the activation of ERK signaling enhances the resistance to cisplatin. Inhibition of 
ERK activity has been shown to increase sensitivities to cisplatin by accumulation of 
p53 in ovarian cancer (Brown et al. 1993). In melanoma, overexpression of activated 
N-RAS has been reported to protect melanoma cells and induce cisplatin resistance 
(Jansen et al. 1997). Treatment of melanoma cells with cisplatin caused a time 
dependent increase in activation of ERK and enhanced cisplatin resistance through 
activation of survival protein RSK1 (Mirmohammadsadegh et al. 2007). The 
molecular mechanisms underlying activation of the ERK pathway by CDDP and 
protecting melanoma cells from death need further investigation.  
 
 
1.2.1.4 Feed-back loop of the RAS/RAF/MEK/ERK pathway 
 
 
The duration and magnitude of kinase activation determine the biological outcome of 
the MAPK pathway. It depends on a balance between the activation of the upstream 
components and various negative regulatory mechanisms, which inhibit pathway 
activation. Studies indicated that activities of specific MAPK phosphatases are 
responsible for negative regulation of the MAPK pathway activation. Activation of 
the MAPK pathway require phosphorylation of both threonine and tyrosine residues. 
Therefore, dephosphorylation of either of these residues is sufficient for kinase 
inactivation. Serine/threonine phosphatases, tyrosine specific phosphatases and dual-
specificity phosphatases are involved in this task (Keyse 2000, Saxena and Mustelin 
2000). Among these three classes of protein phosphatases, dual-specificity MAPK 
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phosphatases (MKPs) are the largest group of phosphatases to specifically regulate 
the phosphorylation and activities of the MAPK pathway.  
 
 
The MKPs are a subgroup of ten catalytically active enzymes within the cysteine-
dependent dual-specificity protein family of phosphatases (DUSPs) (Theodosiou and 
Ashworth 2002). They share a similar structure with a noncatalytic NH2-terminal 
domain and a catalytic COOH-terminal domain. The NH2-terminal domain contains 
highly conserved sequences involved in MAPK recognition, known as the kinase 
interaction motif (KIM). The catalytic COOH-terminal domain shares an active site 
sequence similarity with the prototypic VH-1 DUSP encoded by vaccinia virus 
(Owens and Keyse 2007). Based on the sequence similarity, substrate specificity and 
subcellular localization, these ten MKPs can be divided into three subclasses. The 
first subclass contains DUSP1/MKP-1, DUSP2/PAC-1, DUSP4/MKP-2, and 
DUSP5. These phosphatases are encoded by inducible genes which contain four 
exons with introns in highly conserved positions. They are all nuclear proteins and 
can be rapidly upregulated in response to stimuli at the transcriptional level. All of 
these phosphatases are shown to dephosphorylate ERKs, JNK, and p38 MAPKs. The 
second subclass consists of DUSP6/MKP-3, DUSP7/MKP-X and DUSP9/MKP-4. 
The genes of these phosphatases also have four exons. They all are cytoplasmic 
enzymes and highly selective for ERK1/2. The third subclass of MPKs comprises 
DUSP8/hVH-5, DUSP10/MPK-5 and DUSP16/MKP-7. The genes of these 
phosphatases have six exons. They are located in both cytosol and nucleus and can 
inactivate p38 and JNK MAPKs (Keyse 2008).  
 
 
Although the structures and catalytic mechanism of MPKs are described in detail in 
many studies, the knowledge of their biological functions is less complete. One study 
indicated that DUSP1 knock out mice are resistant to diet-induced obesity (Wu et al. 
2006). However, the main roles of MKPs are regulation of the immune system and in 
cancer development. Some data indicated that DUSP1, DUSP10, and DUSP2 seem 
to be involved in regulation of immune response. DUSP1 is required to regulate 
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cytokine synthesis in response to bacterial lipopolysaccharide (LPS) (Chi et al. 
2006). DUSP1 knock down animals are more sensitive to lethal endotoxic shock and 
have a high rate of induced autoimmune arthritis (Hammer et al. 2006). DUSP10 also 
plays an important role in regulation of immunity through the JNK pathway in 
immune effector cells (Zhang et al. 2004). DUSP10 knock out macrophages could 
produce more pro-inflammatory cytokines in response to LPS. In contrast, DUSP2 is 
a positive regulator of inflammatory response because DUSP2 knock out mice have 
reduced inflammation and macrophages from these mice produce less pro-
inflammatory cytokines exposed to LPS (Jeffrey et al. 2006). Given the roles of the 
MAPK pathway in cancer progression, it is not surprising to see MPKs involved in 
the initiation and development of cancer though regulation of the MAPK pathway. 
High levels of DUSP1 are found in many human epithelial tumours, including 
prostate, colon, and bladder cancers (Loda et al. 1996). Interestingly, overexpression 
of DUSP1 is found in the early stage of these epithelial tumours and then drops 
during tumour progression. For example, DUSP1 expression is high in the early 
stage of prostate cancer, while its expression is lost in later stages of this cancer 
(Magi-Galluzzi et al. 1998). However, DUSP1 is also increased in invasive stages of 
certain cancers. Strong expression of DUSP1 is detected in 60% of invasive ovarian 
carcinomas and the DUSP1 level appears to be a prognostic marker for shorter 
progression-free survival (Denkert et al. 2002a). DUSP1 is also expressed at higher 
levels in poorly differentiated and late stages of breast cancer, which may be related 
to regulation of the JNK pathway (Small et al. 2007). Another member of the MPKs 
involved in tumour progression is DUSP6, the functions of DUSP6 will be discussed 
in detail in the next section.  
 
 
1.2.1.5 DUSP6 functions 
 
 
DUSP6 plays an important role in embryonic development according to knock down 
and overexpression studies in Drosophila, zebrafish and chick embryos. Fibroblast 
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growth factors (FGFs) are secreted molecules that activate the MAPK pathway and 
have crucial functions during embryonic development. DUSP6 is responsible for 
regulation of the MAPK pathway in response to FGF signaling in the early embryo 
of zebrafish (Tsang et al. 2004). Small interfering RNA (siRNA) studies showed that 
DUSP6 could protect cells from apoptosis though controlling the MAPK pathway in 
chicken limb (Kawakami et al. 2003). Overexpression of DUSP6 in Drosophila 
disturbs photoreceptor differentiation and wing vein formation (Kim et al. 2004).  
 
Many studies show that DUSP6 is involved in cancer progression. The first evidence 
came from the studies of its role in pancreatic cancers associated with frequent loss 
of heterozygosity at 12q21 where the DUSP6 gene was located. The expression of 
DUSP6 is selectively abrogated in invasive carcinoma, especially in the poorly 
differentiated type. In contrast, most dysplastic carcinoma cells have high level of 
DUSP6. Moreover, the reintroduction of active DUSP6 into pancreatic cancer cell 
lines could lead to suppression of cell growth and induced apoptosis. Furthermore, 
some invasive carcinomas that had lost expression of DUSP6 also harboured a K-
RAS mutation (Furukawa et al. 2003). This suggests that loss of DUSP6 is associated 
with progression of pancreatic cancer from dysplastic carcinoma to invasive 
carcinoma and absence of DUSP6 combined with K-RAS mutations contribute to 
hyperactivation of ERK. DUSP6 expression levels are also reported to be lower in 
lung cancer and ovarian cancer cells and DUSP6 restoration suppresses cell growth 
(Chan et al. 2008, Okudela et al. 2009). In contrast, DUSP6 and Sprouty 2, an 
inhibitor of the MAPK pathway at the level of RAF, are upregulated in melanoma 
cell lines with BRAF mutation (Bloethner et al. 2005). In addition, DUSP6 is 
overexpressed in human breast cancer cells and keratinocytes stably habouring an H-
RAS mutation (Warmka et al. 2004). The activation of the MAPK pathway in these 
cell lines possibly induces DUSP6 expression at the transcriptional level. While this 
increase in turn increases the negative feedback control of the MAPK pathway to 
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1.2.2 Phosphatidylinositol 3′-kinase (P13K) pathway  
 
 
The P13K pathway is also important in melanoma progression. Activation of RTKs 
by growth factors leads to activation of PI3K, which then converts membrane lipid 
PIP2 into the second messenger, PIP3. This activation step leads to activation of AKT 
kinase, in turn p-AKT phosphorylates several proteins affecting cell growth and 
survival (Fig. 1.3) (Cristina et al., 2007). Phosphatase with tensin homolog (PTEN) is 
a protein and lipid phosphatase that inhibits AKT activation by PI3K (Takata and 
Saida 2006).  
 
 
Figure 1.3 The PI3K pathway  
 




Activation of RTKs by growth factors leads to activation of PI3K, which then converts 
membrane lipid PIP2 into the second messenger, PIP3. This activation step leads to activation of 
AKT kinase and phosphorylation of AKT, which in turn phosphorylates several proteins 
affecting cell growth and survival. PTEN is an inhibitor of the PI3K pathway, which can 
dephosphorylate PIP3. Activation of RAS also increases signalling of the PI3K pathway. NRAS 
and PI3K are oncogenes (indicated by green asterisks) and PTEN is a tumour suppressor 
(indicated by red asterisks) in malignant melanoma. Taken from Dahl and Guldberg, 2007. 
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The expression of phosphorylated AKT protein increases dramatically with 
melanoma invasion and metastasis. Loss of heterozygosity in the region of 
chromosome 10q, which harbours the PTEN locus, was demonstrated in melanomas. 
It has been shown that 30-40% of melanoma cell lines and 5-15% of uncultured 
melanoma specimens carried homozygous deletion and inactivating PTEN mutations 
(Tsao et al. 1998). Interestingly, PTEN mutations are often found coincident with 
BRAF mutations, whereas they are not found together with RAS mutations (Fecher 
et al. 2007). It suggests that there may be cooperation between BRAF activation and 
PTEN loss in melanoma progression.  
 
 
The MAPK pathway is intimately linked with the P13K pathway. RAS can not only 
regulate the MAPK pathway, but also control the PI3K pathway. Moreover, RAF 
activity is negatively regulated by AKT suggesting that cross-talk occurs between 
these two pathways. Interestingly, mutations of RAS and RAF can result in different 
outcomes. Mutations of RAS could lead to activation of both MAPK and PI3K 
pathways. Activation of the PI3K pathway could result in the inhibition of the 
MAPK pathway though cross-talk. Mutations of either BRAF or CRAF could result 
in only activation of the MAPK pathway (McCubrey et al. 2007). 
 
 
1.2.3 p16INK4A and p14ARF 
 
 
CDKN2A mutations are identified in 25% of familial melanoma kindreds (Arlo et al. 
2006). The p14ARF and p16INK4A proteins are both encoded by the CDKN2A gene. 
p16INK4a inhibits cyclin-dependent kinases 4 and 6, thereby causing pRB to 
accumulate in its hypo-phosphorylated form (Fig. 1.4). In this way, pRB acquires 
increased affinity for and inhibits E2F, the transcription factor which is involved in 
cell cycle progression, DNA replication and repair (Michaloglou et al. 2008). ARF, 
known as p19 in the mouse and p14 in the human, antagonizes the function of 
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MDM2 to induce a protective response that depends on the p53 transcription factor 
and its many target genes (Fig. 1.5) (Sviderskaya et al. 2002). Recent studies have 
shown that mutations of the INK4A-ARF locus may favour tumourigenesis from 
melanocytes by impairing senescence and cell death (Sviderskaya et al. 2002). 
Cellular senescence, the acquired inability of normal somatic cells to divide after a 
finite number of divisions, is controlled by key tumour suppressors including p53 
and p16INK4a. The best known form of senescence is affected by the p53 pathway. 
However, expression patterns of senescence mediators and markers in melanocytic 
lesions provide strong evidence that cell senescence in benign naevi does not involve 
p53 upregulation, while p16INK4a is widely expressed. It suggests that p16INK4a rather 
than p53 plays a key role in cellular senescence of benign naevi (Gray-Schopfer et al. 
2006) The inactivation of p16INK4a expression in early melanomas may make it 
possible to bypass cellular senescence and subsequently to acquire epigenetic and 
genetic changes, which may be associated with tumour progression. 
 
 
Figure 1.4 The p16-CDK4/6-RB pathway  
               
 
G1 to S transition   
 
p16 inhibits the G1 cyclin-dependent kinases CDK4 and CDK6 to keep RB in an activated state. 
Inhibition of p16 increases CDK4/6 activity leading to hyperphosphorylation of RB and release 
of E2F transcriptional factors needed to activate genes essential for S phase. In this way, cells can 
pass G1 phase to S phase. CDK4 is an oncogene (indicated by green asterisks) and p16 and RB 
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are tumour suppressors (indicated by red asterisks) in malignant melanoma. Adapted from Dahl 
and Guldberg, 2007. 
 
 
















ARF can release p53 from MDM2-p53 complex and induce protective reponse. For explanation, 
see text. Adapted from Miller and Mihm, 2006.  
 
 
1.2.4 Other genes and pathways involved in melanoma progression  
  
 
It is generally believed that MITF plays an important role in regulation of 
melanocyte specific transcription. Several pathways could affect MITF expression by 
binding to the MITF promoter. MSH binds to the G protein-coupled MC1R, which 
acts through adenylate cyclase to stimulate binding of CREB1 to the MITF promoter. 
WNT and Endothelin signaling could also regulate MITF expression. Several growth 
factors such as C-KIT and hepatocyte growth factor (HGF) are involved in regulation 
of phosphorylation of MITF through the MAPK pathway. Both increased expression 
of MITF and phosphorylation of MITF stimulate its target genes including numerous 
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markers important in melanoma (MLANA, TRPM1, and SILV), genes important for 
survival (BCL2) and genes involved in melanin production (TYR, TRP1 and DCT) 









MITF and β-catenin signalling are also involved in progression of melanoma. For explanation, 
see text. Taken from Miller and Mihm, 2006.  
 
 
High levels of MITF activity result in cell cycle arrest and differentiation, whereas 
low levels of MITF activity lead to cell cycle arrest and death. Therefore, MITF can 
contribute to melanoma development or suppress melanoma progression and its 
ability to control cell fate decisions depends on its expression levels or activity levels. 
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MITF expression or activity may be carefully regulated in melanoma cells to ensure 




Beta-catenin is a key component of the canonical WNT transduction pathway. 
Signalling through this pathway controls a wide range of cellular functions, and 
aberrant WNT signalling can induce progression of cancer (Giles et al. 2003). When 
WNT proteins bind their receptors, they inactivate the kinase GSK3β, an enzyme 
which phosphorylates β-catenin and targets it for destruction in the proteosome. As a 
result, β-catenin accumulates in the cytoplasm and goes to the nucleus where it binds 
to lymphoid enhancer factor-T-cell factor (Fig. 1.6) (Dahl and Guldberg 2007). High 
levels of nuclear β-catenin can increase the expression of MITF (Widlund et al. 2002) 
and cyclin D1 (Patil et al. 2009) and MMP-7 (Miller and Mihm 2006), and these in 
turn increase the survival, proliferation and migration of melanoma cells. Nuclear or 
cytoplasmic localization of β-catenin is a potential indicator of WNT pathway 




1.3 Cisplatin resistance and the NER pathway in melanoma  
 
1.3.1 Cisplatin induced DNA damage and repair  
 
 
Cisplatin, cis-diamminedichloroplatinum (II), or CDDP, was synthesized first in 
1845 but its anticancer activity was not discovered until 1965 (Lippard 1982). 
Cisplatin is most effective in the treatment of testicular tumours (Bosl and Motzer 
1997). The cure rate for testicular cancer is greater than 90% (Bosl and Motzer 
1997). Cisplatin is also used to treat other kinds of malignancies, including ovarian, 
lung, cervical, head and neck, and bladder cancer (Keys et al. 1999, Loehrer and 
Einhorn 1984, Morris et al. 1999, Rose et al. 1999).  




Although the mechanism is not yet fully understood, cisplatin is generally believed to 
kill cancer cells by activating apoptosis leading to cell death (Rosenberg 1985). Both 
prokaryotic and eukaryotic cells deficient in DNA repair are particularly sensitive to 
cisplatin (Beck and Brubaker 1973). Cisplatin and its analogues are heavy metal 
complexes which contain a central atom of platinum, two chloride atoms and two 
ammonia molecules in the cis position. In the cells, one of the cisplatin chloride 
ligands is displaced by water to form a highly reactive charged platinum complex 
[Pt(NH3)2ClH2O]+. This complex binds to the N7 atom of either guanine or adenine 
bases. The remaining choloride ligand is then displaced to allow platinum to bind to 
a second nucleotide base (Jamieson and Lippard 1999). Cisplatin forms various DNA 
adducts, the most notable one is the 1,2-intrastrand crosslink with purine bases. The 
inactive isomer of cisplatin, trans-DDP, can not form this crosslink. It suggests that 
this kind of lesion is involved in the biological activities of cisplatin. In the 1,2-
intrastrand crosslink, the DNA is unwound and bent towards the major grove. 
Interstrand crosslinks caused by cisplatin induce even more steric changes in DNA 
which prevent chromosome segregation and block DNA and RNA polymerases and 
are therefore a particularly toxic class of DNA damage. Other DNA adducts include 
the monofunctional and the 1,3- and longer range intrastrand, and protein-DNA 
crosslinks. Each of these adducts forms a distinct structural element and interacts 
with DNA differently. 
 
 
As mentioned before, cells deficient in DNA repair are more sensitive to cisplatin. It 
suggests that the DNA repair system plays an important role in cisplatin activities. 
Repair of cisplatin induced DNA damage is mainly performed through the nucleotide 
excision repair (NER) pathway (Chu 1994). The inherited disease xeroderma 
pigmentosum (XP) is characterized by hypersensitivity to UV radiation and a 
predisposition toward skin cancer because of deficiency in the NER pathway (Sancar 
1995, Wood 1997). Cell lines cultured from XP patients are hypersensitive to 
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cisplatin (Fraval et al. 1978). It provides the evidence that the NER pathway is 
important in the cellular processing of cisplatin. In addition, the repair of cisplatin 
adducts has been investigated directly in reconstituted repair systems. The activity of 
nucleotide excision repair in E.coli results from the ABC excinuclease which 
includes three subunits, UvrA, UvrB, and UvrC (Sancar 1996). The UvrB gene is 
reported to be important for repair of ciplatin induced DNA damage, indicating NER 
to be the primary pathway to repair these adducts (Popoff et al. 1987). Increased 
expression of several NER genes has been correlated with cisplatin resistance. In 
ovarian cancer, higher levels of expression of XPA, ERCC1, XPF and ERCC3 (XPB) 
have been observed in tumours of patients resistant to cisplatin treatment (Rabik and 
Dolan 2007). In addition, gastric cancers display a correlation between ERCC1 and 
XPF mRNA levels and cisplatin resistance (Matsubara et al. 2008). In contrast, 
testicular cancers with low levels of XPA and ERCC1-XPF are highly responsive to 
cisplatin (Welsh et al. 2004). Furthermore, among these proteins in the NER pathway, 
ERCC1-XPF has been shown to have an important role in determining the overall 
NER capacity of ovarian cell lines resistant to cisplatin (Ferry et al. 2000).  
 
 
The NER endonuclease-complex ERCC1-XPF is also reported to be crucial for the 
repair of cisplatin induced interstand crosslinks (ICL) by making the incision at the 
DNA lesions (Chipchase and Melton 2002, Niedernhofer et al. 2006). The 
mechanism of ICL repair in mammalian cells is still poorly understood.  It is reported 
that the ICL repair is initiated by the formation of a Y structure near the DNA 
damage due to replication folk stalling or with the help of DNA helicase. ERCC1-
XPF complex then cleaves at the 3′ side of one arm of the crosslink and then makes 
an additional cleavage at the 5′ side. The fork collapses and recombination and NER 
events take place to complete the repair (Fisher et al. 2008, Kuraoka et al. 2000). 
Thus, the ERCC1-XPF complex seems to play an important role in initiating the ICL 
repair process for this most toxic lesion in mammals.  
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ERCC1-XPF complex is also thought to be involved in homologous recombination 
(HR) which has been proposed to repair double strand break (DSB) caused by 
cisplatin (Frankenberg-Schwager et al. 2005). The HR mechanism consists of two 
categories: gene conversion and single-strand annealing (SSA). The ERCC1-XPF 
complex is reported to be involved in both SSA and gene conversion to repair DSB 
in mammalian cells (Al-Minawi et al. 2008). However it seems not to be an essential 
factor in the recombination repair pathway. When murine cells deficient in ERCC1 
were examined for induction of interstrand crosslinks by mitomycin, only a moderate 
sensitivity was observed (Melton et al. 1998). It suggests that ERCC1 is not essential 
for homologous recombination and there are other DNA repair pathways to deal with 
this DNA damage. However, impairment of the HR pathway in ICL repair is 
observed in ERCC1 deficient cells, suggesting that the ERCC1-XPF complex plays a 
role in completion of HR in ICL repair (Al-Minawi et al. 2009).  
 
 
Taken together, the ERCC1-XPF complex is involved in multiple DNA repair 
pathways to deal with cisplatin-induced DNA damage. High ERCC1/XPF mRNA 
and protein levels in cancer patients cause enhanced DNA repair and lead to 
chemotherapy resistance. Cancer patients who have lower expression of ERCC1/XPF 
are hypersensitive to cisplatin treatment. This makes the ERCC1/XPF heterodimer a 
potentially interesting drug target.   
 
 
1.3.2 Cisplatin resistance  
 
 
Resistance of tumours to cisplatin is one of the main reasons for failure of cisplatin 
treatment. There are two kinds of resistance to cisplatin: acquired resistance and 
intrinsic resistance. Acquired resistance develops in patients undergoing the cisplatin 
treatment and in cell lines exposed to cisplatin. Some type of malignancies, such as 
ovarian cancer, may be sensitive to cisplatin initially but can acquire resistance to the 
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drug during treatment. Intrinsic resistance occurs when the patient tumours are 
inherently resistant to cisplatin and naturally unaffected by the treatment. Some cell 
lines isolated from these patients are more proficient at removing cisplatin induced 
DNA adducts compared with cell lines with normal cisplatin sensitivity (Zamble and 
Lippard 1995).  
 
Because of its clinical importance, the mechanisms of cisplatin resistance have been 
studied over time. Resistance of tumours to cisplatin seems to be a multifactor 
cellular response, rendering it more difficult to understand the process fully. 
Generally, three main activities have been identified as potential mechanisms 
involved in cisplatin resistance (Kartalou and Essigmann 2001): 
 
1) Inhibition of drug uptake and increase in the production of cellular thione. 
Reduced intracellular accumulation of cisplatin because of decreased uptake or 
increased efflux plays an important role in cisplatin resistance. Another cellular 
response that can modulate cisplatin resistance is to increase the level of 
intracellular thiol (such as metabolic synthesis of glutathione and 
metallothionein) that can react with and inactivate cisplatin.   
 
2) Changes in the concentrations of regulatory proteins. Alteration in the expression 
of oncogenes (such as c-fos, c-myc, H-ras, c-jun, and c-abl) and tumour 
suppressor genes (such as p53) have been implicated in the cellular resistance to 
cisplatin.  
 
3) Increase in the repair of cisplatin DNA adducts. Based on current literature 
review, an increase in DNA repair is the key to determine clinical outcome and 
clinical resistance to cisplatin based chemotherapy in human cancer. The increase 
in DNA repair with cisplatin resistance could be due to enhanced expression of 
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proteins involved in repair. High levels of ERCC1 and PCNA were observed in 
cisplatin resistant tumour cells.   
Many mechanisms involved in cisplatin resistance are still not fully understood. An 
improved understanding of cisplatin resistance may lead to improved chemotherapy 
for cancer.  
 
1.3.3 Nucleotide excision repair  
 
1.3.3.1 Overview of NER 
 
Nucleotide excision repair (NER) is a DNA repair pathway that is involved in 
dealing with a wide range of DNA lesions. It is highly conserved, versatile and 
robust in eukaryotes and present in most organisms. The most common lesions 
processed by NER are those formed by UV radiation (such as cycolobutane-
pyrimidine dimers and 6-4 photoproducts) and DNA adducts induced by compounds 
such as arylamine carcinogens and cisplatin (Gossage and Madhusudan 2007).  
Although NER is not essential for viability, defects in NER may result in at least 
three diseases in human, xeroderma pigmentosum (XP), Cockayne syndrome (CS), 
and trichothiodystrophy (TTD) (Lehmann 1995, Lindahl and Wood 1999, Thoma 
1999). Patients with XP were hypersensitive to UV radiation and had a higher risk of 
skin carcinomas (Friedberg 2003). Sun exposure of XP patients could cause 
progressive degeneration of the skin and eyes (Kraemer et al. 2007). Alteration of the 
NER pathway was also associated with neurological abnormalities and led to 
premature ageing phenotypes.  
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1.3.3.2 Molecular mechanism of NER 
 
The molecular mechanism of NER is complex and involves about 30 distinct 
proteins which are encoded by seven XP complementation groups, XPA to XPG, 
ERCC1 (excision repair cross-complementing group 1), hHR23B (human homolog 
of yeast RAD23), RPA (replication protein A), additional subunits of TFIIH 
(transcription factor with helicase activity), Cockayne syndrome proteins CSA and 
CSB and several other genes (de Boer and Hoeijmakers 1999).  
 
NER is divided into two subpathways in mammals known as transcription-coupled 
repair (TCR-NER) pathway and global genome repair (GGR-NER) pathway. The 
TCR-NER pathway targets lesions specifically in the transcribed strand of expressed 
genes; while the GGR-NER pathway deals with lesions in non-transcribed parts of 
the genome, including the non-transcribed strand of transcribed genes (Friedberg 
2001).  
 
The NER pathway involves the following 4 steps (Fig. 1.7): 
 
1) Recognition of DNA damage. In the GGR pathway, the DNA damage lesions are 
firstly recognized by the XPC-HR23B complex. XPC-HR23B binds to DNA 
distortion caused by the lesion and induces some conformational changes of the  
DNA helix, including local opening of DNA, which allow entry of subsequent 
NER factors, such as TFIIH, XPA, and RPA (Sugasawa et al. 2002, Wakasugi 
and Sancar 1999). XPC-HR23B was not only required for recognition of the 
DNA lesion but also for the recruitment of all the other NER factors in a 
reconstituted system, including transcription factor TFIIH (Volker et al. 2001). 
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The binding properties of XPC-HR23B have been the subject of extensive 
studies: the complex binds efficiently to ssDNA and helix distorting lesions. 
XPC-HR23B recognized 6-4 photoproducts but not cyclobutane pyrimidine 
dimers (CPDs) (Gillet and Scharer 2006). However, the CPDs were still repaired 
by NER. This suggests the existence of an other recognition factor responsible 
for recognition of these lesions. Recently, studies showed that damage-specific 
DNA binding protein (DDB) is involved in the recognition process of CPDs in 
NER (Nichols et al. 2000). The DDB complex is a heterodimer of two 
polypeptides, p127 and p48 (Wakasugi et al. 2001). p48, also known as DDB2, is 
the XPE gene product and was reported to cause conformational change to allow 
DNA lesion binding by the NER machinery (Kulaksiz et al. 2005).  
 
In the TCR pathway, repair of transcription blocking lesions was thought to be 
initiated by an RNA polymerase, which was unable to pass the lesions (Gillet 
and Scharer 2006, Reardon and Sancar 2005). Cockayne syndrome proteins CSA 
and CSB were also involved in recognizing and binding to DNA lesions in TCR 
(de Waard et al. 2004). The CSA protein containing a WD-40 repair motif 
contributes to protein-protein interactions (Henning et al. 1995). CSA was 
known to regulate the ubiquitin ligase activity of the complex containing DDB1, 
cullin 4A, Roc1, and COP9 and this complex could be involved in the 
ubiquitination of RNA polymerase II. Ubiquitination of RNA polymerase II 
would allow access of the repair machinery to the lesion and subsequent 
recovery of RNA synthesis (Groisman et al. 2003). The CSB protein was able to 
remodel chromatin structure and directly interact with core histones. CSB is also 
involved in recruiting other repair proteins to the site of DNA lesions (Bradsher 
et al. 2002).  
 
2) DNA helix unwinding. Once the DNA lesions are identified, the following steps 
in GGR and TCR are similar. XPC-HR23B or CSB and CSA recruit TFIIH to the 
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damage sites (Schaeffer et al. 1994). TFIIH is a ten-subunit complex, including a 
core complex and a CDK activating kinase subunit (Schultz et al. 2000). TFIIH 
was involved in initiation of RNA polymerase II transcription but could, upon 
DNA damage, also be recruited to perform NER functions (Hoogstraten et al. 
2002). ATP-dependent helicases XPB and XPD, two subunits of TFIIH, were 
responsible for 3′ to 5′ direction and 5′ to 3′ direction opening of DNA around the 
lesion (Sancar 1996). After DNA opening by TFIIH, RPA, XPA, and XPG are 
recruited to the site of damage lesions to join the complex (Wakasugi and Sancar 
1998). This complex was thought to be a stable state for the NER reactions where 
all NER factors, except ERCC1-XPF, stably bound to an open DNA bubble 
structure (Mu et al. 1996). RPA and XPA were considered to verify the specific 
NER lesions and promote the accurate assembly of the NER complex (Li et al. 
1995). XPG is believed to be recruited to the complex though interaction with 
TFIIH (Araujo et al. 2001). The functions of XPG will be discussed later.  
 
3) DNA dual incision. In this step, ERCC1-XPF is directly recruited to the NER 
complex by XPA (Li et al. 1995). Two structure-specific endonucleases XPG and 
ERCC1-XPF make the dual incision. XPG belongs to the FEN-1 (flap 
endonuclease) family of structure-specific endonucleases (Lieber 1997). It has a 
defined polarity that cleaves specifically at junctions between the 3′ end of 
ssDNA and the 5′ end of dsDNA. During the NER reaction, XPG makes the 3′ 
incision due to its cleavage polarity (O'Donovan et al. 1994). XPG not only 
performs 3′ incision in NER but is also involved in stabilizing the complex 
(Wakasugi et al. 1997). ERCC1-XPF is an obligate heterodimer and incises DNA 
with specific polarity at the 5′ side of double-strand/single-strand DNA junctions, 
consistent with its 5′ incision during NER (Biggerstaff et al. 1993, Sijbers et al. 
1996). Unlike XPG, addition of ERCC1-XPF to the complex did not change the 
opened DNA structure. It has been reported that XPG could make the 3′ incision 
without ERCC1-XPF, while ERCC1-XPF could not make the 5′ incision in the 
absence of XPG (Tapias et al. 2004).  
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4) Repair synthesis. The excised fragment was removed and the gap was filled by 
two DNA polymerases δ and ε (Thoma 1999). It was observed that replication 
factor-C (RFC) catalyzed the ATP-dependent loading of proliferation cell nuclear 
antigen (PCNA) to DNA near the 3′ terminus of the primer. PCNA then 
facilitates DNA polymerase to add nucleotides in a 5′ to 3′ direction (Gulbis et al. 
1996, Podust et al. 1992). RPA remains bound to the ssDNA following dual 
incision and is involved in PCNA and RFC recruitment (He et al. 1995). Finally, 
the gap is closed by DNA ligase I or DNA ligase III (Nocentini 1999).   
Figure 1.7 Mechanism of the NER pathway  
 
Model for mammalian nucleotide excision repair. Adapted from Matsumura and Ananthaswamy 
2002. For explanation, see text.   
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1.3.3.3 ERCC1 and ERCC1-XPF complex  
 
The gene for ERCC1 is located on chromosome 19q13.2-q13.3 and has 10 exons 
spread over 15kb of the genome. The molecular weight of ERCC1 is about 32.5 KD 
(Park et al. 1995). ERCC1 protein contains 297 amino acids and has two domains. 
The central domain of ERCC1 (residues 96-214) is structurally similar to the XPF 
nuclease domain, but is devoid of nuclease activity (Gaillard and Wood 2001). 
Studies showed that the ERCC1 central domain not only binds to ssDNA/dsDNA 
junctions with a defined cleavage polarity but also interacted with XPA (de Laat et 
al. 1999). The C-terminal tandem helix-hairpin-helix (HhH2) domain of ERCC1 
(residues 220-297) dimerizes with the C-terminal domain of XPF to form the 
functional nuclease and it also binds to DNA (de Laat et al. 1998). As the partner of 
ERCC1, XPF is located on chromosome 16p13.3 and has 11 exons spread over 32kb 
of the genome. The molecular weight of XPF is about 104.5KD. XPF protein 
contains 916 amino acids and has three domains (Aravind et al. 1999). An N-
terminal helicase-like domain (residues 4-457) might contribute to DNA binding 
activities. The central nuclease domain of XPF (residues 656-813) has conserved 
metal-binding residues with a [V/I]ERKX3D motif and functionally important basic 
residues that interact with DNA substrates (Enzlin and Scharer 2002). The C-
terminal domain of XPF (residues 837-905) with HhH2 motif dimerizes with the 
equivalent domain in ERCC1 and may be involved in DNA binding as well (de Laat 
et al. 1999).  
 
The ERCC1-XPF complex is the last factor to join in the NER incision complex. 
Formation of ERCC1-XPF complex is critical for stability of both components and is 
required for catalytic activity of XPF (Gillet and Scharer 2006). As the previous 
section mentioned, the main function of ERCC1-XPF complex is to make an incision 
to the 5′ side of the lesion (Sijbers et al. 1996). It also has additional NER-
independent functions in the repair of interstrand DNA crosslink (ICLs) and in 
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homologous recombination (HR) (Busch et al. 1997, Kuraoka et al. 2000, 
Niedernhofer et al. 2004). ICLs are an extremely toxic class of DNA damage that can 
be generated during normal metabolism or cancer chemotherapy. Although the 
mechanisms of ICL repair are still not clear, genetic data implicated the ERCC1-XPF 
complex as required for ICL repair (Niedernhofer et al. 2004). In the HR pathway, 
the ERCC1-XPF complex was involved in gene conversion and single-strand 
annealing (SSA) in mammalian cells (Al-Minawi et al. 2008).  
 
1.3.3.4 ERCC1 expression  
 
The ERCC1 promoter was located in a region within 170 bp upstream of the normal 
transcriptional start site. However this region lacked the classic promoter regulatory 
elements like CAAT, TATA and GC-boxes (van Duin et al. 1986). On the other 
hand, Wilson observed that a highly conserved region containing a CpG island and 
TATA box was located 5kb upstream of ERCC1 exon1 by comparisons of the entire 
gene from mammalian species (Wilson et al. 2001). Hypermethylation was observed 
in the upstream 5kb region of the ERCC1 promoter of cisplatin sensitive glioma cell 
lines (Chen et al. 2010) and it was suggested that the upstream 5kb region of ERCC1 
may be involved in regulation of ERCC1 expression and associated with cisplatin 
chemosensitivity.  
 
Expressed sequence tag (EST) assemblies for human ERCC1 identified numerous 
splice variants involving exon 1, 2, 3, 7, 8, and 9 that could affect expression of 
ERCC1 (Wilson et al. 2001). A 5′ variant containing a differentially spliced exon1 
which spans the entire promoter region in human had been reported (van Duin et al. 
1986). It suggested at least some ERCC1 transcripts may originate from further 
upstream of ERCC1. In addition, a 42bp deletion, thought to contain the binding site 
for a transcriptional repressor, has been reported in exon1 of the human ERCC1 
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gene. Loss of this sequence was related to higher level of ERCC1 mRNA in ovarian 
cancer specimens (Yu et al. 2001). However, previous group work indicated that 
alternate splicing of this 42bp sequence was not correlated with high levels of 
ERCC1 expression, as suggested by Yu, and therefore its significance remains 
unclear (Winter et al. 2005).  
 
A novel 1.5kb mouse skin-specific Ercc1 transcript was identified by previous group 
work. According to northern blotting and RT-PCR results, the 1.5kb Ercc1 transcript 
was the major transcript in mouse skin compared with the normal 1.1kb Ercc1 
transcript. This novel transcript originated from a promoter about 400bp upstream of 
the normal Ercc1 promoter, not from a promoter further upstream (Song et al. 2011). 
However, whether similar novel transcripts exist in human skin and the functions of 
the novel transcript need further investigation.  
 
1.3.3.5 Regulation of ERCC1 expression  
 
DNA damage induced by cisplatin, alkylating agents, and ionizing radiation resulted 
in the activation of c-Jun-NH2-kinase (JNK)/stress-activated protein kinase (SAPK) 
(Liu et al. 1996). JNK/SAPK is a subfamily of MAP kinase in the RAS pathway 
which enhances the phosphorylation of Jun protein. Phosphorylation of c-jun 
dramatically enhanced the transcriptional activity of the activated protein 1 (AP-1)-
binding sites and AP-1 regulated genes (Binetruy et al. 1991, Pulverer et al. 1991, 
Smeal et al. 1991). The nuclear transcriptional factor AP-1 consisted of either 
homodimers formed between Jun and Fos or homodimers of Jun protein. AP-1 was 
responsible for the activation of a wide variety of genes in different cell types and 
tissues (Adler et al. 1992, Derijard et al. 1994, van Dam et al. 1993). The promoter of 
ERCC1 was located in a region of 170 basepairs upstream of the transcriptional start 
site of the ERCC1 gene (van Duin et al. 1986). The promoter region contained an 
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AP-1 like binding site. Cisplatin exposure had been reported to induce ERCC1 
mRNA in ovarian cancer cells. This ERCC1 mRNA upregulation was preceded by an 
increase in mRNA expression of c-fos and c-jun, an increase in c-jun protein 
phosphorylation and an increase in nuclear extract binding activity to the AP-1 like 
site of ERCC1. It suggested that induction of ERCC1 expression exposed to cisplatin 
resulted from two major factors: an increase in the expression of transactivating 
factors that bind the AP-1 like binding site in the promoter region of ERCC1 and an 
increase in the level of c-jun phosphorylation that enhances its transactivation 
property. These two factors contributed to increase the activity of AP-1 binding to 
the ERCC1 promoter and directly modulate ERCC1 gene expression. (Altaha et al. 
2004, Li et al. 1998a).  
 
In addition to JNK, another MAPK, the extracellular signal regulated kinase (ERK), 
also responds to cisplatin treatment (Mirmohammadsadegh et al. 2007, Wang et al. 
2000, Wang et al. 1998). ERK1/2 is essential in cell proliferation, survival, division, 
and its activity is greatly increased by exposure to cisplatin. ERCC1 induction by 
epidermal growth factor (EGF) depended on the MEK-ERK pathway through 
activation of transcriptional factor GATA-1 (Andrieux et al. 2007). Moreover, 
addition of MEK specific inhibitors, U0126 and PD98959, effectively inhibited 
ERCC1 induction by EGF in prostate carcinoma cells (Yacoub et al. 2003). 
Furthermore, a recent study showed that emodin induced cytotoxicity via ERCC1 
downregulation through ERK1/2 inactivation in human lung cancer cells (Ko et al. 
2010). Taken together, the MEK-ERK pathway may be involved in regulation of 
ERCC1 expression following cisplatin. Analysis of the human ERCC1 promoter 
sequence with TFSEARCH identified several transcription factor motifs that could 
be activated by the MAPK pathway (Andrieux et al., 2007). In particular, that region 
contains two ETS-1 motifs, one GATA motif and two AP-1 motifs, suggesting at 
least one of these may be involved in the ERCC1 increase by cisplatin through the 
MAPK pathway. An investigation of regulation of ERCC1 expression by the MEK-
ERK pathway following cisplatin was one of the aims of this thesis.  
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1.3.3.6 ERCC1 and platinum resistance  
 
A large number of studies show that ERCC1 mRNA and protein levels may be 
associated with cisplatin resistance in human cancer cells and therefore are 
considered as a predictive maker for chemotherapeutic outcome (Kirschner and 
Melton 2010). A positive association has been demonstrated between the level of 
ERCC1 mRNA expression and cisplatin resistance in lung cancer. High expression 
of ERCC1 mRNA has been related to poor response and survival in cisplatin-treated 
non-small-cell lung cancer patients (Rosell et al. 2003). Non-small-cell lung tumour 
patients with lower expression of ERCC1 appear to benefit from adjuvant 
chemotherapy and survive longer than the control group (Olaussen et al. 2006). A 3-
fold ERCC1 mRNA increase has been reported in ovarian cancer cisplatin resistant 
derivatives compared with their parent cell lines (Ferry et al. 2000). In another study, 
cisplatin caused a time and dose dependent increase in ERCC1 mRNA levels in 
A2780/CP70 human ovarian cancer cells (Li et al. 1998a). Ovarian cancer patients 
who were resistant to cisplatin therapy had a higher ERCC1 expression level in their 
tumour tissues than the patients who responded to cisplatin, suggesting that ERCC1 
expression levels have a role in clinical resistance to cisplatin (Dabholkar et al. 1992). 
A study of a panel of 15 early-passage cervical tumour cell lines has demonstrated 
that ERCC1 mRNA expression is a molecular marker for the clinically relevant 
cisplatin sensitivity of human cervical carcinoma cells (Britten et al. 2000). Cisplatin 
based chemotherapy cures over 80% of metastatic testicular germ cell tumours 
(TGCT). Cell lines derived from TGCT are hypersensitive to cisplatin therapy. This 
exceptional sensitivity is due to deficiency in interstrand-crosslink repair and low 
level of expression of ERCC1-XPF (Usanova et al. 2010). In another study, 
investigation of 35 human cell lines derived from cancers indicated that only the 6 
testis tumour cell lines showed significantly lower levels of XPA, XPF and ERCC1 
proteins than  the other groups (Welsh et al. 2004). It suggests that lower levels of 
these nucleotide excision repair proteins are related to extreme chemosensitivity of 
testis tumours to cisplatin based chemotherapy. In patients with advanced squamous 
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cell carcinoma of the head and neck (SCCHN), low expression of ERCC1 was an 
independent predictor for prolonged survival (Jun et al. 2008). Similarly, samples 
from patients with gastric cancer showed that low ERCC1 correlated with a higher 
response to cisplatin-based chemotherapy, while  high ERCC1 was a significant 
predictor of poor survival (Matsubara et al. 2008). ERCC1 also predicted survival in 
bladder cancer treated by platinum-based therapy and median survival was 
significantly higher in patients with low ERCC1 levels (Bellmunt et al. 2007). Taken 
together, the positive correlation between high expression of ERCC1 and cisplatin 
resistance was found in a large variety of cancer types, not just specific to one or two, 
and ERCC1 could be used to predict chemotherapy outcome.  
 
Dowregulation of ERCC1 by antisense RNA could sensitize the highly resistant 
OVCAR10 ovarian cancer cell line to cisplatin. In addition, immunocompromised 
mice transplanted with these antisense cell lines survived longer than the mice 
bearing control cells after cisplatin treatment (Selvakumaran et al. 2003). 
Knockdown of ERCC1 expression by specific siRNA transfection also decreased 
DNA repair abilities in lung cancer and enhanced the cytotoxic effect induced by 
emodin (Ko et al. 2010). On the contrary, introduction of ERCC1 into an ERCC1 
deficient Chinese hamster ovary cell line could restore the ability of DNA repair and 
make cells more resistant to cisplatin treatment (Lee et al. 1993). These data 
indicated that alterating expression levels of ERCC1 can affect the sensitivity of cells 
to cisplatin and further confirmed that ERCC1 played an important role in cisplatin 
resistance.  
 
Studies showed that both Breast Cancer 1 (BRCA1) and ERCC1 expression are 
correlated with resistance to platinum-based chemotherapy in sporadic ovarian 
cancer and low BRCA1 and ERCC1 expression predicted longer survival. 
Furthermore, high levels of both BRCA1 and ERCC1 were related to each other in 
patients with advanced stages of tumour and correlated with shorter survival 
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(Weberpals et al. 2009). It was possible that both of these two proteins take part in 
DSB repair pathways that complement each other. Concomitant low expression 
levels of ERCC1 and ribonucleotide reductase (RRM1) were reported to predict a 
better outcome of NSCLC patients after chemotherapy (Ceppi et al. 2006). In 
contrast, the best prognosis for both disease-free survival and overall survival in 
patients with pancreatic cancer was achieved when both these two proteins were high 
in the primary tumour. However, RRM1 expression seems to be involved in 
gemcitabine (the first line cytotoxic agent treatment of advanced pancreatic cancer) 
resistance. Pancreatic cancer patients with low levels of RRM1 had improved 
survival after gemcitabin treatment (Akita et al. 2009). This demonstrates that it is 
more reliable to use several protein markers to predict disease outcomes before and 
after chemotherapy.  
 
 
A single nucleotide polymorphism (SNP) in ERCC1 codon 118 in exon 4 leads to a 
C to T transition without change in the polypeptide sequence (N118N). This ERCC1 
polymorphism had been linked to decreased levels of ERCC1 mRNA in ovarian 
cancer cell lines. That may explain why patients with C/C genotypes displayed 
reistance to chemotherapy and had a high risk for disease progression and death 
compared to those with C/T or T/T genotypes (Smith et al. 2007). However, the 
association between codon N118N transition and survival after platinum-based 
therapy has been corroborated in some, but not all cancers. In colorectal cancer, the T 
allele was linked to better response to cisplatin in some patients, but associated with 
cisplatin resistance and poor survival in other patients (Stoehlmacher et al. 2004, 
Viguier et al. 2005). For NSCLC patients, the C allele has been related to better 
treatment response and longer survival (Isla et al. 2004, Ryu et al. 2004, Zhou et al. 
2004). However, there is no relationship between ERCC1 genotype and treatment 
response in gastric cancer (Ruzzo et al. 2006). Therefore, the clinical significance of 
this ERCC1 polymorphism in different cancer types needs further investigation.  
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The clinical observations indicated that melanoma was relatively resistant to 
cisplatin; however whether ERCC1 was involved in resistance to cisplatin in 
melanoma cells was still unclear. Our lab generated mouse Ercc1-deficient 
melanocytes using the Cre-lox system. The Ercc1 proficient and deficient 
melanocytes were transplanted into nude mice where they grew as malignant 
melanoma. The Ercc1 proficient xenografts grew very rapidly compared with Ercc1 
deficient xenografts. Moreover, Ercc1 proficient melanoma xenografts developed 
chemotherapy resistance quickly following cisplatin treatment. ERCC1 levels were 
2-fold increased in the cells re-isolated from cisplatin-resistant tumours compared 
with cells from untreated xenografts, while Ercc1 deficient melanoma xenografts 
were cured by cisplatin. This suggested that Ercc1 expression was related to cisplatin 







The work presented in this thesis aims to investigate several pathways related to 
melanoma progression and chemotherapy resistance. Chapter 3 examines the status 
of BRAF, ERK, MEK, and DUSP6 in the RAS/RAF/MEK/ERK (MAPK) pathway 
and AKT, PTEN in the PI3K/AKT (AKT) pathway in our immortal mouse 
melanocyte cell lines and their tumourigenic derivative cell lines to investigate the 
mechanisms involved in melanoma progression in our xenograft model. In chapter 4, 
we hope to find the specific target or critical molecules to drive our immortal mouse 
melanocytes to melanoma cells. Functional analyses employing ectopic 
overexpression reveal the roles of DUSP6 and phosphorylated ERK in melanoma 
progression in our xenograft model. In addition, the roles of DUSP6 in negatively 
regulating ERK1/2 activity and inhibiting tumourigenicity are described in a human 
melanoma cell line. Chapter 5 investigates the role of the MAPK pathway regulated 
ERCC1 and XPF expression in chemotherapy resistance. We analyze the expression 
levels of ERCC1 and XPF after cisplatin treatment. Moreover, using a MEK 
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inhibitor, we provide here correlation between activation of the MAPK pathway and 
ERCC1 and XPF induction in a human melanoma cell line. The roles of DUSP6 in 







































































Material and methods  





2.1 Material  
 
 
2.1.1 General reagents and equipment  
 
 
Amersham: enhanced chemiluminescence solution (ECL) fluorescence kit.  
 
 
Applied Biosystems: 7900HT Fast Real-Time PCR System, High Capacity RNA-to-
cDNA Kit, TaqMan® Universal Master Mix, 384-well plates.  
 
 
Bioline: DNA Hyperladder I, 5X DNA Loading Buffer Blue. 
 
 
Biometra: Thermocycler.  
 
 
BioRad: Gel Doc 2000 System with Quantity One 4.6 software, Mini-PROTEAN 
Electrophoresis System, Mini-Trans Blot Cell.  
 
 




Fermentas: PageRulerTM Plus Prestained Protein ladder.  
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Fisher Scientific: 3M blotting paper, absolute alcohol, chloroform, Na2EDTA, filter 












Millipore (UK) Ltd: disposable sterile filter, Immobilon P PVDF membrane.  
 
 
Pierce Biotechnology: Bicinchoninic acid (BCA).  
 
 
Promega: 25mM magnesium chloride, 10x PCR buffer, 5x PCR buffer, Taq DNA 
polymerase, Oligo dT, RNasin, pGEM-T Easy® Vector Systems. 
 
 
Roche: Protease Inhibitor cocktail tablets. 
 
 
Sigma-Aldrich: ammonium persulphate (APS), DMSO, DTT, Na2EDTA, glycerol, 
propidium iodide, sodium chloride, sodium deoxycholate, sodium hydroxide, 
oligonucleotides, trypsin, Triton X-100, Tween 20. 
 
 
2.1.2 DNA manipulation reagents  




DNA isolation buffer: 10mM Tris HCl pH8.0, 400mM NaCl, 3mM EDTA, 1% 
(w/v) SDS. Stored at 4°C. 
 
 
DNA agarose loading dye: 20% glycerol, 100mM EDTA, 0.1% bromophenol blue or 
orange G. 
 
Proteinase K stock solution: 2mg/ml proteinase K, 100mM EDTA pH7.5, 2% (w/v) 
SDS. Stored at -20°C. 
 
 
PCA: 25 parts redistilled phenol, 24 parts chloroform, 1 part isoamyl alcohol.  
 
 
TAE electrophoresis buffer: 40mM Tris-acetate, 1mM EDTA. 
 
 
TBE electrophoresis buffer: 90mM Tris-HCl, 90mM boric acid, 2mM EDTA, pH8.3. 
 
 
2.1.3 RNA manipulation reagents  
 
 
RNAzolTMB: RNA isolation solvent. 
 
 
TE buffer: 10mM Tris-HCl, 1mM EDTA, pH8.0. 
 
 
2.1.4 Protein manipulation reagents 
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Protein sample buffer (4X): 250mM Tris-HCl, pH6.8, 2% SDS, 20% ß-
mercaptoethanol, 40% glycerol, 0.5% bromophenol blue.  
 
 
RIPA buffer: 25mM Tris-HCl, pH 7.2, 150mM NaCl, 1% Triton X-100, 0.1% SDS, 
1% deoxycholate, 1mM EDTA, 20mM NaF, 100uM orthovanadate, 1 protease 
inhibitor cocktail tablet (Roche Complete)/50ml. 
 
 
Running buffer: 192mM Glycine, 25 mM Tris, 0.1 % (w/v) SDS, pH8.3. 
 
 
SDS PAGE separating gel: 8-15% (w/v) 29:1 acrylamide: bis-acrylamide, 0.1% (w/v) 
SDS, 390mM Tris-HCl, pH8.8, 0.08% (v/v) TEMED, 0.1% (w/v) APS.  
 
 
SDS PAGE stacking gel: 5% (w/v) 29:1 acrylamide: bis-acrylamide, 0.1% (w/v) 
SDS, 129mM Tris-HCl, pH6.8, 0.1% (v/v) TEMED, 0.1% (w/v) APS.  
 
 
Transfer buffer: 192mM Glycine, 25 mM Tris, pH 8.3. 
 
 
TBS: 5mM Tris-HCl, 75mM NaCl, pH 7.4. 
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Oligonucleotides were purchased from Sigma and resuspended in dH2O to 





Table 2.1 PCR primers  
 
Name  Sequence 5'-3' Description 
BRAF exon 
14 forward  
TCCTGTCAGGCAGGTCAATATAG mouse BRAF exon 14 
forward primer  
BRAF exon 
14 reverse 
ATACATACCATGTCCCACTTGTGC mouse BRAF exon 14 
reverse primer  
BRAF exon 
18 forward  
TGTTGACTTTCAGAGGACATACG mouse BRAF exon 18 
forward primer  
BRAF exon 
18 reverse 
CCTGTGAGTAGTGGGAACTGTGAA mouse BRAF exon 18 
reverse primer  
H-exon1-A 
forward  
CTGGCCGTGCTGGCAGTG Normal human 
ERCC1 transcript 
forward primer  
H-exon 2-3 
reverse  
ATTTGTGATACCCCTCGACGAG Normal human 
ERCC1 transcript 
reverse primer  
hskin2RT 
forward 
CCACGACCTCCGCGGTCCTCCAGAACC Larger Human 
ERCC1 transcript 
forward primer  
hskin3RT 
forward  























Table 2.2 q-PCR primers 
 
Name  Code  Description 
ERCC1  
Human  
Hs01012158_ml q-PCR TaqMan ERCC1 primer pair from 
Applied Biosystems.   




Hs00193342_ml q-PCR TaqMan ERCC4 primer pair from 
Applied Biosystems.   
ACTB 
Human  4310881E 
 
q-PCR TaqMan Beta-actin primer pair from 




ERCC1-RT5-NOTSS Custom plus TaqMan larger ERCC1 primer 
pair from Applied Biosystems. 
 
Table 2.3 5′ RACE primers 
 
 
Name  Sequence 5'-3' Description 
H-exon 2-3 
reverse  
ATTTGTGATACCCCTCGACGAG Normal human 
ERCC1 transcript 
reverse primer  
Hskin4RT 
reverse  
TGTACAGAGATCGCCCTGCTCTATGC Larger Human 
ERCC1 transcript 
reverse  primer 
REV1  CGGTCCTCCAGAACCATAGA Larger Human 
ERCC1 transcript 




TTTTTTTV (V=A, C or G) 
Anchor primer  
PCR 
anchor  




2.1.6 Plasmids  
 
 
pcDNA3.1/V5-His-DUSP6/MKP-3 was kindly provided by Professor Toru Furukawa 
(Tohoku University School of Medicine, Japan). This plasmid is able to express a 
histidine and V5 tagged version of DUSP6 from the human cytomegalovirus (CMV) 
promoter and also contains a neomycin selectable marker.  
 
 
The pMCL-MKK1-R4F and pMCL-MKK2-KW71A plasmids were kindly provided 
by Professor Natalie Ahn (University of Colorado, Boulder). pMCL-MKK1-R4F and 
pMCL-MKK2-KW71A are able to express the constitutively active forms of MEK1 
and MEK2 from the CMV promoter. They also contain a hygromycin selectable 
marker. 





2.1.7.1 Primary antibodies 
 
 
Table 2.4 Primary antibodies in this study  
 
 
Code  Target kDa Supplier Dilution 
9101S Phospho-ERK 
(human, mouse） 
42/44KD Cell signaling  1:500 
9102 ERK  
(human, mouse) 
42/44KD Cell signaling 1:1000 
9121S Phospho-MEK1/2 
(human, mouse) 
45KD Cell signaling 1:500 
9122 MEK1/2 
(human, mouse) 
45KD Cell signaling 1:500 
9271S Phospho-AKT 
(human, mouse) 
60KD Cell signaling 1:500 
9272 AKT 
(human, mouse) 
60KD Cell signaling 1:500 
9559 PTEN 
(human, mouse) 
54KD Cell signaling 1:1000 
SC-1207 p16 
(human, mouse) 
16KD Santa Cruz 1:1000 
MAB375 GAPDH (human, 
rat, mouse) 
37KD Chemicon  1:20000 
EPR129Y DUSP6 
(human, mouse) 
42KD Abcam  1:2000 
FL-297 ERCC1 
(human, mouse) 
35KD  Santa Cruz 1:1000 
Ab-5 XPF 
(human, mouse) 




2.1.7.2 Secondary antibodies 
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HRP-conjugated forms of goat anti-rabbit (P0448 1:3000) and rabbit anti-mouse 
(P0260 1:2000) antibodies were from Dako. 
 
2.1.8 Cell culture reagents 
 
 
BD Biosciences: Matrigel™ Basement Membrane Matrix.  
 
 
Beckman-Coulter: Coulter counter, FACScan machine, Isoton®II diluents. 
 
 
Biotium: Calcein AM.  
 
 
Greiner Bio One: Cellstar® cell culture flasks, cell culture dishes, cell culture plates, 
pipettes, cell scrapers. 
 
 
Invitrogen: GIBCO® Dulbecco's Modified Eagle's Medium without calcium (No 
calcium DMEM), Dulbecco's Modified Eagle's Medium (DMEM), GIBCO™ 
Modified Eagle’s Medium (MEM) (2X) ，  RPMI-1640, 400mM L-glutamine, 
100mM non-essential amino acids (NEAA), 100 mM sodium pyruvate (NaPy), 
Geneticin G-418 Sulphate, Hygromycin B.  
 
 
LONZA: Foetal calf serum (FCS). 
 
 
R&D Systems: Methylcellulose Stock Solution.  
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Sigma-Aldrich:: beta-mercaptoethanol, cholera toxin, DMSO, endothelin penicillin 
G, streptomycin, Corning® Transwell® polycarbonate membrane inserts (pore size 




1X HBS (HEPES buffered saline): 25mM HEPES, 140mM NaCl, 1.5mM Na2HPO4, 
pH 6.95.   
 
 
PBS: 140mM NaCl, 3mM KCl, 2mM KH2PO4, 10mM Na2HPO4, pH 7.4. 
 
 
Trypsin-EDTA: 10X trypsin (Cambrex) diluted in PBS to 0.25% (w/v) trypsin, 1mM 
EDTA. Stored at -20°C.  
 
 
2.1.9 Mammalian cells and culture media 
 
 
Table 2.5 Cell lines used in this study  
 
 
Cell   Source  Description 




3-1-1 Melton group 
 
Immortalized mouse 
melanocyte cell line 
3-1-1T1 Melton group 
 
Tumourigenic derivative of  
3-1-1 
3-1-1T2 Melton group 
 
Tumourigenic derivative of  
3-1-1 
5-1 Melton group 
 
Immortalized mouse 
melanocyte cell line 
5-1T1 Melton group 
 
Tumourigenic derivative of  
5-1 
5-1T2 Melton group 
 
Tumourigenic derivative of  
5-1 
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13-4-1 Melton group 
 
Immortalized mouse 
melanocyte cell line 
13-4-2 Melton group 
 
Immortalized mouse 
melanocyte cell line 
13-4-3 Melton group 
 
Immortalized mouse 
melanocyte cell line 
13-4-4 Melton group 
 
Immortalized mouse 
melanocyte cell line 
13-4-5 Melton group 
 
Immortalized mouse 
melanocyte cell line 
13-1 Melton group 
 
Immortalized mouse 
melanocyte cell line 
13-2 Melton group 
 
Immortalized mouse 
melanocyte cell line 
PEO14 Dr. Charlie Gourley, Edinburgh 
Cancer Research Centre 
Human ovarian tumour cell line
A2780 Dr. Charlie Gourley, Edinburgh 
Cancer Research Centre 
Human ovarian tumour cell line
HACAT Professor N.E.Fusenig, German 
Cancer Research Center  
Human keratinocyte cell line 
MRC5V1 Prof. A. Lehmann. MRC Cell Mutation 
Unit, University of Sussex 
Human fibroblast cell line 
 
 
Human melanoma cell cultures were maintained in DMEM media with 10% FCS, 
25U/ml penicillin and 25ug/ml streptomycin. 
 
 
Human ovarian tumour cell cultures were maintained in DMEM media with 10% 
FCS, 25U/ml penicillin and 25ug/ml streptomycin. 
 
 
Human fibroblast cell culture was maintained in DMEM media with 10% FCS, 
25U/ml penicillin and 25ug/ml streptomycin. 
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Human keratinocyte cell culture was maintained in low-calcium DMEM with 8% 
chelexed FCS, 25U/ml penicillin and 25ug/ml streptomycin and 1ug/ml keratinocyte 
growth factor.  
 
 
Mouse melanocyte cell cultures were maintained in RPMI-1640 media with 10% 
FCS, 25U/ml penicillin and 25ug/ml streptomycin. 
 
 
2.1.10 Bacterial strains 
 
 
Sub-cloning Efficiency™ DH5α™ Competent Cells were purchased from 
Invitrogen, and were grown on/in LB medium at 37°C. 
 
 
2.1.11 Bacterial culture media and related reagents 
 
 
Ampicillin stock solution: 50mg/ml ampicillin in dH2O. 0.2μm filter sterilised and 
stored at -20°C. Optimal working concentration in LB was 100μg/ml. 
 
LB Broth media: 10g/L Tryptone, 5g/L Yeast extract, 5g/L NaCl, pH7.4.  
 
 
Blue/white screen LB agar plates: 20μl of 40mg/ml X-gal was spread over LB agar 
plates containing the antibiotic ampicillin. The plates were dried at room temperature 
before being used the same day. 
 
 
X-gal stock solution: 40mg/ml X-gal in dimethylformamide. Stored at -20°C and 
protected from light. 
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2.2 Methods  
 
 
2.2.1 Cell culture  
 
 
2.2.1.1 Mammalian cell culture  
 
 
All cells were cultured using appropriate media in an incubator at 37°C with 5% CO2. 
Media were changed every two days, using aseptic technique inside a Category Ⅱ 
Biological Safety hood. When cells were confluent, the flask was washed with PBS 
before being incubated with trypsin-EDTA solution. Trypsin-EDTA solution can 
mediate the detachment of cells from the surface of the flask. Once cells dissociated 
from the surface, fresh media was added and mixed with the cells. The resulting 
single cell suspension was centrifuged at 1,300 rpm for 5min to pellet cells. The cells 
were resuspended with fresh medium. The required volume of cell suspension was 
mixed with an appropriate volume of fresh media and transferred into a new cell 
culture flask.  
 
 
2.2.1.2 Liquid nitrogen frozen stock  
 
 
For permant storage, cells were trypsined and pelleted as described above and then 
resuspended in appropriate culture medium supplemented with 10% FCS and 10% 
DMSO. The cell stock was frozen slowly in a -70°C freezer and then transferred to a 
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2.2.1.3 Counting of cells  
 
 
Cells were diluted 1:100 in isoton and counted using the Coulter Counter Z series. 
 
 
2.2.1.4 Methylcellulose assay 
 
 
1.8% (w/v) agar solution was prepared in PBS and then boiled. The melted agar 
solution was diluted 1:1 in fresh 2X MEM medium supplemented with 10% Foetal 
Calf Serum (FCS), 100mM non-essential amino acids (NEAA) and 100mM 
penicillin-streptomycin (P/S) and then poured into 6-well tissue culture plate 
(1ml/well) and left until solid. 2.8% (w/v) methylcellulose solution was prepared in 
DMEM medium supplemented with 10% Foetl Calf Serum (FCS), 100mM non-
essential amino acids (NEAA) and 100mM penicillin-streptomycin (P/S). An 
appropriate number of single cells were mixed with 2.8% methylcellulose solution 
and then 2ml was poured on the bottom agar layer. The 6-well tissue culture plate 
was incubated at 37°C and 5% CO2 for up to 2 weeks. The colony number and size 




2.2.1.5 Transwell migration assay  
 
 
Matrigel was diluted 1:1 in ice cold PBS. 100ul of this dilution was added into each 
transwell and incubated 30min at 37°C and 5% CO2 to allow it to set. Cell 
suspensions were prepared in their normal growth medium at an appropriate density. 
100ul of the cell suspension was seeded onto the transwell filters. The transwells 
were placed carefully in the 24-well tissue culture plate and incubated for 3 hours at 
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37°C and 5% CO2 to allow cells to attach to transwell filters (Fig 2.1). Then the 
transwells were washed with serum free DMEM medium 3 times and then set in 
serum free DMEM medium. Fresh DMEM medium supplemented with 10% Foetal 
Calf Serum (FCS), 100mM non-essential amino acids (NEAA) and 100mM 
penicillin-streptomycin (P/S) was gently added onto the top of the matrigel (Fig 2.1). 
The cells can invade into the matrigel in response to a chemotactic stimulus (in this 
case 10% serum) (Fig 2.1). The plate was incubated at 37°C and 5% CO2 for 72 
hours. Then cells were then labelled with calcein AM dye and visualized in the 
matrigel at 15um intervals by confocal sectioning. The relative cell number in each 
section was analyzed using Image J software and expressed relative to the cell 
number in the section that represented the base of the transwell filter.  
 










The transwell sitting in the 24-well tissue culture plate. For explanation, see text. 
 
2.2.1.6 Drug treatments of cells  
 
 
Drug ( cisplatin or PD0325901) was added to the cell culture 24 hours after plating to 
give a designed final concentration. Treated cells were incubated at 37°C and 5% 
CO2 and harvested at appropriate time points.  
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2.2.1.7 Sulforhodamine B (SRB) assay  
 
 
Cells were plated in 96 well tissue culture plates with 150ul of medium per well at 
the appropriate seeding density and incubated at 37°C and 5% CO2. To determine 
cell growth rate, the plates were directly assayed 72-hour (DAY3), 96-hour (DAY4) 
and 120-hour (DAY5) after cell plating. For drug toxicity determinations, 50ul of 
medium with cisplatin was added to each well of the 96-well tissue culture plate to 
give the designed final cisplatin concentration. The plates were assayed 120-hours 
(DAY 5) following the drug treatment. For the assay, 50ul of the 25% TCA solution 
were added to each well, and incubated at 4°C for 1h to fix the cells. Plates were 
washed out under running tap water for 10 times and dried at 60°C in an oven. 50ul 
of 0.057% (w/v) SRB Dye solution were added to each well, incubated at room 
temperature for 30min, washed with 1% (v/v) acetic acid for 4 times and then dried 
at 60°C in an oven. 150ul of 10mM Tris-base solution (pH 10.5) was added to each 
well and incubated at room temperature for 60min to solubilise the protein bound 
dye. The plates were read at 510nm by a plate reader.  
 
 
2.2.1.8 Preparation of genomic DNA from mammalian cell lines  
 
 
Cells were cultured till 70% confluent before being harvested. At the time of 
harvesting, the medium was discarded and cells were rinsed in sterile phosphate-
buffered saline (PBS) twice. Trypsin-EDTA was added and the cells were incubated 
for 2-3min. Post incubation, fresh culture medium was added to deactivate the 
trypsin-EDTA. Then harvested cells were centrifuged at 1,300 rpm for 5min, the 
supernatant was discarded. 750ul DNA isolation buffer and 15ul proteinase K 
solution (20mg/ml) were added to the cells and incubated for 12h at 37℃. Then the 
debris was spun down and the supernatant was transferred to a fresh eppendorf 
containing 750ul PCA. An emulsion was formed by shaking tubes to mix the PCA 
Genetic changes in melanoma progression  
77 
and our samples. The tubes were spun at top speed in a microfuge for 5min. Then the 
supernatant was transferred to another fresh tube. Isopropanol was added to the tubes 
to precipitate DNA. DNA was spun down at top speed for 5min and supernatant was 
poured off. DNA was washed in 750ul of 70% (v/v) ethanol and spun for 3min. 
Supernatant was poured off carefully avoiding DNA loss. DNA was allowed to air 
dry for 10-15min and resuspended in 150ul sterile dH2O. 
 
 
2.2.1.9 Preparation of RNA from mammalian cell lines  
 
 
The total RNA extraction from mammalian cell lines was performed using 
RNAzolTMB. Cells were cultured till 70% confluent before being harvested. First, 
cells were washed by cold PBS twice, and then lysed directly by the addition of 
RNAzolTMB (0.2ml per 106 cells). 0.2ml chloroform per 1ml RNAzolTMB was added 
to extract total RNA by vigorous shaking of the mixture for 30sec. The mixture was 
stored on ice for 5min and then centrifuged at 12,000g at 4°C for 15min. The 
aqueous phase where RNA remained was transferred to a fresh tube and mixed with 
an equal volume of isopropanol. RNA was allowed to precipitate at room 
temperature for 10min and then centrifuged at 7,500g for 5min. The supernatant was 
removed and total RNA was washed using 75% (v/v) ethanol then centrifuged at 
7,500g for 5min. The pellet was allowed to air dry at room temperature and then 
dissolved in 50ul of RNase-free dH2O. Total RNA was stored at -80°C before use.  
 
 
2.2.1.10 Protein extraction from mammalian cell lines  
 
 
Cells were cultured till 70% confluent before being harvested. First, cells were 
washed by cold PBS twice, and then collected in PBS by a cell scraper. After that, 
the harvested cells were centrifuged at 1,300 rpm for 5 minutes to remove PBS. The 
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cell pellet was resuspended in 50-100ul ice-cold RIPA buffer for 15 min and 
centrifuged at 13,000 rpm at 4°C for 15min. The supernatant containing total protein 
extract was collected and stored at -80°C. 
 
 
2.2.2 Molecular Biology Methods  
 
 
2.2.2.1 Polymerase chain reaction  
 
 
Amplification of specific genes from DNA templates was performed by the 
Polymerase chain reaction (PCR). Routine PCRs contained 0.5pmol/ul forward and 
reverse primers, 0.25mM dNTPs, 2.5mM MgCl2, 100ng genomic DNA template, 1U 
Taq DNA polymerase (Promega), Taq PCR buffer (Promega) and water in a 50ul 
reaction volume. A negative control containing no template DNA was also prepared. 
PCRs were carried out by DNA denaturation at 94°C for 5min, followed by 30-38 
cycles of DNA denaturation at 94°C for 1min, primer annealing at 50-70°C for 1min 
and DNA polymerase extension at 72°C for 1min/kb PCR product, with a final 
extension of PCR products at 72°C for 5min after cycling. The primer annealing 
temperature was determined based on specific primer design and empirical 
observations. PCR products were stored at 4°C before use.   
 
 
2.2.2.2 Separation of DNA fragments by electrophoresis  
 
 
DNA fragments were separated by gel electrophoresis using 1-2% (w/v) agarose 
containing 0.5X TBE Buffer and 0.5ug/ml ethidium bromide for visualization. 5X 
loading dye was added to DNA samples prior to loading. Electrophoresis was 
performed at 30-100V in a horizontal tank with 0.5X TBE Buffer. DNA fragment 
bands were visualized by UV irradiation and captured using Gel Doc EQ software. 
DNA Hyperladder I was used as size marker.  
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2.2.2.3 Purification of DNA fragments from agarose gels  
 
 
DNA fragments required for cloning were separated by agarose gel electrophoresis 
and purified using the QIAquick gel extraction kit (QIAGEN) following the 
manufacturer’s instructions.  
 
 
2.2.2.4 Quantification of DNA/RNA 
 
 
The concentration of DNA/RNA was quantified by spectrophotometry at 260nm 
using the NanoDrop Spectrophotometer (ND-1000). 2ul of samples were loaded for 
quantification by measuring absorbance at 260nm after blanking. The purity of DNA 
and RNA samples were estimated by measuring the 260:280 absorbance ratios which 
are between 1.8 and 2.0 for pure preparations. Concentrations were determined based 
on OD260nm of 1.0 given by 50ug/ml of double-strand DNA or 40ug/ml of RNA.  
 
 
2.2.2.5 DNA ligation  
 
 
DNA ligation reactions were performed in a 10ul volume containing 2X Rapid 
Ligation Buffer (132mM Tris-HCl, 20mM MgCl2, 2mM dithiohreitol, 2mM ATP, 
pH7.6), 3 Weiss units T4 DNA ligase and 50ng vector DNA. A 3:1 molar ratio of 
insert DNA to vector DNA was present in each reaction. DNA ligation reactions 
were incubated for either 1h at room temperature or at 4°C overnight, and then 5ul 
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2.2.2.6 Transformation of bacteria by heat shock 
 
 
Aliquots of DH5α competent bacterial cells were thawed on ice. 10-100ng of 
plasmid DNA, or 5ul of a ligation reaction, was added to 50ul competent bacterial 
cells, and mixed gently. A positive control consisting of pUC19 plasmid DNA 
(250pg), and a negative control consisting of dH2O alone, was also included in each 
group of bacterial transformations. The mixture of cells and DNA was incubated on 
ice for 30min, before being heat shocked in a 42°C water bath for 20s and incubated 
on ice for 2min. Then 950ul of LB broth was added and the transformations were 
incubated at 37°C for 1h with shaking (225rpm). Aliquots of the transformations 
were then plated out onto warm LB agar plates containing the appropriate antibiotic. 




2.2.2.7 Amplification of plasmid DNA using DH5α 
 
 
Single bacterial colonies that showed positive in blue/white screening for 
recombination (ie white colonies) were picked out and grown in 3ml LB medium 
containing 50ug/ml ampicillin at 37°C overnight.  
 
 
2.2.2.8 Isolation of plasmid DNA from bacteria  
 
 
Plasmid DNA was isolated from bacteria using Qiagen plasmid DNA Miniprep kit 
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2.2.2.9 DNA sequencing 
 
 
All sequence analysis was carried out by the Sequencing Unit (MRC Human Genetic 
Unit, Edinburgh) using the BigDye Terminator V3.1 Cycle Sequencing kit (ABI). 
DNA sequencing reactions contained 2ul BigDye Terminator v3.1, 50-300ng DNA 
and 3.2pmol primer in a 10ul reaction volume. M13 forward and M13 reverse 
primers were used to sequence BRAF exon14 and exon18 from both sides. The 
PCRs were performed under the following conditions: DNA denaturation at 96°C for 
1min, followed by 25 cycles of DNA denaturation 96°C for 30sec, primer annealing 
at 50°C for 15sec and extension at 60°C for 4 min. PCR products were cleaned up by 
ethanol and air dried in the dark at room temperature for 15min and then sent to the 
Sequencing Unit for analysis.   
 
 
2.2.2.10 Transfection of mammalian cells by electroporation  
 
 
50ug of plasmid DNA was suspended in 800ul 1X HBS. Cells were harvested, 
counted and washed with cold 1X HBS. 106 cells were then mixed with the plasmid 
DNA in 1X HBS and incubated at room temperature for 15min. The plasmid 
DNA/cell suspension was transferred to an electroporation cuvette and electroporated 
at an appropriate voltage and 500µF capacitance. After that, the mixture in the 
cuvette was incubated at room temperature for 10min. The cells were transferred to 
90mm dishes containing fresh culture media with 10% FCS and incubated at 37°C 
and 5% CO2. 
 
 
2.2.2.11 Transfection of mammalian cells by calcium phosphate  
 
 
Cells were plated to 90mm dishes at the required density and incubated overnight at 
37°C and 5% CO2. 10ug plasmid DNA was suspended in 1ml 1X HBS. 62ul of 2M 
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CaCl2 was slowly added to the suspension drop by drop and incubated at room 
temperature for 45min. Cell culture medium was replaced with plasmid DNA/CaCl2 
mixture and incubated at room temperature for 20min. After that, appropriate cell 
growth medium was added to the dishes and they were incubated overnight at 37°C 
and 5% CO2.  
 
 
2.2.2.12 Selection of stable transformants  
 
 
In generating stable long-term clones it was necessary to identify clones in which the 
DNA had integrated into the host genome. This was accomplished by the inclusion 
of a drug resistance marker in the transfected DNA and subsequent selection with the 
appropriate drug. The concentration of the drug used for selection varied according 
to the antibiotic and the cell line used. Cells were maintained in non-selective 
medium for 2-3 days post-transfection before they were replated in selective media. 
The selection was maintained for 1-2 weeks with frequent media changes to 
eliminate dead cells and continued until discrete colonies were visualized. The 




2.2.2.13 5′ RACE assay  
 
 
Characterisation of the 5′ end of the human larger ERCC1 transcript was carried out 
using the 2nd Generation 5′/3′ RACE kit (Roche) following the manufacturer’s 
instruction (Fig 2.2). In brief, the first strand of cDNA was synthesised from total 
RNA using an ERCC1-specific primer H exon 2-3 with deoxynucleotides and reverse 
transcriptase. The synthesised cDNA was then purified using High Pure PCR 
Product kit (Roche) and a homoploymeric A-tail was added to the 3′ end of the 
cDNA using terminal transferase. The tailed cDNA was PCR amplified using a 
second ERCC1-specific primer Hskin 4RT REV in combination with oligo dT-
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anchor primer. To further amplify this cDNA, a further round of nested PCR was 
performed using internal primers PCR-anchor and REV1. The PCR products were 
separated by 1.5% agarose gel and cloned into the p-GEM T-EASY vector for 
sequencing analysis.  
 
 




Using the RNA of human ovarian cell line PEO14 with cisplatin treatment for 48h and H exon 2-3 primer 
Purification 
Using High Pure PCR product purification kit 
Tailing 
Using dATP and terminal transferase
PCR
Using Hskin 4RT REV and Oligo dT-anchor primer 
Specific PCR product 
Nested PCR




2.2.2.14 Reverse transcription of RNA 
 
 
Reverse transcription of RNA was performed in a 15ul volume using High Capacity 
RNA-to-cDNA Master Mix containing MgCl2, dNTPs, recombinant RNase inhibitor 
protein, reverse transcriptase, random primers and Oligo(dT) primer and stablizers. 
The reverse transcription of RNA reactions contained 3ul RNA (10-1000ng), 8ul 
deionized water and 3ul High Capacity RNA-to-cDNA Master Mix. The reverse 
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transcription of RNA was carried out for 25°C for 5min; 42°C for 30min, 85°C for 
1min. cDNA products were stored at 4°C before use.  
 
 
2.2.2.15 Real-time quantitative polymerase chain reaction  
 
 
Real-time quantitative polymerase chain reactions were used to quantify the cDNAs 
of interest using Taqman® Gene Expression Assay and Applied Biosystems 7900HT 
Fast Real-Time PCR System. The Taqman probe contains a reporter dye at the 5′ end 
of the probe and a quencher dye at the 3′ end of the probe. During the reaction, 
cleavage of the probe by AmpliTaq Gold DNA Polymerase separates the reporter 
dye and the quencher dye, which leads to increased fluorescence of reporter. 
Accumulation of PCR products is detected directly by monitoring the increase of 
fluorescence of the reporter dye. real-time quantitative polymerase chain reactions 
were prepared in a 20ul volume containing 1ul specific 20X Taqman Gene 
Expression Assay, 10ul 20X Taqman Gene Expression Master Mix, 4ul cDNA 
template (10-100ng), 5ul RNase-free water. The specific Taqman Gene Expression 
Assays each contain specific forward and reverse primers. The Taqman Gene 
Expression Master Mix is optimized for TaqMan reactions and contains AmpliTaq 
Gold DNA Polymerase, AmpErase UNG, dNTPs with dUTP, Passive Reference dye, 
and optimized buffer components. Each cDNA sample was assayed in triplicate with 
the specific primer pair. To evaluate the primers and PCR efficiency, a dilution series 
of a cDNA sample was also analysed in triplicate with the specific primer pair. In 
addition, a no template cDNA reaction was included as the negative control. Routine 
real-time quantitative polymerase chain reaction conditions were as followed: 
AmpliTaq Gold Enzyme activation at 95°C for 10min, then 40 cycles of DNA 
denaturation at 95°C for 10min, primer annealing and DNA polymerase extension at 
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2.2.3 Protein detection  
 
 
2.2.3.1 Protein quantification  
 
 
Protein concentrations were measured using the BCA Assay Kit (Pierce) in a 96-well 
plate. Samples were diluted 1:10 in dH2O to 25ul. dH2O was used as the blank 
control. 200ul of the reagents of the BCA Assay Kit were mixed with protein sample 
and incubated at 37°C for 30min. The OD values of the protein samples were 
determined at 562 nm using a plate Spectrophotometer (MRX, Dynatech). The 
concentrations of protein samples were calculated based on the standard curve 






Proteins were separated on the basis of their molecular weight by denaturing SDS 
polyacrylamide gel electrophoresis (SDS PAGE). SDS-PAGE was prepared using a 
Mini-PROTEAN3 electrophoresis system (Bio-Rad). Two sequential gels were 
actually made up. The bottom gel, called the resolving gel, was to separate protein. 
Concentration of polyacrylamide in the resolving gel depended on the molecular 
weight of the protein of interest. The top gel, called the stacking gel, was to form 
thin, sharply defined bands. After the gels were set up, the comb in the stacking gel 
was removed and the gels were clamped to the electrophoretic apparatus. Then the 
top electrolyte compartment was filled with running buffer. Appropriate amounts of 
protein sample were prepared with 4X sample buffer and were heated at 95°C for 
5min to improve denaturation before being added to the bottom of the gel well. 5ul 
of PageRulerTM Plus Prestained Protein ladder (Fermentas) was loaded as size 
marker. Protein samples were separated by electrophoresis in running buffer at 80V 
for the stacking gel and 100V for the resolving gel. 
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2.2.3.3 Western blotting  
 
 
Equivalent amounts of total protein were separated by 10% SDS-PAGE. After that, 
protein was transferred from SDS PAGE onto PVDF membrane according to the 
method of Towbin (1979) at 40 mA at 4°C overnight. The membrane was washed 
with TBS-T once, and then blocked with 5% non-fat milk or 5% BSA for 1 hour at 
room temperature and detected with primary antibody at optimal concentrations in 
5% (w/v) milk or 5% (w/v) BSA for 1 hour at room temperature or overnight at 4°C. 
After the primary antibody incubation, membrane was washed with TBS-T for 5min, 
3 times and then detected with an appropriate secondary antibody at optimal 
concentrations in 5% non-fat milk or 5% BSA for 45-60 min. Finally, the membrane 
was washed with TBS-T 3 times, 10 min each. Immunoreactive bands were 
visualized using enhanced chemiluminescence solution (ECL) or ECL-Plus 
(Amersham biosciences, Buckinghamshire, UK).  
 
 
2.2.2.4 Fluorescent ECL plus western blot detection with Storm 
image analysis system  
 
 
After protein transfer and antibody incubation, the PVDF membrane was incubated 
in ECL or ECL Plus detection reagent for 5min. The wet membrane was covered 
with a plastic hybridization bag slowly to avoid air bubbles. After that, the membrane 
was scanned using the Blue Fluorescence/Chemifluorescence scan mode 840 with a 
PMT voltage setting of between 650 and 800V. The intensities of bands on the 


















































Identification of a new type of 
tumourigenic mouse melanocytes 





Malignant melanoma is the most aggressive tumour of the skin. If melanoma is 
diagnosed early it can be cured by surgical excision, with about 80% of melanoma 
patients being cured in this way. However, metastatic malignant melanoma is 
resistant to current therapeutic approaches and spreads very quickly, with a median 
survival of 6 to 9 months (Balch et al. 2001). Recent studies indicated that a 
combination of altered regulation of various effectors in different molecular 
pathways was involved in the progression of normal melanocytes to malignant 
melanoma (Smalley et al. 2006). A better understanding of molecular changes 
underlying melanoma progression will contribute to the diagnosis, prognosis, 
classification and treatment of melanoma.  
 
 
Both the MAPK and the PI3K pathways were reported to be constitutively active in 
melanoma (Meier et al. 2005). Up to 70% of melanoma was characterized by 
mutations in BRAF. Mutations of BRAF have been proposed to activate the MAPK 
pathway. The most frequent BRAF mutation involved a glutamate for valine 
substitution at position 600 (V600E) (Brose et al. 2002, Gorden et al. 2003). In 
addition, 5-36% of primary melanomas had NRAS mutations (Carr and Mackie 
1994). However, some reports also indicated that the mutations in these genes were 
mutually exclusive, and mutation frequencies of RAS and BRAF in primary 
melanoma did not seem to correlate with overall survival (Houben et al. 2004, 
Shinozaki et al. 2004). Moreover, only about 54% of primary human melanomas had 
ERK activation (Cohen et al. 2002, Uribe et al. 2006, Zhuang et al. 2005), whereas 
93% of primary melanomas with BRAF V600E mutation had activated ERK (Uribe 
et al. 2006). Previous studies also showed that some subtypes of melanoma without 
BRAF or NRAS mutations did not have high level of activation of ERK (Shields et 
al. 2007). Furthermore, DUSP6, which can dephosphorylate activated ERK and shut 
down the MAPK pathway, is often lost in pancreatic, lung and ovarian cancers. 
Down regulation of DUSP6 may promote activation of ERK and uncontrolled cell 
growth (Bermudez et al. 2010).  
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PTEN deletion results in activation of the PI3K pathway. PTEN somatic mutations 
were found in 30% of melanoma cell lines and 10% of human tumour material (Lin 
et al. 2008). Recent studies indicated activation of AKT was associated with the 
activation of NF-kB which is thought to be an important transcription factor involved 
in the control of cell proliferation, survival and apoptosis in melanoma (Dhawan et al. 
2002). Moreover, The PI3K-AKT pathway regulated proliferation of melanoma cells 
through the inactivation of GSK-3b, preventing cyclin D1 degradation. (Diehl et al. 
1998). In addition, the activation of AKT resulted in suppression of apoptosis of 
melanoma cells though inactivation of many pro-apoptotic proteins including BAD 
and caspase-9 (Palmieri et al. 2009). Furthermore, AKT activation could lead to 
phosphorylation and inactivation of RAF. This inactivation of the MAPK pathway 
may result in loss of differentiation or senescence (Palmieri et al. 2009, Zimmermann 
and Moelling 1999) .  
 
 
Data obtained from genetic and molecular studies over the past few years have 
indicated that CDKN2A mutations were more frequent in patients with a strong 
familial history of melanoma (Miller and Mihm 2006). CDKN2A is located on 
chromosome 9p21 and encodes two proteins: p16 and p14, which are known as 
tumour suppressors (Michaloglou et al. 2008). Studies showed that p16 was 
associated with melanocyte senescence. Activation of the MAPK pathway can 
induce cellular growth arrest by promoting cellular senescence. BRAF mutations 
were found to induce p16 expression and senescence in primary human melanocytes 
in vitro. Mutations of CDKN2A could result in inactivation of p16 and contribute to 




In our laboratory, immortal mouse melanocyte cell lines were derived from primary 
melanocyte cell culture of epidermis of newborn mice by infection with a retrovirus 
expressing SV40 T antigen (David Melton, unpublished). Studies showed that SV40 
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large T-antigen transformed human melanocytes cycled much more quickly and had 
a reduced requirement for basic fibroblast growth factor (bFGF), an essential 
melanocyte mitogen. However, the cells did not undergo complete transformation to 
the malignant phenotype remaining anchorage dependent and unable to form 
xenografts (Zepter et al. 1995). These features suggest that introduction of SV40 
large T antigen into melanocytes produces an intermediate stage between the normal 
and malignant cell which may render these cells unusually susceptible to additional 
genetic changes necessary for full expression of the malignant phenotype. The 
tumourigenicity of some of these cell lines has been investigated in xenograft assays. 
All 12 xenografts of the human melanoma cell line, A375, grew very rapidly, taking 
only 21 days to reach the maximum permitted size. Compared to this, all 12 
xenografts of our mouse melanocyte line, 5-1, showed a long latent period before 
commencing rapid growth until all reached the maximum permitted size by 59 days. 
Xenografts of our mouse melanocyte cell line, 3-1-1, showed an even longer latent 
period before commencing rapid growth and then only 2 of 12 xenografts grew, 
reaching the maximum permitted size by 115 days. Cells from some 5-1 and 3-1-1 
xenografts were reisolated into culture for analysis. Histologicaly, all 5-1 and 3-1-1 
xenografts showed the characteristics of malignant melanoma. Cells reisolated from 
3-1-1 tumours were xenografted to mice again and all formed large tumours in mice 
in 27 days, much more quickly than the parent cell line 3-1-1. 
 
 
Figure 3.1 Mouse xenograft model  
 
 
















A375 ( human melanoma  
control cell 
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Mouse melanocyte cell lines (3-1-1, 5-1) were isolated by infection of primary mouse 
melanocyte cultures with retrovirus expressing SV40T antigen. These cell lines with A375 
(human melanoma control) were xenografted to mice. 5-1 tumour (T) and 3-1-1 tumour cell lines 
were the cell lines re-isolated back into culture from independent 5-1 and 3-1-1 tumours. # 3-1-




Figure 3.2 Growth rates of A375, 5-1, 3-1-1 and 3-1-1T1 xenograft  
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A, Growth of A375, 5-1 and 3-1-1 xenografts in nude mice. The data are provided by Professor 
David Melton. The light blue line represents the average volume of xenografts from 6 mice with 
2 A375 xenografts per mouse. The purple line represents the average volume of xenografts from 
6 mice with 2 5-1 xenografts per mouse. The dark blue line represents the average volume of 
xenografts from 6 mice with 2 3-1-1xenografts per mouse.  
 
B, Growth of 3-1-1T1 xenografts in nude mice. The data are provided by David Melton. The 
dark blue line represents the average volume of xenografts from 6 mice with 2 3-1-1T1 
xenografts per mouse.  
 
 
The aim of this chapter is to investigate the genetic changes in our immortal 
melanocyte cell lines needed to form tumours in the xenograft experiment through 
comparison of 5-1 and 3-1-1 with 5-1 Tumour and 3-1-1 Tumour cell lines. 
 
 





3.2.1 Comparison of expression of phosphorylated ERK1/2 in our 
immortal mouse melanocyte cell lines and human melanoma cell line  
 
 
Previous studies showed that the MAPK pathway was involved in classic melanoma 
progression (Smalley 2003). To investigate the genetic changes in our immortal 
melanocyte cell lines needed to form tumours in the xenograft experiment, we 
decided to compare the expression of phosphorylated ERK1/2 in the MAPK pathway 
between our mouse tumour cell lines and their parental cell lines.  
 
 
Protein lysates obtained from our immortal mouse melanocyte cell lines (3-1-1, 3-1-
1T1, 3-1-1T2, 5-1, 5-1T1, 5-1T2) and human melanoma cell line (A375) were 
subjected to western blot analysis using an anti-phospho-ERK antibody to detect p-
ERK1 (42KD) and p-ERK2 (44KD). Total ERK and GAPDH levels of these samples 
were also determined by western blot to correct for different amounts of protein in 
the various samples. Experiments were repeated at least three times. p-ERK levels 




Human melanoma cell line A375 showed high expression of p-ERK as expected. 
However, to our surprise, the expression of p-ERK was significantly lower in our 
tumour cell lines than their parental cell lines (Fig 3.3A). Quantification analysis 
showed that the expression of p-ERK in 3-1-1 tumour cell lines decreased about 10-
fold compared to 3-1-1, while the expression of p-ERK in 5-1 tumour cell lines 
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A, Western blots showing protein levels of phosphorylated ERK (p-ERK) (top panel), and total 
ERK (t-ERK) (middle panel) and loading control GAPDH (bottom panel) in mouse melanocytes 
3-1-1, 3-1-1T1, 3-1-1T2, 5-1, 5-1T1, 5-1T2 and human melanoma A375 cells.  
 
B, Histogram showing mean level of p-ERK (+ SEM) from three independent experiments. p-
ERK levels are expressed relative to total ERK levels and are normalized to human melanoma 
A375 cells. One way ANOVA with Bonferroni’s Multiple Comparison Test was applied for 
statistical analysis between 3-1-1, 5-1 and their derivatives 3-1-1T1, 3-1-1T2, 5-1T1, 5-1T2. ***, 
P < 0.001.  
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3.2.2 Comparison of expression of phosphorylated MEK1/2 in our 
immortal mouse melanocyte cell lines and human melanoma cell line   
 
 
To investigate whether lower expression of p-ERK comes from inactivation of its 
upstream effector, we next detected the expression of phosphorylated MEK1/2 in our 
mouse tumour cell lines and their parental cell lines. As described before, protein 
lysates obtained from our immortal mouse melanocyte cell lines (3-1-1, 3-1-1T1, 3-
1-1T2, 5-1, 5-1T1, 5-1T2) and human melanoma cell line (A375) were subjected to 
western blot analysis using an anti-phospho-MEK1/2 antibody to detect p-MEK1/2. 
Total MEK1/2 and GAPDH levels of these samples were also determined by western 
blot to correct for different amounts of protein in the various samples. Experiments 
were repeated at least three times. p-MEK1/2 levels are expressed relative to total 
MEK1/2 levels and are normalized to human melanoma A375 cells. 
 
 
Our results indicated that human melanoma cell line A375 showed high expression 
of p-MEK1/2 as expected, while our tumour cell lines had lower expression of p-
MEK1/2 than their parental cell lines (Fig 3.4A). Quantification analysis showed that 
the expression of p-MEK1/2 in tumour cell lines was about 4-fold lower than their 
parental cell lines (Fig 3.4B). This suggested that lower expression of p-ERK may be 
due to a failure of upstream activation and that the MAPK pathway was shut down in 
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A, Western blots showing protein levels of phosphorylated MEK1/2 (p-MEK1/2) (top panel), and 
total MEK1/2 (MEK1/2) (middle panel) and loading control GAPDH (bottom panel) in mouse 
melanocytes 3-1-1, 3-1-1T1, 3-1-1T2, 5-1, 5-1T1, 5-1T2 and human melanoma A375 cells.  
 
B, Histogram showing mean level of p-MEK1/2 (+ SEM) from three independent experiments. p-
MEK1/2 levels are expressed relative to total MEK levels and are normalized to human 
melanoma A375 cells. One way ANOVA with Bonferroni’s Multiple Comparison Test was 
applied for statistical analysis between 3-1-1, 5-1 and their derivatives 3-1-1T1, 3-1-1T2, 5-1T1, 
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3.2.3 Comparison of expression of DUSP6 in our immortal mouse 
melanocyte cell lines and human melanoma cell line 
 
 
DUSP6 is the phosphatase that dephospharylates ERK1/2 and regulates the MAPK 
pathway through a feedback loop (Bermudez et al. 2010, Patterson et al. 2009). 
Higher expression of DUSP6 was found in melanoma cell lines with BRAF 
mutations (Bloethner et al. 2005). We suspected that overexpression of DUSP6 may 
also contribute to lower expression of p-ERK in our tumourigenic cell lines. 
Therefore, the levels of DUSP6 were detected in our immortal mouse cell lines and 
their tumour derivatives by western blotting. As described before, protein lysates 
obtained from our mouse immortal melanocyte cell lines (3-1-1, 3-1-1T1, 3-1-1T2, 
5-1, 5-1T1, 5-1T2) and human melanoma cell line (A375) were subjected to western 
blot analysis using an anti-DUSP6 antibody to detect DUSP6. The predicted 
molecular weight of DUSP6 is 42KD, this anti-DUSP6 antibody can detect a band of 
approximately 42KD/44KD. GAPDH levels of these samples were also determined 
by western blot to correct for different amounts of protein in the various samples. 
Experiments were repeated at least three times. DUSP6 levels are expressed relative 
to GAPDH levels and are normalized to human melanoma A375 cells. 
   
 
It was clear that the expression of DUSP6 was significantly higher in our tumour cell 
lines than their parental cell lines (Fig 3.5A). Quantification analysis showed that the 
expression of DUSP6 in 3-1-1 tumour cell lines increased about 4 to 6-fold compared 
to 3-1-1, while the expression of DUSP6 in 5-1 tumour cell lines increased 3 to 4-
fold compared to 5-1. DUSP6 expression levels of human melanoma cell line A375 
were higher than in our immortal melanocytes, but lower than in their tumour 
derivatives (Fig 3.5B). There was good inverse relationship between p-ERK and 
DUSP6 expression in our mouse cell line panel. It was possible the increased DUSP6 





Genetic changes in melanoma progression  
97 









































































A, Western blots showing protein levels of DUSP6 (top panel) and loading control GAPDH 
(bottom panel) in mouse melanocytes 3-1-1, 3-1-1T1, 3-1-1T2, 5-1, 5-1T1, 5-1T2 and human 
melanoma A375 cells.  
 
B, Histogram showing mean level of DUSP6 (+ SEM) from three independent experiments. 
DUSP6 levels are expressed relative to GAPDH levels and are normalized to human melanoma 
A375 cells. One way ANOVA with Bonferroni’s Multiple Comparison Test was applied for 
statistical analysis between 3-1-1, 5-1 and their derivatives 3-1-1T1, 3-1-1T2, 5-1T1, 5-1T2. ***, 
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3.2.4 Comparison of expression of phosphorylation of AKT in our 
immortal mouse melanocyte cell lines and human melanoma cell line 
 
 
Previous studies showed that the PI3K-AKT pathway was activated in human 
cancers (Cully et al. 2006, Hennessy et al. 2005). AKT activation can result in the 
phosphorylation and inactivation of RAF. This causes a decrease in downstream 
MEK and ERK activation and may lead to loss of differentiation or senescence 
(Palmieri et al. 2009, Zimmermann and Moelling 1999). Since our tumour cell lines 
shut down the MAPK pathway, it was possible that the PI3K-AKT pathway was 
activated and lower expression of p-ERK was because of hyperactivated AKT. To 
investigate this possibility, we examined expression of phosphorylation of AKT in 
our mouse cell line panel by western blotting. As described before, protein lysates 
obtained from our immortal mouse melanocyte cell lines (3-1-1, 3-1-1T1, 3-1-1T2, 
5-1, 5-1T1, 5-1T2) and human melanoma cell line (A375) were subjected to western 
blot analysis using an anti-phospho-AKT antibody to detect p-AKT. Total AKT and 
GAPDH levels of these samples were also determined by western blot to correct for 
different amounts of protein in the various samples. Experiments were repeated at 
least three times. p-AKT levels are expressed relative to total AKT levels and are 
normalized to human melanoma A375 cells. 
   
 
However, we found our tumour cell lines with low expression of p-ERK also had 
lower expression of p-AKT than their parental cell lines (Fig 3.6A). Our result also 
showed that molecular weight of p-AKT in the 3-1-1 tumourigenic cells was slightly  
higher than their parental cell line. Quantification analysis showed that the 
expression of p-AKT in 3-1-1 tumour cell lines was about 2-fold lower than 3-1-1, 
while the expression of p-AKT of 5-1 tumour cell lines was about 4 to 8-fold lower 
than 5-1. Human melanoma cell line A375 expressed similar low p-AKT levels as 
our mouse tumour cell lines (Fig 3.6B). This indicated inactivation of the MAPK 
pathway in our tumourigenic cell lines was not because of activation of the PI3K-
AKT pathway.  
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A, Western blots showing protein levels of phosphorylated AKT(p-AKT) (top panel), and total 
AKT (t-AKT) (middle panel) and loading control GAPDH (bottom panel) in mouse melanocytes 
3-1-1, 3-1-1T1, 3-1-1T2, 5-1, 5-1T1, 5-1T2 and human melanoma A375 cells.  
 
B, Histogram showing mean level of p-AKT (+ SEM) from three independent experiments. p-
AKT levels are expressed relative to total AKT levels and are normalized to human melanoma 
A375 cells. One way ANOVA with Bonferroni’s Multiple Comparison Test was applied for 
statistical analysis between 3-1-1, 5-1 and their derivatives 3-1-1T1, 3-1-1T2, 5-1T1, 5-1T2. ***, 
P < 0.001. 
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3.2.5 Detection of PTEN in our immortal mouse melanocyte cell lines 
and human melanoma cell line 
 
 
PTEN is a lipid phosphatase that inhibits AKT activation by PI3K. PTEN somatic 
mutations were found in 30% of melanoma cell lines and 10% of human tumour 
materials (Lin et al. 2008). To investigate whether our tumour cell lines have lost 
PTEN, we detected expression of PTEN in our mouse cell line panel by western 
blotting. As described before, protein lysates obtained from our mouse immortal 
melanocyte cell lines (3-1-1, 3-1-1T1, 3-1-1T2, 5-1, 5-1T1, 5-1T2) and human 
melanoma cell line (A375) were subjected to western blot analysis using an anti-
PTEN antibody to detect PTEN. GAPDH levels of these samples were also 
determined by western blot to correct for different amounts of protein in the various 
samples. The expression of PTEN was equal in our cell line panel, there was no 
evidence indicating any PTEN loss (Fig 3.7).  
 
 
























































Western blots showing protein levels of PTEN (top panel) and loading control GAPDH (bottom 
panel) in mouse melanocytes 3-1-1, 3-1-1T1, 3-1-1T2, 5-1, 5-1T1, 5-1T2 and human melanoma 
A375 cells. 
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3.2.6 Comparison of expression of p16 in mouse melanocyte cell lines 
 
 
In addition to 3-1-1 and 5-1 immortal mouse melanocyte cell lines, another immortal 
mouse melanocyte cell line was isolated at the same time. The #13 lines remained 
static for a long time and appeared senescent before a series of derivative subclones 
were eventually isolated, while mouse melanocyte cell lines 3-1-1, 5-1 and their 
tumour derivative cell lines grew quickly in cell culture. Since p16 was reported to 
contribute to melanocyte senescence, we decided to detect the p16 expression in 
these two types of mouse melanocyte cell lines.  
 
 
As described before, protein lysates obtained from mouse melanocyte cell line 13 
derivatives 13-4-1, 13-4-2, 13-4-3, 13-4-4, 13-4-5 and 3-1-1, 5-1 and their tumour 
derivative cell lines were subjected to western blot analysis using an anti-p16 
antibody to detect p16. GAPDH levels of these samples were also determined by 
western blot to correct for different amounts of protein in the various samples. Our 
results indicated that all the derivatives of the senescent cell line # 13 had lost p16 
expression, but 3-1-1, 5-1 and their tumour derivative cell lines 3-1-1T1 and 5-1T1 
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Western blots showing protein levels of p16 (top panel) and loading control GAPDH (bottom 
panel) in mouse melanocytes cell lines 3-1-1, 3-1-1T1, 5-1, 5-1T1 and # 13 cell lines including 
13-4-1, 13-4-2, 13-4-3, 13-4-4, 13-4-5. 
 
 
3.2.7 Investigation of the possibility of BRAF V600E mutations in 
our mouse melanocyte cell lines and their tumour derivatives  
 
 
BRAF mutations are detected frequently in human melanoma. Numerous variant 
mutations have been identified involving codon 600 and neighbouring codons in 
exon 15, and less frequently in exon 11 (Spittle et al. 2007). We compared the mouse 
BRAF and human BRAF genes and predicted BRAF mutations may occur frequently 
in exon 18 and exon 14 of the mouse BRAF gene. These exons are equivalent to 
exon 15 and exon 11 in the human BRAF gene. To further characterize MAPK 
pathway activation in our panel of cell lines, we investigated whether there were 
mutations in these exons using the PCR sequencing method. However, the 
sequencing results did not provide any strong evidence for BRAF activating 
mutations associated with melanoma in any of our immortal mouse cell lines. For the 
exon 18 PCR products from genomic DNA, the sequence of 2 out of 10 5-1 
sequenced sublones and 3 out of 9 5-1T1 sequenced subclones indicated sequence 
alteration. For the exon 14 PCR products from genomic DNA, the sequence of 2 out 
of 10 3-1-1 sequenced subclones, 2 out of 10 3-1-1 T1 sequenced subclones and 2 
out of 10 5-1 T1 sequenced subclones indicated sequence alteration (Table 3.1). 
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However, for both exons, the alteration point in each subclone from the same cell 
line was different and these alterations were regarded as PCR or sequencing errors 
rather than as evidence for BRAF mutations.  
 
 
Table 3.1 Sequence alterations on sequenced subclones of immortal mouse melanoctye cell 
lines. The table shows the rate of alterations in exon 14 and exon 18 of sequenced subclones of 
the mouse BRAF gene from our immortal mouse melanocytes and their tumourigenic 
derivatives.  The alteration sites of exon 14 are at positions 1613 and 1695 for 3-1-1, 1621 and 
1645 for 3-1-1T1 and 1628 and 1637 for 5-1T1. The alteration sites of exon 18 are at positions 
2047 and 2133 for 5-1 and 2041, 2085 and 2127 for 5-1T1. 
 
 
3.2.8 Detection of anchorage independent growth ability of our 
mouse melanocyte cell lines and their tumour derivatives 
 
 
The ability to form colonies in methylcellulose is a good in vitro surrogate for an in  
vivo tumourigenicity assay (Lauring et al. 2008, Runge et al. 1985). The 
methylcellulose system required fewer additives than necessary in the soft agar 
system. In addition, the quantification of the colony size and colony number in the 
methylcellulose system was easier than in the soft agar system. More important, 
colony growth of our immortal mouse melanocyte cell lines in the soft agar system 
was less predictable and often unsuccessful. Therefore, we decided to use the 
methylcellulose assay to assess the anchorage independent growth ability of our 
mouse melanocyte cell lines and their tumour derivatives.   
 
10000 cells of 3-1-1, 3-1-1T1, 3-1-1T2 and 5-1, 5-1T1, 5-1T2 were seeded into 
methylcellulose. Colony size and number were detected under the microscope every 
3/9 2/100/9 0/10 Exon 18
2/10 0/102/102/10 Exon 14 
5-1 T15-13-1-1 T13-1-1
The rate of 
Cell line 
Exon 
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three days for 12 days. Image J software was used to analyze the relative colony size 
and colony number per photographic field at day 12. Minimum colony size cut off 
was set at 30um for Day 12. The data collected from three independent experiments 
indicated our mouse tumourigenic cell lines formed larger and more colonies than 
their parental cell lines (Fig 3.9A, Fig 3.9B). Quantification analysis showed that the 
average colony size of the 3-1-1 tumour cell lines increased 2 to 3-fold compared to 
3-1-1; the colony number of the 3-1-1 tumour cell lines also increased 2.5 to 3-fold 
compared to 3-1-1 (Fig 3.9C, Fig 3.9D). The increase in 5-1 tumour cell lines was 
larger than 3-1-1 tumour cell lines: the average colony size of 5-1 tumour cell lines 
increased 7 to 23 fold compared to 5-1; the colony number of 5-1 tumour cell lines 
also increased 3 to 4-fold compared to 5-1 (Fig 3.9E, Fig 3.9F) These data suggested 
that our tumour cell lines had enhanced anchorage independent growth ability and 
that this may contribute to their ability to form tumours more easily in mice. 
 
 
Figure 3.9 Detection of anchorage independent growth ability of our immortal 














5-1  5-1T2 


































A, 3-1-1, 3-1-1T1, 3-1-1T2 and 5-1, 5-1 T1, 5-1 T2 were mixed with methylcellulose and seeded 
into 6-well plates to form colonies for 12 days. Images are representative of 3-1-1, 3-1-1T2, 5-1 
and 5-1T2 colonies at Day 12.  
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B, 3-1-1, 3-1-1T1, 3-1-1T2 and 5-1, 5-1 T1, 5-1 T2 were mixed with methylcellulose and seeded 
into 6-well plates to form colonies for 12 days. Images are representative of 5-1 and 5-1T2 wells 
at Day 12.  
 
C, Average colony size of 3-1-1, 3-1-1T1, 3-1-1T2. Colony areas were measured with Image J 
software. Histogram shows mean colony size (+ SEM) from three independent experiments. 
Average colony size of 3-1-1T1 and 3-1-1T2 are standardised to 3-1-1. One way ANOVA with 
Bonferroni’s Multiple Comparison Test was applied for statistical analysis between 3-1-1 and 3-
1-1T1, 3-1-1T2 **, P<0.01. ***, P < 0.001. 
 
D, Total number of colonies counted per photographic field. Each field is approximately 0.59 
mm2 of culture dish. At least 6 fields were counted for each dish. Histogram shows mean colony 
number (+ SEM) from three independent experiments. One way ANOVA with Bonferroni’s 
Multiple Comparison Test was applied for statistical analysis between 3-1-1 and 3-1-1T1, 3-1-
1T2. **, P<0.01. 
 
E, Average colony size of 5-1, 5-1T1, 5-1T2. Colony areas were measured with Image J 
software. Histogram shows mean colony size (+ SEM) from three independent experiments. 
Average colony size of 5-1T1 and 5-1T2 are standardised to 5-1. One way ANOVA with 
Bonferroni’s Multiple Comparison Test was applied for statistical analysis between 5-1 and 5-
1T1, 5-1T2. ***, P < 0.001. 
 
F, Total number of colonies counted per photographic field. Each field is approximately 0.59 
mm2 of culture dish. At least 6 fields were counted for each dish. Histogram shows mean colony 
number (+ SEM) from three independent experiments. One way ANOVA with Bonferroni’s 
Multiple Comparison Test was applied for statistical analysis between 5-1 and 5-1T1, 5-1T2. **, 
P<0.01. ***, P < 0.001.  
 
3.2.9 Detection of invasive ability of our mouse melanocyte cell lines 
and their tumour derivatives 
 
Matrigel is considered as an in vitro model for basement membrane and is generated 
from EHS sarcoma cells. Matrigel contains not only basement membrane 
components (collagens, laminin, and proteoglycans), but also matrix degrading 
enzymes. Migration through an extracellular matrix is a prerequisite for local 
Genetic changes in melanoma progression  
107 
invasion and metastasis (Kleinman and Martin 2005). The transwell migration assay 
is a useful tool to compare invasive ability between our tumour cell lines and their 
parental cell lines. Our immortal mouse cell lines (3-1-1, 3-1-1T1, 3-1-1T2 and 5-1, 
5-1T1, 5-1T2) and human melanoma cell line A375 as a positive control were seeded 
onto transwell filters to invade into matrigel in response to a chemotactic stimulus (in 
this case 10% serum). After 72 hours, cells were labelled with calcein AM dye and 
visualized in the matrigel at 15um intervals by confocal sectioning. The cell number 
invading to 45um was expressed relative to the cell number in the section that 
represented the base of the transwell filter. Our mouse tumourigenic cell lines 
displayed greater chemotactic invasion relative to their parental cell lines (Fig 3.10A, 
Fig 3.10C). Quantification analysis showed that the relative cell number at 45um 
increased 1.5-fold compared to 3-1-1 and increased 8-fold compared to 5-1 (Fig 
3.10B, Fig 3.10D). The difference within the 5-1 series in the transwell migration 
assay was larger than in the 3-1-1 series. Human melanoma cell lines A375 invaded 
further in matrigel than any of our immortal mouse cell lines.  
 
Figure 3.10 Detection of invasive ability of our immortal mouse melanocytes by 






0um 15um 30um 45um 60um 75um 90um 
Invasion 
 
Genetic changes in melanoma progression  
108 
B 






























































































         
A, 3-1-1, 3-1-1T1, 3-1-1T2 and A375 were seeded on transwell filters and allowed to invade 
through Matrigel along a serum gradient. After 96 hours cells were labelled with calcein AM and 
visualized in the Matrigel at 15μm intervals by Olympus FV1000 confocal microscopy.  
 
B, Histogram shows the quantitation of invasion at 45um for panel A. The amount of dye 
(positive pixels) was calculated for each z-section using Image J software, and expressed relative 
to the signal in the section that represented the base of the transwell filter. One way ANOVA 
with Bonferroni’s Multiple Comparison Test was applied for statistical analysis between 3-1-1 
and 3-1-1T1, 3-1-1T2, A375. *, P < 0.05. **, P < 0.01.***, P < 0.001.  
 
C, 5-1, 5-1T1, 5-1T2 and A375 were seeded on transwell filters and allowed to invade through 
Matrigel along a serum gradient. After 96 hours cells were labelled with calcein AM and 
visualized in the Matrigel at 15μm intervals by Olympus FV1000 confocal microscopy.  
 
D, Histogram shows the quantitation of invasion at 45um for panel C. The amount of dye 
(positive pixels) was calculated for each z-section using Image J software, and expressed relative 
to the signal in the section that represented the base of the transwell filter. One way ANOVA 
with Bonferroni’s Multiple Comparison Test was applied for statistical analysis between 5-1 and 
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3.3 Discussion  
 
 
To begin the characterization of our mouse melanocyte cell lines, we investigated the 
expression of a series of cell cycle control and proliferation markers by western-
blotting: p-ERK, p-MEK, DUSP6, P-AKT, PTEN and p16.  
 
 
The MAPK pathway plays an important role in various cellular responses, including 
cell proliferation, differentiation, survival and apoptosis. Constitutive activation of 
the MAPK pathway seemed to link with development and progression of tumours 
(Ramos 2008). Therefore, the activation of the MAPK pathway in our mouse 
melanocyte cell lines was examined. To our surprise, the results indicated that our 
tumourigenic cell lines have lower expression of p-ERK than their parental cell lines 
5-1 and 3-1-1. Our results agreed with a report that ERK was phosphorylated in only 
a minority of melanoma cells. This report showed regulated MAP kinase signalling 
in the majority of tumour cells rather than a continuous activation of this pathway 
(Houben et al. 2008). In contrast, it was reported that ERK phosphorylation appeared 
in the majority of cutaneous melanoma (Cohen et al. 2002). However, the authors did 
not report on the proportion of phospho-ERK-positive tumour cells. Recently Zhuang 
described that about 65% and 77% of cells were phospho-ERK-positive in 
melanomas (Zhuang et al. 2005). While Uribe showed that ERK phosphorylation 
was detected in only a low proportion of melanoma cells. Moreover, 15% of the 
primary tumours were completely p-ERK negative (Uribe et al. 2006). Rarely, a high 
proportion of phospho-ERK-positive cells were observed in metastatic melanoma 
(Mirmohammadsadegh et al. 2007).  
 
 
As described previously, in xenograft experiments, A375 formed tumours very 
quickly, while 5-1 and 3-1-1 formed tumours very slowly. However when we 
xenografted 3-1-1 Tumour 1a into mice again, it formed tumours much more quickly 
than 3-1-1. Is absence of p-ERK related to melanoma progression in this xenograft 
assay? The importance of absence of p-ERK in cancer progression had been 
Genetic changes in melanoma progression  
111 
previously described in prostate cancer (Paweletz et al. 2001). Recently, a melanoma 
subtype with epithelial characteristics, which lacked p-ERK activation, had been 
reported (Curtin et al. 2006, Shields et al. 2007). Moreover, melanoma lacking 
activation of the RAS-RAF-MEK-ERK pathway had increased expression of cyclin–
dependent kinase 4 (CDK4) and cyclin D1 (CCND 1) which were downstream 
components of the RAS and BRAF pathway. That implied that their upregulation can 
occur through alternative molecular mechanisms (Curtin et al. 2006). It was possible 
that our 5-1 and 3-1-1 tumourigenic cell lines with a low level of p-ERK had the 
same characteristics as these types of melanoma. The role of lower expression of p-




We next examined expression of p-MEK to assess the overall activation of the 
MAPK pathway. The result indicated that p-MEK expression levels of 5-1 tumour 
and 3-1-1 tumour cell lines are lower than their parental cell lines. Activation of 
MEKs can phosphorylate Tyr and Thr residues of ERKs, causing their activation. 
Moreover, ERKs seemed to be the only substrates of MEKs and these kinases served 
as the specificity determining components of ERKs (Shaul and Seger 2007). 
Therefore, the low expression of p-ERK in our tumour cell lines may be due to low 




The delayed phase of ERK inactivation involves specific phosphatases with a dual 
specificity for Ser/Thr and Tyr. They are known as the dual specificity phosphatase 
(DUSP) family. While DUSP1 and DUSP4 are nuclear and dephosphorylate both 
ERKs and the p38 and JNK, DUSP6 is cytoplasmic and specific to the ERKs 
(Bluthgen et al. 2009). DUSP6 can dephosphorylate ERKs and reduce the expression 
of p-ERK. Upregulated genes in melanoma cell lines with MAPK pathway activation 
were described, including DUSP6 and Sprouty 2 (Bloethner et al. 2005). There was 
increasing evidence that DUSP6 may be abnormally regulated and so 
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dephosphorylate ERKs in tumours (Bermudez et al. 2010). We suspected that a 
signal for ERK inhibition in our tumour cell lines may come from DUSP6. Therefore, 
DUSP6 expression in our panel of cell lines was detected. As expected the level of 
DUSP6 was higher in the 3-1-1 and 5-1 tumour cell lines than their parent cell lines. 
However, whether over-expression of DUSP6 was a cause of the malignant 




The inactivation of the MAPK pathway in our mouse tumourigenic cell lines leaves 
room for speculation that other pathways may contribute to melanoma progression in 
the mouse xenograft assay. Previous studies showed that the PI3K-AKT pathway was 
an established regulator of cell survival in many human cancers (Cully et al. 2006, 
Hennessy et al. 2005). High expression of p-AKT was correlated with melanoma 
progression and worse patient survival in melanomas (Dai et al. 2005). Importantly, 
phosphorylation of RAF by AKT inhibited activation of the MAPK pathway and 
changed the cellular response in a human breast cancer cell line from cell cycle arrest 
to proliferation (Zimmermann and Moelling 1999). Therefore, we speculated that 
inactivation of the MAPK pathway in our tumour cell lines may arise because of 
hyperactivation of the P13K pathway. However, our result indicated that 5-1 and 3-1-
1 had higher expression of p-AKT than 5-1 and 3-1-1 tumourigenic cell derivatives. 
The cell lines with a low level of p-ERK had lower expression of p-AKT as well. 
These data suggested that the PI3K-AKT pathway was not activated in our tumour 
cell lines and there was not a simple relationship between levels of p-AKT and p-
ERK and tumourigenesis. The reasons for the possible high molecular weight of p-
AKT in the 3-1-1 tumourigenic cells compared to the 3-1-1 parental cells are not 
clear and needed further investigation.  
 
 
PTEN (phosphatase and tensin homolog deleted on chromosome 10) functioned as a 
highly effective tumour suppressor in a wide variety of tumour tissues (Suzuki et al. 
2008) by regulating the PI3K/AKT pathway (Maehama and Dixon 1998). Loss of 
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PTEN had been implicated in the development of melanoma (Wu et al. 2003) and a 
high frequency of PTEN mutations had been detected in malignant melanomas 
(Bonneau and Longy 2000). The potential genetic interaction among NRAS, BRAF, 
and PTEN may play a critical role in melanoma development. PTEN expression was 
also detected in our cell line panel by western blot. PTEN expression was equal in all 
our cell lines and there was no evidence for any PTEN loss. 
 
Mutations in BRAF were found through the genome-wide cancer sequencing 
programe, and were reported to occur in 50-70% of human melanoma. One specific 
mutation was V600E BRAF mutation, accounting for more than 90% of all BRAF 
mutations in melanoma (Dahl and Guldberg 2007). However whether BRAF 
mutations occurred in mouse melanoma was not clear. We did not find any activating 
mutations associated with melanoma in our immortal mouse cell lines. However, this 
study had some limitations. Firstly, we did not have a mouse BRAF mutation 
positive control. Secondly, we only sequenced exon 14 and exon 18 of the mouse 
BRAF gene not the whole mouse BRAF sequence. Although these exons were 
equivalent to exon 15 and exon 11 of human BRAF gene where mutations were most 
frequently found, we can not rule out that mouse BRAF mutations occurred in other 
exons in our cell lines.  
 
 
Our results also showed that derivatives of another immortal mouse melanocyte cell 
line, #13, which remained static for an extensive period had all lost p16 expression, 
while 5-1 and 3-1-1 which grew rapidly had retained high expression of p16. This 
was in contrast to a previous study which showed that p16 played a very important 
role in cell senescence and the absence of p16 may favour melanoma progression 
(Sviderskaya et al. 2002). A possibility was that although derivatives of the immortal 
mouse melanocyte cell line, #13, had lost p16, there were other tumour suppressors 
associated with melanocyte senescence that retarded cell growth. The p53 tumour 
suppressor was mutated or otherwise inactivated in a wide range of human cancers 
(Dahl and Guldberg 2007). Recently, a powerful genetic model of murine melanoma 
was established to assess the functional roles of p53 and ARF in murine 
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melanomagenesis. The result demonstrated p53-independent tumour suppressive 
activity of ARF. ARF can function as a melanoma tumour suppressor in the absence 
of p53 (Widlund and Fisher 2007). We can not rule out the possibility that p53 and 
ARF rather than p16 were responsible for the senescence of our mouse melanocyte 
cell line 13 and its derivatives.  
 
 
The methylcellulose assay and transwell migration assays showed the tumourigenetic 
and invasive ability of our mouse tumourigenic cells. Our results indicated that 5-1 
and 3-1-1 tumourigenic cell lines formed larger and more colonies in the 
methylcellulose assay compared to their parent cell lines 3-1-1 and 5-1. Moreover, 5-
1 and 3-1-1 tumour cell lines invaded further than their parental cell lines 3-1-1 and 
5-1 in transwell migration assays. These agreed with our previous study that our 
mouse tumourigenic cell lines formed tumours more quickly than their parental cell 
line in the mouse xenograft assay. Furthermore, the methylcellulose assay and 
transwell migration assay provided good tools to detect biologic characteristics of 
our immortal mouse cell lines. These two assays can be used to examine 
tumourigenic changes following transfection in vitro. 
 
 
To sum up, we identified a subtype of mouse melanoma cell lines in our mouse 
xenograft assay. These cell lines showed several characteristics that were uncommon 
in classic melanoma: (A) decreased ERK activation and MEK activation; (B) 
increased expression of DUSP6; (C) decreased levels of p-AKT; (D) without BRAF 
mutation; (F) without PTEN deletion. These data suggested that these mouse 
tumourigenic cell lines represented a molecularly distinct and unappreciated subtype 
of melanoma. Meanwhile, through analysis of our immortal mouse cell lines, we 
raised two main questions: firstly, is a lower level of p-ERK and higher expression of 
DUSP6 in our mouse tumourigenic cell lines related to melanoma progression in the 
mouse xenograft model? Secondly, why do the #13 cell line and its derivatives 
without p16 grow so poorly? Further investigations on our immortal mouse cell lines 
were needed.  
 











































Roles of DUSP6 in melanoma progression 
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4.1 Introduction  
 
 
During the progression of melanomagenesis, melanoma cells escape the normal cell 
growth and control systems and gain the ability to invade the surrounding tissues and 
organs. The RAS/RAF/MEK/ERK pathway plays an important role in cell growth, 
cell survival and invasion (Smalley 2003). Melanoma is known to harbour activating 
mutations in both RAS and BRAF (Dahl and Guldberg 2007), however the extent to 
which activation of their downstream factor ERK1/2 contributes to melanoma 
progression is still controversial.  
 
 
The MKPs constitute a distinct subgroup of ten catalytically active enzymes within 
the larger family of cysteine-dependent dual-specificity protein phosphatases. The 
discovery of most of the DUSPs has occurred in the last 7 years, initiating a large 
amount of interest in their role and regulation. Recently, studies showed that DUSP6, 
dual-specificity phosphatase 6, was a negative feedback regulator for the 
Ras/Raf/MEK/ERK pathway, playing important roles in the maintenance of cellular 
homeostasis in response to growth factors (Amit et al. 2007, Bermudez et al. 2010). 
Disruption of this feedback loop could therefore cause neoplastic, and even 
malignant, transformation (Bermudez et al. 2010, Patterson et al. 2009). However, 




My previous work had identified lower p-ERK expression and higher DUSP6 
expression in mouse melanocytes which formed tumours very quickly in a mouse 
xenograft assay compared to the non-tumourigenic parental melanocyte lines. The 
aims of the work in this chapter were to examine: firstly, whether the high level of 
DUSP6 was related to melanoma progression in the xenograft assay; secondly, 
whether absence of p-ERK contributed to melanoma progression in the xenograft 
assay.   









Previous studies showed that DUSP6 acted as a negative regulator of the MAPK 
pathway in pancreatic cancer, ovarian cancer and lung cancer (Keyse 2008). In our 
study, our mouse melanocye tumour cell lines expressed high DUSP6 but low 
phospho-ERK1/2 expression levels. We suspected that overexpression of DUSP6 
resulted in reduction of phospho-ERK1/2 in our mouse tumour cell lines.  
 
 
To investigate the regulatory mechanism of DUSP6 on ERK1/2 in our mouse 
melanocyte cell lines, the pcDNA3.1/V5-His-DUSP6/MKP-3 vector was introduced 
by electroporation into the 5-1 non-tumourigenic cell line which had low levels of 
DUSP6. This plasmid was able to express a histidine and V5 tagged version of 
DUSP6 from the human cytomegalovirus (CMV) promoter and also contained a 
neomycin selectable marker. Electroporation was used because, unlike some other 
transfection methods, it has no reagent-induced cytotoxicity towards the cells and 
can achieve good transfection efficiencies in our immortal mouse melanocytes. The 
5-1 cell line was selected for the following studies, because 5-1 and its tumour 
derivatives showed larger difference in the methylcellose assay and the transwell-
migration assay compared to the 3-1-1 series. Cells with stable expression of DUSP6 
were selected with G418 for 7 days. About 100 pooled resistant colonies were used 
for western analyses. The DUSP6 expression level of pooled resistant colonies 
detected by western blot showed a better measure of the average DUSP6 expression 
of resistant colonies than measurements on individual colonies, where DUSP6 
expression could be dependent on specific position effects on the integrated 
transgene in different colonies. 
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Protein lysates obtained from 5-1, 5-1 DUSP6 transfection pool, 5-1T1 and 5-1T2 
were subjected to western blot analysis using DUSP6 antibody to detect DUSP6 
expression and an anti-phospho-ERK antibody to detect p-ERK1 (42KD) and p-
ERK2 (44KD). Total ERK and GAPDH levels of these samples were also 
determined by western blot to correct for different amounts of protein in the various 
samples. As described before, 5-1 expressed low levels of DUSP6 and high levels of 
phospho-ERK1/2, while 5-1 tumour cell lines expressed a high level of DUSP6 and a 
low level of phospho-ERK1/2 (Fig. 4.1A). Quantification analysis showed that 
DUSP6 expression increased 7-fold for 5-1 tumourigenic cell lines compared to 5-1, 
while the expression level of phospho-ERK1/2 reduced around 10-fold for 
tumourigenic cell lines compared to 5-1 (Fig. 4.1B, Fig 4.1C). Moreover, the DUSP6 
expression level dramatically increased in the 5-1 DUSP6 transfection pool 
compared to non-transfected 5-1 cells as expected. Ectopic expression of DUSP6 in 
5-1 cells reduced the expression level of phospho-ERK1/2 to that seen in 5-1 T1 and 
T2 (Fig. 4.1A). Quantification analysis showed that DUSP6 expression increased 6-
fold for 5-1 DUSP6 transfection pool compared to 5-1, while the expression level of 
phospho-ERK1/2 reduced around 10-fold for 5-1 DUSP6 transfection pool compared 
to 5-1 (Fig. 4.1B, Fig 4.1C). These data suggested that DUSP6 negatively regulated 



































































Figure 4.1 DUSP6 is a negative regulator of ERK1/2 activity in mouse 
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A, pcDNA3.1/V5-His-DUSP6/MKP-3 vector was transfected into 5-1 cells by electroporation. 
Western blots show protein levels of DUSP6 (top panel), phosphorylated ERK (p-ERK) (second 
panel), total ERK (third panel) and loading control GAPDH (bottom panel) in 5-1, 5-1 DUSP6 
transfection pool, 5-1T1 and 5-1T2 cells. Stable overexpression of DUSP6 reduced 
phosphorylated ERK (P-ERK) level in the 5-1 DUSP6 transfection pool.  
 
B, Histogram shows level of DUSP6. DUSP6 levels are expressed relative to loading control 
GAPDH and are normalized to 5-1.  
 
C, Histogram shows level of phosphorylation ERK (p-ERK). p-ERK levels are expressed relative 
to total ERK levels and are normalized to 5-1.  
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4.2.2 Effect of DUSP6 on anchorage independent growth activity of 
our immortal mouse melanocytes  
 
 
As described in Chapter 3, absence of DUSP6 may be associated with 
tumourigenicity in our mouse xenograft model. To determine the involvement of 
DUSP6 in melanoma progression of our immortal mouse cell lines, we assessed 
anchorage independent growth ability of the DUSP6 transfection pool by 
methylcellulose assay. 10000 cells of 5-1, 5-1 DUSP6 transfection pool, 5-1T1 and 
5-1T2 were seeded into methylcellulose. Colony size and number were determined 
under the microscope every three days for 12 days in total. Image J software was 
used to analyze the relative colony size and colony number per photographic field at 




The results showed that overexpression of DUSP6 stimulated colony formation in the 
methylcellulose assay. As described before in Chapter 3, the data collected from 
three independent experiments indicated that 5-1 tumour cell lines formed more and 
larger colonies than their parental cell line 5-1. Moreover, the DUSP6 transfection 
pool formed more and larger colonies than non-transfected 5-1 cells (Fig. 4.2A, Fig. 
4.2D). Quantification analysis of microscope images by Image J indicated that the 
average colony size of DUSP6 transfection pool increased 5-fold compared to non-
transfected 5-1 cells and the colony number of the DUSP6 transfection pool also 
increased nearly 3-fold compared to non-transfected 5-1 cells (Fig. 4.2B, Fig. 4.2C). 
This result suggests that high DUSP6 expression contributes to tumourigenicity of 
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Figure 4.2 DUSP6 overexpression contributes to colony formation of our mouse 
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A, 5-1, 5-1 DUSP6 transfection pool, 5-1 T1 and 5-1 T2 were mixed with methylcellulose and 
seeded into 6-well plates to form colonies for 12 days. Images are representative of 5-1 and 5-1 
DUSP6 transfection pool colonies at Day 12.  
5-1  5-1 DUSP6 
5-1  5-1 DUSP6
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B, Average colony size of 5-1, 5-1 DUSP6 transfection pool, 5-1 T1 and 5-1 T2. Colony areas 
were measured with ImageJ software. Histogram shows mean colony size (+ SEM) from three 
independent experiments. Average colony size of 5-1 DUSP6 transfection pool, 5-1 T1 and 5-1 
T2 are standardized to 5-1. One way ANOVA with Bonferroni’s Multiple Comparison Test was 
applied for statistical analysis between 5-1 and 5-1 DUSP6 transfection pool. ***, P < 0.001. 
 
C, Total number of colonies counted per photographic field. Each field is approximately 0.59 
mm2 of culture dish. At least 6 fields were counted for each dish. Histogram shows mean colony 
number (+ SEM) from three independent experiments. One way ANOVA with Bonferroni’s 
Multiple Comparison Test was applied for statistical analysis between 5-1 and 5-1 DUSP6 
transfection pool. ***, P < 0.001. 
 
D, 5-1, 5-1 DUSP6 transfection pool, 5-1 T1 and 5-1 T2 were mixed with methylcellulose and 
seeded into 6-well plates to form colonies for 12 days. Photos are representative of entire wells 
from 5-1 and 5-1 DUSP6 transfection pool at Day 12 . 
 




As we had demonstrated in Chapter 3 that our mouse tumour cell lines with high 
levels of DUSP6 invaded further in the transwell-migration assay than their parental 
non-tumourigenic cell lines, we hypothesized that the DUSP6 transfection pool had 
enhanced capacity for invasion compared to non-transfected 5-1 cells. We therefore 
utilized the quantitative in vitro invasion assay to assess the ability of the DUSP6 
transfection pool to invade into matrigel in response to a chemotactic stimulus (in 
this case 10% serum). 5-1, 5-1 DUSP6 transfection pool, 5-1T1 and 5-1T2 were 
seeded onto transwell filters. After 72 hours, cells were labelled with calcein AM dye, 
and visualized in the matrigel at 15um intervals by confocal sectioning. The relative 
cell number invading at 45um into 3D-gels was expressed relative to the cell number 
in the section that represented the base of the transwell filter. As described before, 5-
1 tumour cell lines invaded further than 5-1 in matrigel. The relative cell number at 
45um was around 0.37 for the tumour lines, compared to only 0.002 for 5-1. 
Moreover, the 5-1 DUSP6 transfection pool also displayed much more chemotactic 
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invasion relative to non-transfected 5-1 (Fig. 4.3A). Quantification analysis indicated 
that relative cell number of 5-1 DUSP6 transfection pool at 45um into 3D-gels was 
0.15, 55-fold more than non-transfected 5-1 (Fig. 4.3B). These data showed that 5-1 
DUSP6 transfection pool had similar increased invasive ablility as the 5-1 tumour 
cell lines and the increased DUSP6 expression was needed for invasion of our mouse 
melanoma cells. 
 









0um 15um 30um 45um 60um 75um 
Invasion 
 
   
B 





























A, 5-1, 5-1 T1, 5-1 T2 and 5-1 DUSP6 transfection cells were seeded on transwell filters and 
allowed to invade through Matrigel along a serum gradient. After 96 hours cells were labelled 
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with calcein AM and visualized in the Matrigel at 15μm intervals by Olympus FV1000 confocal 
microscopy.  
 
B, Histogram shows the quantitation of invasion at 45um. The amount of dye (positive pixels) 
was calculated for each z-section using Image J software, and expressed relative to the signal in 
the section that represented the base of the transwell filter. One way ANOVA with Bonferroni’s 
Multiple Comparison Test was applied for statistical analysis between 5-1 and 5-1 DUSP6 
transfection pool. **, P < 0.01. 
 
 
4.2.4 Constitutive activation of MEK1/2 increases phosphorylation 
of ERK1/2 in our mouse tumour cells  
 
 
As described in Chapter 3, our mouse tumour cell lines had lower phosphorylation 
levels of ERK1/2 than their parental cell lines, but formed tumours more quickly in 
the xenograft assay and displayed enhanced anchorage independent-growth and 
invasive abilities. Therefore, we suspected that lower phosphorylation levels of 
ERK1/2 may contribute to melanoma progression in our mouse xenograft model.  
 
 
To investigate the functional significance of ERK1/2 activation in our mouse tumour 
cell lines, we ectopically expressed constitutively active versions of MEK1 and 
MEK2 in the 5-1 T2 cell line which had low expression of p-ERK. The pMCL-
MKK1-R4F and pMCL-MKK2-KW71A plasmids were able to express the 
constitutively actived form of MEK1 and MEK2 from the CMV promoter. They also 
contained a hygromycin selectable marker. MEK1 and MEK2 are the upstream 
activators of ERK1 and ERK2 (Cobb 1999). Introduction of constitutively active 
MEK1 and MEK2 can result in increased phosphorylation of ERK1/2 (Seger et al. 
1992). The 5-1 T2 cell line was selected for subsequent experiments because 5-1 T2 
and its parental cell line 5-1 showed larger differences in the methylcellose assay and 
transwell migration assay compared to the 3-1-1 series. Polyclonal populations of 
transfected clones were selected in Hygromycin and used for subsequent studies. 
Expression of ectopic MEK1 and MEK2 in the 5-1T2 transfected population was 
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confirmed by western blotting. A recent study indicated that the activation of the 
MAPK pathway can increase the expression of DUSP6 through regulation of 
transcriptional factor ETS2 (Furukawa et al. 2008). To investigate whether activation 
of the MAPK pathway by expression of ectopic MEK1 and MEK2 can regulate 
DUSP6 expression in the 5-1T2 cell line, DUSP6 levels were also detected by 
western blotting.  
 
 
Protein lysates obtained from 5-1, 5-1T1, 5-1T2 and 5-1T2 MEK1 and MEK2 
transfection pool were subjected to western blot analysis using an anti-phospho-
MEK antibody to detect p-MEK1/2 (45KD) expression, an anti-phospho-ERK 
antibody to detect p-ERK1 (42KD) and p-ERK2 (44KD) expression and a DUSP6 
antibody to detect DUSP6 expression. Total MEK1/2, ERK and GAPDH levels of 
these samples were also determined by western blot to correct for different amounts 
of protein in the various samples. As described before, 5-1 had high levels of 
phosphorylated MEK1/2 and ERK1/2 but low levels of DUSP6, while 5-1 tumour 
cell lines expressed low levels of phospho-MEK1/2 and phospho-ERK1/2 but high 
levels of DUSP6 (Fig. 4.4A). Quantification analysis showed that the ratio of 
phospho-MEK1/2 over total MEK1/2 was 1.7 for 5-1, compared to 0 for 5-1 
tumourigenic cell lines, while the expression level of phospho-ERK1/2 reduced 
around 12-fold for tumourigenic cell lines compared to 5-1 (Fig 4.4B, Fig 4.4C). The 
ratio of DUSP6 over GAPDH was around 6-fold increased for tumourigenic cell 
lines compared to 5-1 (Fig 4.4D). Moreover, ectopic expression of constitutively 
active MEK1/2 dramatically increased the phosphorylation level of MEK1/2 which 
resulted in activation of ERK1/2 as expected (Fig. 4.4A). In addition, the activation 
of the MAPK pathway in 5-1T2 MEK1 and MEK2 transfection pool upregulated 
DUSP6 expression as expected (Fig. 4.4A). Quantification analysis showed that the 
ratio of phospho-MEK1/2 over total MEK1/2 was 3.2 for the 5-1 T2 MEK1 and 
MEK2 transfection pool, compared to 0 for non-transfected 5-1 T2, while expression 
level of phospho-ERK1/2 increased around 13-fold for the 5-1 T2 MEK1 and MEK2 
transfection pool compared to non-transfected 5-1 T2 (Fig 4.4B, Fig 4.4C). In 
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addition, the ratio of DUSP6 over GAPDH increased almost 2-fold for the 5-1 T2 
MEK1 and MEK2 transfection pool compared to non-transfected 5-1 T2. 
 
 
Figure 4.4 MEK1/2 is a positive regulator of ERK1/2 activity in transformed 






























































































































A, MEK1 and MEK2 vectors were transfected together into 5-1T2 cells by electroporation. 
Western blots show protein levels of phosphorylated MEK1/2 (p-MEK1/2) (top panel), total 
MEK (second panel), phosphorylated ERK (p-ERK) (third panel), total ERK (fourth panel) and 
loading control GAPDH (bottom panel) in 5-1, 5-1T1 and 5-1T2 and 5-1T2 MEK1 and MEK2 
transfection pool. Increased levels of p-MEK led to increased phosphorylated ERK (P-ERK) and 
DUSP6 levels in the 5-1T2 MEK1 and MEK2 transfection pool.  
 
B, Histogram shows level of phosphorylation of MEK1/2 (p-MEK1/2). p-MEK1/2 levels are 
expressed relative to total MEK1/2 levels and are normalized to 5-1. 
 
C, Histogram shows level of phosphorylation of ERK (p-ERK). p-ERK levels are expressed 
relative to total ERK levels and are normalized to 5-1.  
 
D, Histogram shows level of DUSP6. DUSP6 levels are expressed relative to GAPDH levels and 
are normalized to 5-1.  
 
 
4.2.5 Effect of constitutive activation of MEK1/2 on anchorage 
independent growth activity of transformed mouse melanocytes   
 
 
To determine the involvement of ERK1/2 in melanoma progression of our immortal 
mouse melanocytes, we assessed the anchorage independent growth ability of the 
constitutively activated MEK1/2 transfection pool by methylcellulose assay. 10000 
cells of 5-1, 5-1T1, 5-1T2 and 5-1T2 MEK1/2 transfection pool were seeded into 
methylcellulose. Colony size and number were detected under the microscope every 
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three days for 12 days in total. Image J software was used to analyze the relative 
colony size and colony number per photographic field at day 12. Minimum colony 
size cut off was set at 30um for Day 12.  
 
  
The results showed that enforced expression of constitutively active MEK1/2 slightly 
decreased colony size and total colony number, but this reduction was not significant  
in the methylcellulose assay. As described before, the data collected from three 
independent experiments indicated that 5-1 tumour cell lines formed more and larger 
colonies than their parental cell line 5-1. Moreover, the 5-1T2 MEK1/2 transfection 
pool formed less and smaller colonies than non-transfected 5-1T2 cells (Fig. 4.5A, 
Fig 4.5D). Quantification analysis indicated that the average colony size and total 
colony number of 5-1T2 MEK1/2 transfection pool slightly decreased compared to 
non-tansfected 5-1T2 cells (Fig. 4.5B, Fig. 4.5C). However, one way ANOVA with 
Bonferroni’s Multiple Comparison Test statistical analysis showed that there was no 
significant difference between 5-1T2 and 5-1T2 MEK1/2 transfection pool in the 
methylcellulose assay.  
 
 
Figure 4.5 Increased p-MEK levels do not inhibit colony formation of our 
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A, 5-1, 5-1T1, 5-1T2 and 5-1T2 MEK1/2 transfection pool were mixed with methylcellulose and 
seeded into 6 well-plates to form colonies for 12 days. Photos are representative of 5-1T2 and 5-
1T2 MEK1/2 transfection colonies pool at Day 12.  
 
B, Average colony size of 5-1, 5-1T1, 5-1T2 and 5-1T2 MEK1 and MEK2 transfection pool. 
Colony areas were measured with ImageJ software. Histogram shows mean colony size (+ SEM) 
from three independent experiments. Average colony size of 5-1T1, 5-1 T2 and 5-1T2 MEK1/2 
transfection pool are standardised to 5-1. One way ANOVA with Bonferroni’s Multiple 
Comparison Test was applied for statistical analysis. There was no significant difference between 
5-1T2 and 5-1T2 MEK1/2 transfection pool. 
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C, Total number of colonies counted per photographic field. Each field is approximately 0.59 
mm2 of culture dish. At least 6 fields were counted for each dish. Histogram shows mean colony 
number (+ SEM) from three independent experiments. One way ANOVA with Bonferroni’s 
Multiple Comparison Test was applied for statistical analysis. There was no significant difference 
between 5-1T2 and 5-1T2 MEK1/2 transfection pool. 
 
D, 5-1, 5-1T1, 5-1T2 and 5-1T2 MEK1/2 transfection pool were mixed with methylcellulose and 
seeded into 6-well plates to form colonies for 12 days. Photos are representative of an entire well 
from 5-1T2 and 5-1T2 MEK1/2 transfection pool at Day 12.  
           
 
4.2.6 Effect of constitutive active MEK1/2 on invasive ability of 
transformed mouse melanncytes  
 
 
As demonstrated in Chapter 3, our mouse tumour cell lines with lower 
phosphorylation levels of ERK1/2 can invade further in matrigel than their parental  
cell lines, we hypothesized that lower expression of ERK1/2 may be involved in 
invasion of our mouse tumour cell line. Therefore, we introduced constitutively 
active MEK1/2 into the 5-1 tumour cell line to activate ERK1/2. A quantitative in 
vitro invasion assay was used to assess the ability of the MEK1/2 transfection pool to 
invade into matrigel in response to a chemotactic stimulus (in this case 10% serum). 
5-1, 5-1T1, 5-1T2 and 5-1T2 MEK1 and MEK2 transfection pool were seeded onto 
transwell filters. After 72 hours, cells were labelled with calcein AM dye and 
visualized in the matrigel at 15um intervals by confocal sectioning. The cell number 
invading at 45um into 3D-gels was expressed relative to the cell number in the 
section that represented the base of the transwell filter. As described before, 5-1T1 
and 5-1T2 invaded further than 5-1 in matrigel. The relative cell number at 45um 
was around 0.20 for the tumour lines, compared to 0.026 for 5-1. Moreover, ectopic 
expression of constitutively active MEK1/2 significantly suppressed the invasive 
capacity of 5-1T2 cells (Fig. 4.5A). Quantification analysis indicated that the relative 
cell number of 5-1T2 MEK1/2 transfection pool at 45um into 3D-gels was 0.07, 3-
fold less than non-transfected 5-1T2 cells (Fig. 4.5B). These data showed that 5-1T2 
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MEK1/2 transfection pool had similar reduced invasive ablility as 5-1 and that lower 
levels of p-ERK may contribute to invasive ablility of our mouse melanocytes.   
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A, 5-1, 5-1 T1, 5-1 T2 and 5-1T2 MEK1 and MEK2 transfection pool cells were seeded on 
transwell filters and allowed to invade through Matrigel along a serum gradient. After 96 hours 
cells were labelled with calcein AM and visualized in the Matrigel at 15μm intervals by Olympus 
FV1000 confocal microscopy.  
 
B, Histogram shows the quantitation of invasion at 45um. The amount of dye (positive pixels) 
was calculated for each z-section using Image J software, and expressed relative to the signal in 
the section that represented the base of the transwell filter. One way ANOVA with Bonferroni’s 
Multiple Comparison Test was applied for statistical analysis between 5-1T2 and 5-1T2 MEK1/2 
transfection pool. ***, P < 0.001. 
 
 




Our study already showed that DUSP6 overexpression increased the tumourigenic 
potential of our transformed mouse melanocytes. To investigate the effect of DUSP6 
in classic human melanoma cells, the pcDNA3.1/V5-His-DUSP6/MKP-3 vector was 
introduced into the A375 human melanoma cell line by CaPO4 transfection. This 
plasmid was able to express a histidine and V5 tagged version of DUSP6 from the 
CMV promoter and also contained a neomycin selectable marker. A375 was selected 
for this study as it was a classic human melanoma cell line harbouring the BRAF 
V600E mutation which occurs in around 70% of human melanoma patients. The 
calcium phosphate transfection method is generally used to generate stably 
transfected cell lines, allowing for long term gene expression studies. However one 
of the disadvantages of this transfection method is its toxicity especially to some cell 
types. A375 cells were better able to withstand the reagent-induced toxicity while our 
immortal mouse melanocytes could not survive in the culture medium with CaPO4. 
A375 cells stably expressing DUSP6 were selected with G418 for 7 days. As before, 
the pooled resistant colonies were used for western analyses. 
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Protein lysates obtained from two independent A375 dishes: A375 1 and A375 2, and 
A375 DUSP6 transfected pool 3 and A375 DUSP6 transfected pool 4 were subjected 
to western blot analysis using a DUSP6 antibody to detect DUSP6 expression and an 
anti-phospho-ERK antibody to detect p-ERK1 (42KD) and p-ERK2 (44KD). Total 
ERK and GAPDH levels of these samples were also determined by western blot to 
correct for different amounts of protein in the various samples. Our data indicated 
that the DUSP6 expression levels dramatically increased in A375 DUSP6 
transfection pools compared to non-transfected A375 cells as expected (Fig. 4.7A). 
Quantification analysis showed that DUSP6 expression increased 2 to 3.2-fold for 
DUSP6 transfection pool compared to non-transfected A375 (Fig. 4.7B). Ectopic 
expression of DUSP6 in A375 cells reduced the expression levels of phospho-
ERK1/2 (Fig. 4.7A) Quantification analysis showed that the level of p-ERK reduced 
2 to 3-fold for DUSP6 transfection pools compared to non-transfected A375 (Fig. 
4.7C). These data suggested that DUSP6 negatively regulated ERK1/2 in human 
melanoma cells as well.  
 
 
Figure 4.7 DUSP6 is a negative regulator of ERK1/2 activity in human 
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A, The pcDNA3.1/V5-His-DUSP6/MKP-3 vector was transfected into A375 cells by CaPO4. 
Western blots show protein levels of DUSP6 (top panel), phosphorylated ERK (p-ERK) (second 
panel), total ERK (third panel) and loading control GAPDH (bottom panel) in A375 1, A375 2, 
A375 DUSP6 transfection pool 3 and A375 DUSP6 transfection pool 4. Stable overexpression of 
DUSP6 reduced phosphorylated ERK (P-ERK) level in the A375 DUSP6 transfection pools.  
 
B, Histogram shows level of DUSP6. DUSP6 levels are expressed relative to loading control 
GAPDH and are normalized to mean level of A375 1 and A375 2. 
 
C, Histogram shows level of phosphorylation of ERK (p-ERK). p-ERK levels are expressed 
relative to total ERK levels and are normalized to mean level of A375 1 and A375 2.  
 
 
4.2.8 Effect of DUSP6 on anchorage independent growth activity of 
human melanoma cells  
 
 
In our distinct subtype of mouse melanoma, DUSP6 played an important role in 
colony formation in methylcellulose. To investigate whether DUSP6 was also 
involved in colony formation in classic human melanoma cells, we assessed 
anchorage independent-growth ability of the A375 DUSP6 transfection pool by 
methylcellulose assay. 5000 cells of A375, A375 DUSP6 transfection pool 3 and 
A375 DUSP6 transfection pool 4 were seeded into methylcellulose. Colony size and 
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software was used to analyze the relative colony size and colony number per 
photographic field at day 7. Minimum colony size cut off was set at 50um for Day 7. 
 
 
In contrast to the methylcellulose assay results of our distinct subtype of mouse 
melanoma, enforced expression of DUSP6 suppressed colony formation in human 
melanoma cells. The data collected from three independent experiments indicated 
A375 DUSP6 transfection pools formed less and smaller colonies than non-
transfected A375 cells (Fig. 4.8A, Fig. 4.8D). Quantification analysis per 
photographic field by Image J showed that the average colony size of A375 DUSP6 
transfection pools was reduced 2-fold compared to non-transfected A375 cells; the 
colony number of the DUSP6 transfection pools was also decreased 2-fold compared 
to non-transfected A375 cells (Fig. 4.8B, Fig. 4.8C). These data suggested that 
overexpression of DUSP6 can reduce anchorage independent growth ability of A375 
human melanoma cells.  
 
 
Figure 4.8 DUSP6 overexpression inhibits colony formation in human 























































































A, A375, A375 DUSP6 transfection pool 3 and A375 DUSP6 transfection pool 4 were mixed 
with methylcellulose and seeded into 6-well plates to form colonies for 12 days. Photos are 
representative of A375 and A375 DUSP6 transfection pool 3 colonies at Day 12.  
 
B, Average colony size of A375, A375 DUSP6 transfection pool 3 and A375 DUSP6 transfection 
pool 4. Colony areas were measured with Image J software. Histogram shows mean colony size 
(+ SEM) from three independent experiments. Average colony size of A375 DUSP6 transfection 
pool 3 and A375 DUSP6 transfection pool 4 are standardised to A375. One way ANOVA with 
Bonferroni’s Multiple Comparison Test was applied for statistical analysis between A375 and 
A375 DUSP6 transfection pools. **, P < 0.01. 
 
C, Total number of colonies counted per photographic field. Each field is approximately 0.59 
mm2 of culture dish. At least 6 fields were counted for each dish. Histogram shows mean colony 
number (+ SEM) from three independent experiments. One way ANOVA with Bonferroni’s 
Multiple Comparison Test was applied for statistical analysis between A375 and A375 DUSP6 
transfection pool. **, P < 0.01. 
 
D, A375, A375 DUSP6 transfection pool 3 and A375 DUSP6 transfection pool 4 were mixed 
with methylcellulose and seeded into 6-well plates to form colonies for 12 days. Photos are 




A375 A375 DUSP6 
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4.2.9 Effect of DUSP6 on invasive ability of human melanoma cells  
  
 
In our distinct subtype of mouse melanoma cells, enforced expression of DUSP6 
increased invasive ability. To investigate the effect of DUSP6 on invasive ability of 
human melanoma cells, the transwell migration assay was used to assess the ability 
of the DUSP6 transfection pools to invade into matrigel in response to a chemotactic 
stimulus (in this case 10% serum). A375, A375 DUSP6 transfection pool 3, A375 
DUSP6 transfection pool 4 were seeded onto transwell filters. After 72 hours, cells 
were labelled with calcein AM dye and visualized in the matrigel at 15um intervals 
by confocal sectioning. The cell number invading at 45um into 3D-gels was 
expressed relative to the cell number in the section that represented the base of the 
transwell filter. Invasion was significantly reduced in the A375 DUSP6 transfected 
pools (relative cell number around 0.05), compared to 0.24 in non-transfected A375 
(Fig. 4.9A). Quantification analysis indicated that the relative cell number of A375 
DUSP6 transfection pools 45um into the 3D-gels decreased 3-5 fold compared to 
non-transfected A375 (Fig. 4.9B). In contrast to the transwell migration assay results 
of our distinct subtype of mouse melanoma, the result with classic human melanoma 
cells suggested that the enforced expression of DUSP6 can reduce invasive ability of 
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A, A375, A375 DUSP6 transfection pool 3 and A375 DUSP6 transfection pool  4 were seeded on 
transwell filters and allowed to invade Matrigel towards a serum gradient. After 96 hours cells 
were labelled with calcein AM and visualized in the Matrigel at 15μm intervals by Olympus 
FV1000 confocal microscopy.  
 
B, Histogram shows the quantitation of invasion at 45um. The amount of dye (positive pixels) 
was calculated for each z-section using Image J software, and expressed relative to the signal in 
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the section that represented the base of the transwell filter. One way ANOVA with Bonferroni’s 
Multiple Comparison Test was applied for statistical analysis between A375 and A375 DUSP6 






DUSP6 was overexpressed in our mouse melanocyte tumour cell lines compared to 
their parental non-tumourigenic cell lines. Overexpression of DUSP6 was associated 
with low levels of phospho-ERK1/2 in our mouse tumour cells. Moreover, ectopic 
expression of DUSP6 increased anchorage independent growth ability and invasive 
ability of our mouse non-tumourigenic melanocytes. This may contribute to the 
ability to form tumours in the xenograft assay. DUSP6 also negatively regulated 
phosphorylation of ERK1/2 in human melanoma cell line, but ectopic expression of 
DUSP6 led to decreased anchorage independent growth ability and invasive ability. 
Considering that these opposing results were obtained with different species and 
subtypes of melanoma, we will discuss the results for mouse and human separately.  
 
 
Some studies showed that activation of the MAPK pathway may be involved in the 
oncogenic behaviour of classic melanoma (Smalley 2003). The activation of RAS 
and BRAF was frequently found in metastatic melanoma. The mutated RAS and 
BRAF can result in activation of ERK1/2. Activated ERK1/2 transfers into the 
nucleus to induce expression of various genes (Dahl and Guldberg 2007). However, 
previous studies have also identified subgroups of melanoma lacking mutations in 
NRAS and BRAF genes (Goel et al. 2006). Some distinct melanoma subtypes with 
overexpression of c-kit and CDK4 did not require ERK activation (Smalley et al. 
2008). The MAPK activity was subject to regulation even in BRAF/NRAS mutant 
melanoma cells and high activity of the MAPK pathway may be important only in 
distinct subsets of melanoma cells (Houben et al. 2008). Furthermore, some studies 
indicated that the absence of cytoplasmic ERK activation became an independent 
adverse prognostic factor in primary cutaneous melanoma and it was speculated that 
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melanomas may be associated with activation of some other pathway leading to 
tumour progression and adverse outcome (Jovanovic et al. 2008). Our results also 
indicated that our tumourigenic mouse melanocyte cell lines have a lower 
phosphorylation level of ERK1/2. Meanwhile, these cell lines showed high 
expression levels of DUSP6. DUSP6 is one of the MKPs members which binds to 
and inactivates ERK1/2 in mammalian cells. DUSP6 plays an important role in 
regulating the duration, magnitude and subcellular compartmentalization of ERK1/2 
expression through a negative feedback mechanism. Disruption of this feedback loop 
was directly relevant to the initiation and development of pancreatic cancer, lung 
cancer and ovarian cancer (Bermudez et al. 2010). The roles of DUSP6 in melanoma 
are still unclear. We suspected that overexpression of DUSP6 was associated with 
the lower levels of p-ERK in our mouse tumour cells. If higher expression of DUSP6 
promotes growth of our transformed melanocytes in the xenograft assay, then 
enforced expression of DUSP6 in the non-transformed parental cells should 
inactivate ERK and contribute to melanoma progression. Therefore, a vector 
harbouring DUSP6 was introduced into the 5-1 cell line to test the effect of DUSP6 
overexpression. Indeed, the result showed that exogenous expression of DUSP6 
dramatically decreased the phosphorylation of ERK1/2. Moreover, overexpression of 
DUSP6 increased anchorage independent growth ability and invasive ability of our 
immortal mouse melanocytes. This suggests that DUSP6 is involved in melanoma 
progression and contributes to the transformation of our immortal mouse 
melanocytes in the xenograft assay.  
 
 
One question remaining is at which stage the DUSP6 expression increase occurs in 
5-1 and 3-1-1 cell lines. One possibility is that high levels of DUSP6 preexist in 
some cells in the 5-1 and 3-1-1 populations prior to xenograft. These cells then grow 
fast in the mouse xenografts and form tumours. We can not rule out another 
possiblility that genetic changes occur in some xenografted cells which are then 
selected by their ability to form a tumour. Either possibility would explain how 
DUSP6 expression was increased in the tumourigenic derivatives.   
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To investigate whether absence of ERK1/2 was required for melanoma progression 
in our xenograft assay, we next introduced vectors harbouring constitutively active 
MEK1 and MEK2 into the 5-1 T2 cell line which had high expression of DUSP6 and 
low expression of p-ERK. Constitutively active MEKs act as dual specificity kinases 
and phosphorylate the regulatory Tyr and Thr residues of ERKs in the cascade (Shaul 
and Seger 2007). If inactivation of MEKs is responsible for the lower level of 
phosphorylation of ERK1/2 and tumour formation in the xenograft assay, exogenous 
expression of constitutively active MEK1 and MEK2 should activate ERK and 
suppress melanoma progression. Our data indicated that exogenous expression of 
constitutively active MEK1/2 increased levels of phosphorylation of ERK1/2 as 
expected. In addition, this efficiently suppressed invasion of 5-1T2 cells in the 
transwell migration assay. It suggested that inactivation of the MAPK pathway 
contributed to invasion of our mouse tumour cells. Furthermore, exogenous 
expression of constitutively active MEK1 and MEK2 inhibited the colony formation 
in the methylcellulose assay, but the differences of colony size and colony number 
between the 5-1T2 MEK1 and MEK2 transfection pools and non-transfected 5-1T2 
cells were not significant. The ability of anchorage independent growth of our mouse 
tumour cells may be more dependent on increased expression of DUSP6 and ERK 
inactivation, rather than reduced activation of ERKs by MEKs. Exogenous 
expression of constitutively active MEK1 and MEK2 not only increased the level of 
phospho-ERK but also increased DUSP6 expression in our mouse tumourigenic cells. 
It agrees with a report which showed that the activation of the MAPK pathway can 
increase the expression of DUSP6 through regulation of transcriptional factor ETS2 
(Furukawa et al. 2008). An increase of DUSP6 would contribute to anchorage 
independent-growth of our mouse tumour cells and so impair the suppression of 
colony formation induced by introduction of constitutively active MEK1 and MEK2. 
We also can not rule out the possibility that DUSP6 controlled the anchorage 
independent growth of our mouse tumour cells through other uncharacterized targets 
and pathways rather than the MAPK pathway. In either case this would explain why 
we did not observe the significant changes in the methylcellulose assays following 
introduction of constitutively active MEK1 and MEK2.  
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In this study, the DUSP6 plasmid was introduced into the classic human melanoma 
cell line A375 as well. The human melanoma cell line A375 which expresses the 
oncogenic BRAF V600E mutation has constitutively elevated ERK activity and 
activation of the MAPK pathway is required for its proliferation. A MEK inhibitor 
that blocked this constitutive activation of ERK1/2, inhibited DNA synthesis and 
induced cell death in A375 cells (Cheng et al. 2007). If the MAPK pathway 
contributes to proliferation of A375 human melanoma cells, enforced expression of 
DUSP6 may decrease phosphorylation of ERK1/2 and stop or retard the A375 cell 
growth. To investigate this hypothesis, DUSP6 was introduced to A375 cells. We 
demonstrated that exogenous expression of DUSP6 dephosphorylated ERK1/2 in 
DUSP6 transfected A375 pools. Although the DUSP6 transfected A375 pools had 
the same growth rate as non-transfected A375 cells in cell culture (see Chapter 5), 
DUSP6 A375 transfected pools formed smaller and fewer colonies than non-
transfected A375 cells in the methylcellulose assay. These data suggested that 
DUSP6 can not only regulate the activation of the MAPK pathway in our mouse 
immortal cells but also can control the MAPK pathway in human melanoma cells. 
Furthermore, the enforced expression of DUSP6 decreased anchorage-independent 
growth ability of the A375 human melanoma cell line. Our data provided the first 
direct evidence for the role of DUSP6 on human melanoma development. This 
finding was comparable with previous observations in human pancreatic cancers. 
The upregulation of DUSP6 was reported in the majority of dysplastic cells in 
pancreatic tumours, but downregulation was seen in invasive carcinoma cells. 
Adenovirus-mediated transfer of DUSP6 into cultured pancreatic cancer cells led to 
suppression of growth and induction of apoptosis (Furukawa et al. 2003). In addition, 
knockdown of endogenous DUSP6 increased ERK1/2 activity which contributed to 
cell proliferation and anchorage-independent growth ability of the A2780 ovarian 
cell line. On the contrary, enforced expression of a DUSP6 in DUSP6 deficient 
ovarian cell line suppressed cell growth, anchorage-independent growth ability and 
tumour growth in nude mice (Chan et al. 2008). Recent study also indicated that 
overexpression of DUSP6 markedly inhibited the growth of lung cancer cell lines 
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and that the expression decreased with the progression of grade and stage of lung 
cancers (Okudela et al. 2009).  
 
 
Our results also indicated that A375 DUSP6 transfected cells are less invasive than 
non-transfected A375 cells in matrigel. It was possible that enforced expression of 
DUSP6 inhibited melanoma cell invasion through inactivation of the MAPK 
pathway. As described in the general introduction (Chapter 1), the MAPK pathway 
played important roles in classic melanoma invasion. Firstly, constitutive activation 
of the MAPK pathway appears to be associated with downregulated E-cadherin 
expression. Inactivation of the MAPK pathway can block the decrease of E-cadherin 
and inhibit melanoma invasion (Meier et al. 2005). In addition, the constitutive 
activation of the MAPK pathway can upregulate integrin expression which 
contributes to melanoma survival and invasive growth in ECM (Schwartz et al. 1995). 
The expression of αVβ3 integrin was involved in melanoma invasion (Albelda et al. 
1990). Furthermore, the constitutive activation of the MAPK pathway increased 
expression and activity of proteolytic enzymes that helped melanoma cells degrade 
the ECM. MMP-2 and MMP-9, which degrade basement membrane collagen, were 
reported to be particularly important proteolytic enzymes involved in melanoma 
invasion (MacDougall et al. 1999, Vaisanen et al. 1999). Treatment of A375 
melanoma cells with MEK inhibitors U1026 and PD98059 reduced matrigel invasion. 
This suppression of invasion was associated with inhibition of MMP-9 and uPA 
expression (Ge et al. 2002). Enforced expression of DUSP6 dephosphorylated 
ERK1/2 and blocked the MAPK pathway in A375 human melanoma cell line. This 
inactivation may result in upregulated expression of E-cadherin and downregulated 
expression of integrin and MMPs which reduce the matrigel invasion of classic 
human melanoma cells.  
 
 
As demonstrated, overexpression of DUSP6 in our immortal mouse melanocyte cells 
led to increased tumourigenicity and invasive ability, while enforced expression of 
DUSP6 in classic human melanoma cell caused inhibition of anchorage-independent 
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colony formation and invasion in matrigel. One reason for the difference may result 
from the species difference. It is possible that mice and humans have different 
mechanisms involved in melanoma formation. We can not rule out that DUSP6 may 
interact with different targets and control different pathways in human and mouse 
cells. We also considered that our mouse tumour cell lines may resemble a distinct 
molecular subtype of human melanoma with decreased levels of p-ERK and p-AKT 
which were uncommon in classic melanoma (Curtin et al. 2006, Shields et al. 2007). 
In addition, our mouse tumour cells did not have a BRAF V600E equivalent 
mutation, while A375 human melanoma cells harboured the BRAF V600E mutation. 
Some studies showed that there were different mechanisms underlying melanoma 
progression in melanoma cell lines with BRAF mutations and those without BRAF 
mutations (Bloethner et al. 2005, Pratilas et al. 2009, Ryu et al. 2007). Therefore, 
DUSP6 may play different roles in our distinct subtype of mouse melanoma 
compared to classic human melanoma A375. 
 
 
There is limited information about the roles of DUSP6 on melanoma progression. 
Our studies provide the first direct evidence that DUSP6 may be involved in 
development of melanoma. Our results also demonstrated that introduction of 
constitutively active MEK1/2 to our mouse tumourigenic melanocytes inhibited 
invasion in matrigel. The previous studies of roles of the MAPK pathway activation 
on development of mouse melanoma are controversial. One study showed that 
introduction of constitutively active MAP kinase kinase (MAPKK) into immortalized 
melanocytes L10BIOBR led to tumourigenesis in nude mice (Govindarajan et al. 
2003). However, another study also indicated that metastasis in an orthotopic murine 
model of melanoma is not dependent of elevated phosphorylated ERK (Rozenberg et 
al. 2010). In addition, growth of oncogenic BRAF overexpressing tumours with 
hyperactivation of ERK was inhibited in nude mice (Maddodi et al. 2010).  
 
 
To sum up, we investigated the functions of DUSP6 in melanoma cells in this 
chapter. We concluded that DUSP6 regulated phosphorylation of ERK1/2 in both our 
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tumourigenic mouse melanocytes and human melanoma cell lines. In our distinct 
subtype of mouse melanoma, overexpression of DUSP6 may contribute to melanoma 
formation in the xenograft assay. Introduction of constitutively active MEK1 and 
MEK2 into our mouse tumourigenic cells can suppress the invasion in matrigel, but 
did not result in significant changes of anchorage independent growth in the 
methylcellulose assay. In classic human melanoma, inhibition of anchorage 
independent growth and invasion were observed after exogenous expression of 
DUSP6. DUSP6 may act as a tumour suppressor in classic melanoma cells. We hope 
our efforts will contribute to better understanding the mechanisms underlying of 
melanoma progression and assist the development of new therapeutic interventions 































































Cisplatin resistance and ERCC1  





Cisplatin (CDDP) is one of the most widely used chemotherapeutic agents for 
treatment of tumours. It is particularly active against germ-cell tumours, prolongs 
survival in ovarian cancer and in non-small cell lung cancer, and plays an important 
role in the treatment of oesophageal, cervical, gastric and prostate cancer (Lebwohl 
and Canetta 1998). However, the efficacy of cisplatin is hampered by resistance of 
cancer cells to its cytotoxicity. The cellular toxicity of cisplatin occurs primarily 
through its ability to bind to DNA to generate DNA adducts leading to intrastrand or 
interstrand cross links which disrupt the structure of the DNA molecule, leading to 
steric changes in the helix. Cells can become resistant to cisplatin through enhanced 
ability to remove DNA adducts and so repair cisplatin-induced lesions in DNA 
(Martin et al. 2008). 
 
 
Nucleotide excision repair (NER) levels are involved in determining resistance or 
sensitivity to cisplatin (Rabik and Dolan 2007). The nucleotide excision repair 
system can recognize cisplatin induced DNA lesions, which alter the helical structure 
of the DNA molecule, followed by complex formation to unwind the DNA around 
the lesions and excise them. The excised portion is resynthesized and ligated to repair 
the cisplatin induced DNA damage and rescue DNA replication and transcription 
over the damage region (Rabik and Dolan 2007). ERCC1 is one of the critical repair 
genes in NER. ERCC1 forms a complex with xeroderma pigmentosum 
complementation group F protein to excise cisplatin induced DNA lesions (Evans et 
al. 1997). Overexpression of ERCC1 was found in various types of cancers, 
including non-small cell lung cancer (NSCLC), ovarian, colorectal and gastric 
cancers and this overexpression was related to the formation of cellular and clinical 
drug resistance. By contrast, with lack of ERCC1 expression, repair of cisplatin 
induced DNA adducts disappeared and cancer cells were more sensitive to cisplatin 
(Gossage and Madhusudan 2007). However, whether cisplatin treatment can increase 
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ERCC1 expression in melanoma cell lines and, if so, what kinds of mechanisms are 
involved in ERCC1 overexpression by cisplatin is still unclear. 
 
 
The MAPK signaling pathway is constitutively activated via multiple mechanisms in 
malignant melanoma (Oliveria et al. 2006). The MAPK signal transduction pathway 
regulates cell survival, proliferation and invasion, key functions in the progression of 
melanoma (Hoshino et al. 1999). Treatment of melanoma cell lines with cisplatin did 
not cause the anticipated decrease of ERK1/2 phosphorylation, to the contrary, it 
resulted in increased ERK1/2 phosphorylation (Mirmohammadsadegh et al. 2007). 
Moreover, a recent study shows that the MAPK pathway plays an important role in 
the regulation of ERCC1 expression by EGF in human hepatoma cells (Andrieux et 
al. 2007). Therefore, we wished to investigate the possibility that cisplatin activates 




DUSP6 is a member of the subfamily of protein tyrosine phosphatases known as 
dual-specificity phosphatases. DUSP6 can dephosphorylate ERK1/2 by protein-
protein interaction via a mitogen-activatated protein kinase interaction motif within 
the N-terminal ERK1/2-binding domain (Bermudez et al. 2010). A recent study has 
shown that cisplatin might cause degradation of DUSP6, which in turn leads to 
aberrant ERK1/2 activation and contributes to chemoresistance of human ovarian 
cancer cells (Chan et al. 2008). In addition, cisplatin-mediated transcriptional 
inhibition of DUSP6 contributes to the delayed and long lasting accumulation of 
ERK 1/2 phosphorylation that is driven by cisplatin in neurons (Gozdz et al. 2008). 
However, there is a lack of similar reports in other human cancers so far. We 
postulated that decreased DUSP6 levels contribute to activation of ERK1/2 during 
cisplatin treatment in melanoma cells. 
 
 
In our study, we analyzed ERCC1 expression as well as XPF expression in the 
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human melanoma cell line A375 treated by cisplatin. The results provide evidence 
that p-ERK levels show a time dependent increase after cisplatin treatment, while 
ERCC1 and XPF expression are both augmented by cisplatin. Use of a MEK 
inhibitor showed ERCC1 induction was dependent on the MAPK pathway. The 
DUSP6 level decreased after cisplatin treatment, while overexpression of DUSP6 
inhibited ERCC1 induction by cisplatin and reduced resistance to cisplatin. 
 
 
5. 2 Results  
  
 
5.2.1 Detection of ERK phosphorylation and ERCC1 and XPF 
induction after cisplatin treatment in a melanoma cell line  
 
 
To evaluate the molecular mechanisms of cisplatin induced drug resistance in 
melanoma, human melanoma A375 cells were treated with cisplatin (6uM) for 12h, 
24h, 36h, 48h and 72h. Protein lysates obtained at various times from untreated and 
CDDP-treated cells were subjected to western blot analysis using an anti-phospho-
ERK antibody to detect p-ERK1 (42KD) and p-ERK2 (44KD) and an anti-ERCC1 
antibody to detect ERCC1 (39KD) induction. Total ERK and GAPDH levels of these 
samples were also determined by western blot to correct for different amounts of  
protein in the various samples (Fig. 5.1A).  
 
 
Cisplatin treatment caused a time dependent increase in levels of phosphorylated 
ERK1/2 while total ERK 1/2 expression was unaffected. Activation of ERK1/2 
increased 24 h after incubation with cisplatin and eventually attained a peak 3.5-fold 
increase at 48 h after cisplatin administration. The activation of ERK1/2 was 
decreased by 72 h (Fig. 5.1B). Cisplatin induced a similar time dependent ERCC1 
increase. Expression of ERCC1 protein was increased at 24h and peaked at 48h with 
an approximate 5-fold increase after cisplatin exposure. The induction of ERCC1 by 
cisplatin was also reduced at 72h (Fig. 5.1C).  























Given that ERCC1 was induced in the melanoma cell line A375 by cisplatin 
treatment, it was important to detect the XPF protein level too since it forms a 
complex with ERCC1 to excise cisplatin induced DNA lesions. Human melanoma 
cell line A375 was treated with cisplatin (6uM) for 12h, 24h, 36h and 72h. XPF and 
loading control GAPDH levels from samples at various times were detected by 
western blot. As shown in the upper panel, cisplatin induced a time dependent XPF 
increase up to 72 hours (Fig. 5.2A). The protein quantification analysis showed a 2 to 
5-fold XPF induction after cisplatin treatment (Fig. 5.2B). Next, the role of ERK1/2 
in the regulation of ERCC1 and XPF was investigated in more detail.  
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A, Western blots showing protein levels of ERCC1 (top panel), phosphorylated ERK (p-ERK) 
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and loading control GAPDH (middle panel) and total ERK (t-ERK) (bottom panel) in human 
melanoma A375 cells treated with cisplatin (6uM) for 12, 24, 36, 48 and 72h. 
 
B, Histogram showing mean level of p-ERK (+ SEM) from three independent experiments. p-
ERK levels are expressed relative to total ERK levels and are normalized to the non-cisplatin 
treated control.  
 
C, Histogram showing mean level of ERCC1 (+ SEM) from three independent experiments. 
ERCC1 levels are expressed relative to loading control GAPDH levels and are normalized to the 
non-cisplatin treated control.  
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A, Western blots showing protein levels of XPF (top panel) and loading control GAPDH (bottom 
panel) in human melanoma A375 cells treated with cisplatin (6uM) for 12, 24, 36 and 72h. Cross-
reacting bands, XPF and GAPDH bands are indicated by arrows on the right.  
 
B, Histogram showing level of XPF. XPF levels are expressed relative to loading control 
GAPDH and are normalized to the non-cisplatin treated control. There is no error bar for this 
experiment as it was only done once.  
 
 
5.2.2 MAPK pathway regulates ERCC1 protein level following 
cisplatin treatment  
 
 
A specific inhibitor of MEK1/2, PD0325901, has been developed, which is highly 
selective in preventing ERK activation (Ciuffreda et al. 2009).  It was used to 
evaluate whether ERK activation regulated ERCC1 induction following cisplatin 
treatment. Human melanoma cell line A375 was treated with cisplatin (6uM), 
PD0325901 (1uM), or both cisplatin and PD0325901 for 24h, 48h and 72h. 
PD0325901 was added 30 min before cisplatin treatment. Protein lysates obtained at 
various times from untreated and treated cells were subjected to western blot analysis 
using an anti-phospho-ERK antibody and an anti-ERCC1 antibody to detect 
phosphorylated ERK and ERCC1 induction. Total ERK and GAPDH levels of these 
samples were also determined by western blot to correct for different amounts of 
protein in the various samples.  
 
As shown in Figure 3A, PD0325901 successfully inhibited ERK1/2 activation 
following cisplatin treatment (Fig. 5.3A). ERK1/2 phosphorylation levels in cisplatin 
treated cells significantly increased about 3-fold at 48h, while there were no bands 
showing ERK1/2 activation in the cells treated with PD0325901 or in cells treated 
with both cisplatin and PD0325901 (Fig. 5.3B). Neither cisplatin nor PD0325901 
affected total ERK1/2 expression (Fig. 5.3A).  
 
As in the previous experiment cisplatin treatment resulted in increased ERCC1 
protein levels, the peak was at 4.5-fold the control level at 48 hours (Fig 5.3C). The 
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MEK inhibitor efficiently prevented this cisplatin-induced increase in ERCC1 
protein. PD0325901 on its own did not affect the basal level of ERCC1 protein at 48 
and 72 hours (Fig 5.3C). I conclude that ERK activation plays an important role in 
the regulation of ERCC1 levels after cisplatin treatment in melanoma cells. 
 
 

































































































































































































































































































































A, Western blots showing protein levels of phosphorylated ERK (p-ERK)  (top panel), total ERK 
(t-ERK) (second panel), ERCC1 (third panel) and loading control GAPDH (bottom panel) in 
human melanoma A375 cells treated with cisplatin (6uM), MEK inhibitor, PD0325901 (1uM), or 
both cisplatin and MEK inhibitor for 24h, 48h and 72h. PD0325901 was added 30 min before 
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B, Histogram showing mean level of p-ERK (+ SEM) from three independent experiments. p-
ERK levels are expressed relative to total ERK levels. At each time point, p-ERK levels are 
standardized to the non-cisplatin treated control. Control, CDDP, MEK inhibitor and both MEK 
inhibitor and CDDP groups are plotted in blue, purple, yellow and green columns, respectively. 
One way ANOVA with Bonferroni’s Multiple Comparison Test was applied for statistical 
analysis among control, cisplatin, PD0325901 and both cisplatin and PD0325901 groups. *, P < 
0.05 and ***, P < 0.001.  
 
C, Histogram shows mean level of ERCC1 (+ SEM) from three independent experiments. 
ERCC1 levels are expressed relative to loading control GAPDH levels. At each time point, 
ERCC1 levels are standardized to the non-cisplatin treated control. Control, CDDP, MEK 
inhibitor and both MEK inhibitor and CDDP groups are plotted in blue, purple, yellow and green 
columns, respectively. One way ANOVA with Bonferroni’s Multiple Comparison Test was 
applied for statistical analysis among control, cisplatin, PD0325901 and both cisplatin and 
PD0325901 groups. **, P < 0.01.  
 
 




To determine whether ERCC1 and XPF transcription levels were also increased 
following cisplatin treatment and whether the MAPK pathway regulated ERCC1 and 
XPF mRNA induction, human melanoma cell line A375 was treated with cisplatin 
(6uM), PD0325901 (1uM), or both cisplatin and PD0325901 for 24h, 48h and 72h. 
As before, PD0325901 was added 30 min before cisplatin treatment. Total mRNA 
was extracted at various times from treated cells and control cells. Reverse 
transcription was performed and ERCC1 and XPF mRNA levels were determined by 
performing real time RT-PCR. Beta-actin was used as the internal control in order to 
normalize the expression of ERCC1 and XPF. A standard curve was first run for each 
gene specific PCR reaction in order to demonstrate whether PCR efficiencies of 
target and internal control gene were approximately equal. If the absolute value of 
the slope of the plot of log dilution factor vs. ΔCT < 0.1, then the comparative CT 
method can be used to analyze real time RT-PCR data (Livak and Schmittgen 2001). 
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The relative efficiency plot for ERCC1 vs. Beta-actin showed that the absolute value 
of the slope was 0.0467 (Fig. 5.4A) and the relative efficiency plot for XPF vs. Beta-
actin showed that the absolute value of the slope was 0.0551(Fig 5.4B), so both 
passed this test. Therefore, the comparative CT method was used to measure relative 
concentrations of ERCC1 and XPF mRNA. 
 
 
As in the previous protein experiment cisplatin treatment also resulted in increased 
ERCC1 mRNA levels, the peak was at 3.5-fold the control level at 48 hours (Fig 5.5). 
The MEK inhibitor efficiently prevented this cisplatin-induced increase in ERCC1 
mRNA. PD032501 on its own did not affect the basal level of ERCC1 mRNA at 48 
and 72 hours (Fig 5.5). It suggested that ERK activation played an important role in 
the regulation of ERCC1 transcriptional levels after cisplatin treatment in melanoma 
cells. Cisplatin treatment also resulted in increased XPF mRNA levels; the peak was 
at 2.5 fold the control level at 24 hours. Although XPF mRNA induction by cisplatin 
was slightly reduced by the MEK inhibitor, unlike the changes with ERCC1 mRNA, 
statistical analysis indicated that this reduction was not significant. PD032501 on its 
own did not affect the basal level of XPF mRNA at 48 and 72 hours (Fig. 5.6). 
 
 




y = 0.0467x + 2.3993
Log (dilution factor)
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B 
y = -0.0551x + 7.3063
Log (dilution factor)

















    
 
A, Relative qPCR efficiency plot for ERCC1 and Beta-actin. Delta CT values are the means of 
three independent experiments. The absolute value of the slope of log dilution factor vs. delta CT 
is 0.0467.  
 
B, Relative qPCR efficiency plot for XPF and Beta-actin. Delta CT values are the means of three 
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The histogram shows the mean level (+ SEM) of ERCC1 mRNA relative to beta-actin mRNA in 
human melanoma cells determined from three independent experiments by qPCR. Cells are 
untreated (blue), or treated with cisplatin (6uM) (purple), or treated with the MEK inhibitor, 
PD0325901 (1uM) (yellow), or treated with both cisplatin and MEK inhibitor (green). The MEK 
inhibitor was added 30 minutes before cisplatin treatment. Samples were collected at 24, 48 and 
72h. One way ANOVA with Bonferroni’s Multiple Comparison Test was applied for statistical 
analysis among control, cisplatin, PD0325901 and both cisplatin and PD0325901 groups. ***, P 
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Figure 5.6 XPF transcriptional levels are regulated by cisplatin but are not 








































































The histogram shows the mean level (+ SEM) of XPF mRNA relative to beta-actin mRNA in 
human melanoma cells determined from three independent experiments by qPCR. Cells were 
untreated (blue), or treated with cisplatin (6uM) (purple), or treated with the MEK inhibitor, 
PD0325901 (1uM) (yellow), or treated with both cisplatin and MEK inhibitor (green). The MEK 
inhibitor was added 30 minutes before cisplatin treatment. Samples were collected at 24, 48 and 
72h. One way ANOVA with Bonferroni’s Multiple Comparison Test was applied for statistical 
analysis among control, cisplatin, PD0325901 and both cisplatin and PD0325901 groups. *, P < 
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5.2.4 DUSP6 changes following cisplatin treatment  
 
 
It has been demonstrated that the level of ERK1/2 phosphorylation increased after 
cisplatin treatment in a melanoma cell line in a previous study 
(Mirmohammadsadegh et al. 2007). However mechanisms of activation of ERK1/2 
during cisplatin treatment were still unclear. As ERK1/2 could be inactivated by 
dephosphorylation, it was possible that inhibition of DUSP6 could lead to 
accumulation of active ERK1/2 (Bermudez et al. 2010). To test whether inhibition of 
DUSP6 may be involved in cisplatin effects on human melanoma, A375 cells were 
treated with cisplatin (6uM) for 24h, 48h and 72h. Protein lysates obtained at various 
times from untreated and treated cells were subjected to western blot analysis using 
an anti-phospho-ERK antibody and an anti-DUSP6 antibody to detect 
phosphorylated ERK and DUSP6. Total ERK and GAPDH levels of these samples 
were also determined by western blot to correct for different amounts of  protein in 
the various samples. 
 
 
As in the previous experiment, western blot results showed that ERK1/2 
phosphorylation levels significantly increased during cisplatin treatment, while 
DUSP6 levels decreased under the same conditions (Fig. 5.7A). Protein 
quantification analysis revealed around a 3-fold ERK1/2 activation increase at 48 
hours after cisplatin treatment (Fig. 5.7B). On the contrary, cisplatin reduced 
expression of DUSP6 3-fold at 48 hours (Fig. 5.7C). Cisplatin did not affect basal 
levels of total ERK and GAPDH. There was a good reverse correlation between 
ERK1/2 phosphorylation and DUSP6 expression. The data suggested that DUSP6 
may be involved in MAPK pathway activation and ERCC1 induction during cisplatin 
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Figure 5.7 DUSP6 may be involved in the MAPK pathway activation after 





























































































































A, Western blots showing protein levels of phosphorylated ERK (p-ERK) (top panel), total ERK 
(T-ERK) (second panel), DUSP6 (third panel) and loading control GAPDH (bottom panel) in 
human melanoma A375 cells treated with cisplatin (6uM) for 24h, 48h, 72h. PD0325901 was 
added 30 min before cisplatin treatment.  
 
B, Histogram showing mean level of p-ERK (+ SEM) from three independent experiments. p-
ERK levels are expressed relative to total ERK levels. At each time point, p-ERK levels are 
standardized to the non-cisplatin treated control. One way ANOVA with Bonferroni’s Multiple 
Comparison Test was applied for statistical analysis between control and cisplatin groups. *, P < 
0.05 and ***, P < 0.001.  
 
C, Histogram showing mean level of DUSP6 (+ SEM) from three independent experiments. 
DUSP6 levels are expressed relative to loading control GAPDH levels. At each time point, 
DUSP6 levels are standardized to the non-cisplatin treated control. One way ANOVA with 
Bonferroni’s Multiple Comparison Test was applied for statistical analysis between control and 
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5.2.5 DUSP6 overexpression inhibited induction of ERCC1 and XPF 
mRNA following cisplatin treatment  
 
 
To investigate whether DUSP6 reduction was involved in ERCC1 and XPF induction 
following cisplatin treatment, human melanoma cell line A375 was transfected with 
plasmids carrying the DUSP6 gene and the hygromycin resistance selection marker. 
Cells stably expressing DUSP6 were selected with Hygromycin. Two independent 
pools of resistant colonies were used for the following experiments. Successful 
transfection was confirmed by western blots for DUSP6 as described in Chapter 4. 
Because 48h treatment with cisplatin seemed to be optimal for the ERCC1 and XPF 
increase as well as for ERK activation in our culture conditions, this time point was 
selected to study the cisplatin effect on DUSP6 transfected A375 cell pools and non-
transfected A375 cells. Relative concentrations of ERCC1 and XPF mRNA were 
detected by real time RT-PCR as described before. DUSP6 overexpression in A375 
significantly reduced ERCC1 basal mRNA levels around 5-fold, but did not affect 
XPF basal mRNA levels (Fig. 5.8A, Fig. 5.8B). Furthermore, as in the previous 
experiment ERCC1 and XPF mRNA levels were augmented in non-transfected A375 
cells stimulated by cisplatin. On the contrary, under the same condition of cisplatin 
treatment, overexpression of DUSP6 in A375 cells resulted in no induction of 
ERCC1 and XPF mRNA compared with non-transfected cells (Fig. 5.8C, Fig. 5.8D). 
These studies were performed in triplicate. The data suggested that DUSP6 
negatively regulated ERCC1 and XPF induction by cisplatin treatment in melanoma 






















































































































































































































































































Figure 5.8 DUSP6 overexpression inhibits induction of ERCC1 and XPF mRNA 
after cisplatin treatment  
 
A                                                                 B 





















A, Histogram showing the mean level (+ SEM) of ERCC1 mRNA relative to beta-actin mRNA in 
human melanoma A375, A375 DUSP6 transfection pool 3 and A375 DUSP6 transfection pool 4 
determined from three independent experiments by qPCR. Samples were collected at 48h. 
ERCC1 mRNA levels of A375 DUSP6 transfection pools were standardized to non-transfected 
A375. One way ANOVA with Bonferroni’s Multiple Comparison Test was applied for statistical 
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B, Histogram showing the mean level (+ SEM) of XPF mRNA relative to beta-actin mRNA in 
human melanoma A375, A375 DUSP6 transfection pool 3 and A375 DUSP6 transfection pool 4 
determined from three independent experiments by qPCR. Samples were collected at 48h. XPF 
mRNA levels of A375 DUSP6 transfection pools were standardized to non-transfected A375.  
One way ANOVA with Bonferroni’s Multiple Comparison Test was applied for statistical 
analysis between A375 and A375 DUSP6 transfection pools. There was no significant difference 
between A375 DUSP6 transfection pools and non-transfected A375.  
 
C, Histogram showing the mean level (+ SEM) of ERCC1 mRNA relative to beta-actin mRNA in 
human melanoma A375, A375 DUSP6 transfection pool 3 and A375 DUSP6 transfection pool 4 
determined from three independent experiments by qPCR. Cells were untreated (blue), or treated 
with cisplatin (6uM) (purple). Samples were collected at 48h. For each cell line ERCC1 mRNA 
levels after cisplatin treatment were standardized to the non-treated control. One way ANOVA 
with Bonferroni’s Multiple Comparison Test was applied for statistical analysis between control 
and cisplatin groups. ***, P < 0.001.  
 
D, Histogram showing the mean level (+ SEM) of XPF mRNA relative to beta-actin mRNA in 
human melanoma A375, A375 DUSP6 transfection pool 3 and A375 DUSP6 transfection pool 4 
determined from three independent experiments by qPCR. Cells were untreated (blue), or treated 
with cisplatin (6uM) (purple). Samples were collected at 48h. For each cell line XPF mRNA 
levels after cisplatin treatment were standardized to the non-treated control. One way ANOVA 
with Bonferroni’s Multiple Comparison Test was applied for statistical analysis between control 
and cisplatin groups. *, P < 0.05. 
 
 
5.2.6 DUSP6 overexpression reduced cisplatin resistance of 
melanoma cells  
 
 
In order to further understand the effect of reduction of ERCC1 and XPF induction 
by overexpression of DUSP6 on cisplatin resistance, cytotoxicity of the cells to 
cisplatin was determined by the Sulforhodamine B assay. A growth rate experiment 
was firstly carried out in control medium with the different cell populations. The 
growth rates of non-transfected A375 cells, DUSP6 transfected A375 cell pool 3 and 
DUSP6 transfected A375 cell pool 4 were determined by Sulforhodamine B assay. 
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Cells were plated into 96-well plates with starting cell density 300 cells/ well and 
150ul culture media. The plates were harvested at day 3, day4 and day5. The relative 
growth of the different cell populations was analyzed and plotted using a histogram. 
The data showed that there was no significant difference in growth rate between non-
transfected A375 cells and DUSP6 transfected A375 cell pools (Fig. 5.9). Thus any 
difference in the response to cisplatin between the cell lines could not be explained 
simply on the basis of different growth rates of the untreated cell lines.  
 
 
The sensitivities of non-transfected A375 cells, DUSP6 transfected A375 cell pool 3 
and DUSP6 transfected A375 cell pool 4 to cisplatin were examined by 
Sulforhodamine B assay. Cells were plated into 96-well plates as described before. 
The desired amount of cisplatin mixed with 50ul culture media was added to each 
well to make a total volume of 200ul media with a final concentration of cisplatin 
ranging from 0.1uM to 3uM. For corresponding controls, 50ul culture media without 
cisplatin was added to each well. The plates were incubated for 5 days. Then the 
plates were harvested and assayed.   
 
 
The growth of non-transfected A375 cells, DUSP6 transfected A375 cell pool 3 and 
DUSP6 transfected A375 cell pool 4 with different concentration of cisplatin relative 
to untreated controls was analyzed and plotted using a growth curve. Figure 5.10 
shows the relative growth on day 5. The half maximal inhibitory concentration (IC50) 
was used to compare sensitivities of different cell populations to cisplatin. IC50 is a 
measure of the effectiveness of a compound in inhibiting biological or biochemical 
function. This quantitative measure indicates how much of a particular drug is 
needed to inhibit a given biological process by half. It is commonly used as a 
measure of antagonist drug potency in pharmacological research (Soothill et al. 
1992). Our data showed the cells with DUSP6 overexpression were more sensitive to 
cisplatin compared with non-transfected cells. The IC50 for A375 was 0.59+0.05uM 
while the IC50 for A375 transfection pool 3 was 0.30+0.02uM. In a separate 
experiment, the IC50 for A375 was 0.51+0.03uM while the IC50 for A375 
transfection pool 4 was 0.31+0.02uM (Figure 5.10). One way ANOVA with 
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Bonferroni’s Multiple Comparison was applied for statistical analysis of IC50 
between A375 and A375 transfection pools and showed that the IC50 values in the 
DUSP6 overexpression pools were significantly reduced compared to A375.  
 
 

































Gowth rate of human melanoma A375 cells and A375 DUSP6 transfection pools 3 and 4 were 
determined by SRB growth assay. Histogram shows the O.D value at 510nm for the SRB assay. 
Mean O.D level (+ SEM) from 8 independent wells of A375, A375 DUSP6 transfection cell pool 
3 and A375 DUSP6 transfection cell pool 4 are plotted as blue, purple and yellow columns. Y-
axis shows the O.D values while X-axis shows different days following cell plating. Statistical 
analysis was performed by one way ANOVA with Bonferroni’s Multiple Comparison Test. 
There were no statistically significant differences between A375 and DUSP6 transfection cell 





















































































Figure 5.10 DUSP6 overexpression sensitizes human melanoma A375 cells to 
cisplatin 
 
A                                                                  B                                                                   
 
A, Resistance to cisplatin of human melanoma A375 cells and A375 DUSP6 transfection pool 4 
were determined by SRB growth assay. Cells in 96-well plates were treated with various 
concentration of cisplatin for 5 days before being stained and extracted to determine the amount 
of growth. Growth of cisplatin treated cells is expressed relative to untreated control cells. Data 
shown are mean levels (+ SEM) from three independent experiments. The IC50 for A375 was 
0.51+0.03uM, the IC50 for A375 transfection pool 4 was 0.31+0.02uM. One way ANOVA with 
Bonferroni’s Multiple Comparison was applied for statistical analysis of IC50 between A375 and 
A375 transfection pool 4. ***, P < 0.001. 
 
B, Resistance to cisplatin of human melanoma A375 cells and A375 DUSP6 transfection pool 3 
were determined by SRB growth assay. Cells in 96-well plates were treated with various 
concentration of cisplatin for 5 days before being stained and extracted to determine the amount 
of growth. Growth of cisplatin treated cells was expressed relative to untreated control cells. Data 
shown are mean levels (+ SEM) from three independent experiments. The IC50 for A375 was 
0.59+ 0.05uM, the IC50 for A375 transfection pool 3 was 0.30+0.02uM. One way ANOVA with 
Bonferroni’s Multiple Comparison was applied for statistical analysis of IC50 between A375 and 
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5.2.7 Longer ERCC1 transcripts following cisplatin treatment  
 
 
A previous study in our group showed that a larger Ercc1 transcript encoded ERCC1 
protein in mouse skin and cultured mouse keratinocytes and this novel transcript 
originated from an upstream promoter, but no such transcript has previously been 
clearly demonstrated in human cells (Song et al. 2011). As cisplatin induced an 
ERCC1 mRNA increase following cisplatin treatment in human melanoma A375 
cells, we postulated that larger ERCC1 transcripts in human cells could also be 
induced by cisplatin.  
 
 
An RT-PCR assay was used to detect novel ERCC1 transcripts originating upstream 
of the normal transcription initiation site. Several novel forward primers were 
designed located upstream of the normal human ERCC1 initiation site as shown in 
Figure 5.11A. If novel ERCC1 transcripts originating upstream existed, these primers 
in combination with reverse primer H-exon 2-3, which is located in ERCC1 exon 2, 
should generate PCR products from 291bp to 419bp (Fig. 5.11A). H-exon1-A 
forward primer in combination with H-exon 2-3 reverse primer was used to detect 
the exon1 to exon2 region of all ERCC1 transcripts (Fig. 5.11A) (Winter et al. 2005). 
The 164bp PCR product seen with the exon1 to exon2 region was generated by 
alternative splicing of a 42bp region in ERCC1 exon1 from the expected 206bp band. 
Loss of this sequence during splicing has been reported before (Winter et al. 2005).   
 
 
The search for larger ERCC1 transcripts was carried out first in human melanoma 
cell line A375. The total mRNA was extracted from untreated human melanoma 
A375 cells. Reverse transcription was performed to generate a pool of A375 cDNA. 
PCR using H-exon1-A and H-exon 2-3 was then performed on the A375 cDNA pool 
to amplify the sequence between ERCC1 exon 1 and exon 2. PCRs using different 
combinations of novel primers with H-exon 2-3 were also performed on the A375 
cDNA pool to amplify any transcripts initiating upstream and extending through 
exon 2. The PCR products were electrophoresed on a 1.5% agarose gel and 
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visualized by ethidium bromide staining. As shown in the Figure 5.11B, for the 
products common to all ERCC1 transcripts, two clear bands at the predicted sizes of 
206bp and 164bp were observed. For the larger products from upstream transcripts, 
two bands 42bp apart were detected with all primer pairs (Fig. 5.11B). The sizes of 
the gel bands with the different primer pairs agreed with our prediction (Fig. 5.11B). 
This result indicated that novel larger ERCC1 transcripts originating upstream of 
ERCC1 existed in human melanoma cells. Although the RT-PCR assay was only 
semi-quantitative, it was noted that the ratio of alternatively spliced to the normal 
product appeared different between the total and upstream transcripts. Quantification 
of ERCC1 RT-PCR bands was achieved by densitometry and expressed as the ratio 
of signal from the alternative spliced band relative to signal from the normal band. 
The ratio of the alternative spliced band relative to normal band in the ERCC1 all 
transcripts assay was 0.5, while in the upstream ERCC1 transcripts assay the ratio 
was around 1.6. It suggested that more of the transcripts originating upstream 
contained the alternative splice than those originating from the normal start site (Fig. 
5.11B).   
 
 
To investigate whether the larger ERCC1 transcripts were present in other human 
cell lines and whether they could be induced by cisplatin, semi-quantitative RT-PCR 
analysis of ERCC1 transcripts was carried out on human melanoma cell line A375, 
ovarian cancer cell lines A2870 and PEO14, human keratinocyte cell line HACAT 
and human fibroblast cell line MRC5V1 following 48h cisplatin (6uM) treatment, or 
combined cisplatin and MEK inhibitor (PD0325901, 1uM) treatment. The primer 
pair Hexon1A and Hexon2-3 was used to detect all ERCC1 transcripts, while the 
primers Hskin3RT specific to ERCC1 transcripts initiating upstream, and Hexon2-3 
were used to detect the larger ERCC1 products from upstream transcripts. The RT-
PCR assays were performed as described before.  
 
 
For the products common to all ERCC1 transcripts, two bands at the predicted 164bp 
and 206bp size were observed in all samples (Fig. 5.12). For the larger products from 
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upstream transcripts, two bands at the predicted 333bp and 375bp size were detected 
as well (Fig. 5.12). The data indicated that all the human cell lines assayed had larger 
ERCC1 larger transcripts; although the amounts seemed to vary. Moreover, in all 
cases, the level of the upstream transcript was increased following cisplatin treatment, 
Although the levels of the increase varied between cell lines, this induction was 
abrogated by the MEK inhibitor (Fig. 5.12). Furthermore, although the resolution of 
these gels was not as good as in Figure 5.11B, the ratio of the alternatively spliced 
band relative to the normal band again appeared to be higher for upstream transcripts 
than normal transcripts (Fig. 5.12).  
 
Figure 5.11 An upstream ERCC1 transcript in human cell lines 
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A, schematic of human ERCC1 gene showing the exons, location of the normal transcription 
initiation site (blue arrow) and presumed location of the upstream initiation site (red arrow). The 
positions of primers used to detect all ERCC1 transcripts (T) and predicted sizes of PCR products 
are indicated. The positions of the various primers used to detect the upstream ERCC1 transcripts 
(U) and predicted size of PCR products are also indicated. Normal and alternatively spliced 
products (generates a 42bp smaller product in all cases) are demonstrated.  
 
B, RT-PCR on mRNA extracted from human melanoma A375 cells. T, detection of all ERCC1 
transcripts with primer pair of Hexon1A and H-exon 2-3.  U, detection of ERCC1 transcripts 
initiating upstream with primer pairs of hskin2RT and H-exon2-3, hskin3RTand H-exon2-3, 
hskin4RTand H-exon2-3, hskin5RTand H-exon2-3. The sizes all the PCR products are indicated.  
Quantification of ERCC1 RT-PCR bands was achieved by densitometry and expressed as the 
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Figure 5.12 Cisplatin induces an upstream ERCC1 transcript  
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ERCC1 transcripts were analyzed in human melanoma (A375), ovarian cancer (A2780,PEO14), 
keratinocyte (HACAT) and fibroblast (MRC5V1) cell lines. Cells were untreated or treated for 
48h with cisplatin (6uM) or both cisplatin (6uM) and MEK inhibitor, PD0325901 (1uM) before 
RNA was extracted and RT-PCR was carried out. T, detection of all ERCC1 transcripts with 
primer pair Hexon1A and H-exon 2-3. U, detection of ERCC1 transcripts initiating upstream with 
primer pair hskin3RT and H-exon 2-3. Blue arrows, product common to all transcripts; red 
arrows, product from upstream transcripts. PCR was performed with the following thermocycling 
profiles: 35 cycles (30 for melanoma cell line A375) of 94°C for 1min, 60°C for 1min and 72°C 
for 1min.  
 
 
5.2.8 Regulation of ERCC1 upstream transcript levels 
 
 
To investigate the relationship between total ERCC1 transcripts, upstream ERCC1 
transcripts and cisplatin induction quantitatively, Taqman qPCR analysis of total 
ERCC1 transcripts and ERCC1 upstream transcripts was performed on human 
melanoma cell line A375 and ovarian cancer cell lines A2780 and PEO14 following 
48h cisplatin (6uM) treatment, or combined cisplatin and MEK inhibitor 
Genetic changes in melanoma progression  
172 
(PD0325901, 1uM) treatment. Beta-actin was used as the internal control in order to 
normalize the expression of total ERCC1 and larger ERCC1 transcripts. Relative 
concentrations of total ERCC1 were detected by qPCR as described before. For the 
upstream transcript detection, a custom Taqman q-RT PCR assay was ordered based 
on the 139bp of ERCC1 5′ upstream sequence between Hskin5RT and the normal 
ERCC1 initiation site. A standard curve of qPCR for larger ERCC1 and Beta-actin 
was run first. If the absolute value of the slope of the plot of log dilution factor vs. 
ΔCT < 0.1, then the comparative CT method can be used to analyze real time RT-PCR 
data (Livak and Schmittgen 2001). The relative efficiency plot for larger ERCC1 vs. 
Beta-actin showed that the absolute value of the slope was 0.0888 which passed the 
test (Fig. 5.13). Therefore, the comparative CT method could be used to measure 
relative concentrations of larger ERCC1 mRNA. 
 
 
Cisplatin treatment caused a 4.1-fold, 2.6-fold and 6.5-fold increase in larger ERCC1 
mRNA in human melanoma cell line A375, ovarian cancer cell lines A2780 and 
PEO14, respectively. In each case, the MEK inhibitor efficiently prevented this 
cisplatin-induced increase in larger ERCC1 mRNA (Fig. 5.14A, C, E). This 
confirmed our RT-PCR results that expression of upstream ERCC1 transcripts were 
increased following cisplatin treatment and this increase was regulated by the MAPK 
pathway. Cisplatin treatment also resulted in a 3.3-fold, 2.3-fold and 1.6-fold 
increase in total ERCC1 mRNA in human melanoma cell line A375, and ovarian 
cancer cell lines A2780 and PEO14, respectively. In addition, the MEK inhibitor  
completely abrogated the cisplatin-induce total ERCC1 mRNA increase in human 
melanoma cell line A375, but did not significantly reduce this induction in ovarian 
cancer cell lines A2780 and PEO14 (Fig. 5.14B, D, F).  
 
 
We also compared the larger ERCC1 and total ERCC1 mRNA basal levels between 
human melanoma cell line and ovarian cancer cell lines. Larger ERCC1 mRNA basal 
levels were 2 to 7-fold higher in melanoma cell line A375 than ovarian cell lines 
A2780 and PEO14 (Fig 5.15A). Moreover, total ERCC1 mRNA basal levels were  
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10 to 20-fold higher in melanoma cell line A375 than ovarian cell lines A2780 and 
PEO14 (Fig 5.15B). 
 
 
To further investigate the contribution that cisplatin induction of the larger ERCC1 
mRNA made to the increase in total ERCC1 mRNA after cisplatin, the ratios of 
larger ERCC1 relative to total ERCC1 mRNA were analyzed using the relative 
standard method in human melanoma cell line A375 and ovarian cancer cell lines 
A2780 and PEO14 following 48h cisplatin (6uM) treatment, or combined cisplatin 
and MEK inhibitor (PD0325901, 1uM) treatment. After cisplatin treatment, the ratios 
of larger ERCC1 relative to total ERCC1 mRNA in human melanoma cell line A375 
increased from 15% to 28%, while for ovarian cancer cell lines A2780 and PEO14, 
the increases were from 54% to 72% and 41% to 98%, respectively (Fig 5.16A, B, C). 
Moreover, the cisplatin induced increase in the larger ERCC1/total ERCC1 mRNA 
ratio increase was inhibited by the MEK inhibitor in all three cell lines (Fig 5.16A, B, 
C).  
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Relative qPCR efficiency plot for larger ERCC1 and beta-actin transcripts. delta CT values are 
the means from three independent experiments. The absolute value of the slope of log dilution 
factor vs. delta CT is 0.0888. 
 
 
Figure 5.14 Cisplatin induced expression of the larger ERCC1 transcript  
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A, Histogram shows the mean level (+ SEM) of larger ERCC1 mRNA relative to beta-actin 
mRNA in human melanoma cell line A375 determined from three independent experiments by 
qPCR. In this panel and in panels B-F, Cells were untreated, or treated with cisplatin (6uM), or 
treated with both cisplatin and MEK inhibitor for 48h. The MEK inhibitor was added 30 minutes 
before cisplatin treatment. One way ANOVA with Bonferroni’s Multiple Comparison Test was 
applied for statistical analysis among control, cisplatin, and both cisplatin and PD0325901 groups. 
*, P < 0.05. **, P < 0.01. ***, P < 0.001.  
 
B, Histogram shows the mean level (+ SEM) of total ERCC1 mRNA relative to beta-actin 
mRNA in human melanoma cell line A375 determined from three independent experiments by 
qPCR.  
 
C, Histogram shows the mean level (+ SEM) of larger ERCC1 mRNA relative to beta-actin 
mRNA in human ovarian cell line A2780 determined from three independent experiments by 
qPCR. 
 
D, Histogram shows the mean level (+ SEM) of total ERCC1 mRNA relative to beta-actin 
mRNA in human ovarian cell line A2780 determined from three independent experiments by 
qPCR. 
 
E, Histogram shows the mean level (+ SEM) of larger ERCC1 mRNA relative to beta-actin 




















































































































F, Histogram shows the mean level (+ SEM) of total ERCC1 mRNA relative to beta-actin mRNA 
in human ovarian cell line PEO14 determined from three independent experiments by qPCR. 
 
 
Figure 5.15 Basal levels of larger ERCC1 and total ERCC1 transcripts  
 
A                                                                B   
                                                       
 
A, Histogram shows the mean level (+ SEM) of larger ERCC1 mRNA relative to beta-actin 
mRNA in human melanoma cell line A375, ovarian cell lines PEO14 and A2780 determined 
from three independent experiments by qPCR. Data were normalized to the mean level of larger 
ERCC1 mRNA relative to beta-actin mRNA in human melanoma cell line A375. One way 
ANOVA with Bonferroni’s Multiple Comparison Test was applied for statistical analysis 
between human melanoma cell line A375, ovarian cell lines PEO14 and A2780. **, P < 0.01. ***, 
P < 0.001.  
 
B, Histogram shows the mean level (+ SEM) of total ERCC1 mRNA relative to beta-actin 
mRNA in human melanoma cell line A375, ovarian cell lines PEO14 and A2780 determined 
from three independent experiments by qPCR. Data were normalized to the mean level of total 
ERCC1 mRNA relative to beta-actin mRNA in human melanoma cell line A375. One way 
ANOVA with Bonferroni’s Multiple Comparison Test was applied for statistical analysis 
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Figure 5.16 Ratio of larger ERCC1/total ERCC1  
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A, Histogram shows the mean ratio (+ SEM) of larger ERCC1 mRNA over total ERCC1 mRNA 
in human melanoma cell line A375 determined from three independent experiments by qPCR. 
Larger ERCC1 mRNA and total ERCC1 mRNA levels were each calculated relative to beta-actin. 
In this panel and in panels B and C, Cells were untreated, or treated with cisplatin (6uM), or 
treated with both cisplatin and MEK inhibitor for 48h. The MEK inhibitor was added 30 minutes 
before cisplatin treatment. One way ANOVA with Bonferroni’s Multiple Comparison Test was 
applied for statistical analysis among control, cisplatin, and both cisplatin and PD0325901 groups. 
**, P < 0.01.  
 
B, Histogram shows the mean ratio (+ SEM) of larger ERCC1 mRNA over total ERCC1 mRNA  
in ovarian cancer cell line A2780 determined from three independent experiments by qPCR. 
Larger ERCC1 mRNA and total ERCC1 mRNA levels were each calculated relative to beta-actin. 
**, P < 0.01. ***, P < 0.001. 
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C, Histogram shows the mean ratio (+ SEM) of larger ERCC1 mRNA over total ERCC1 mRNA 
in ovarian cancer cell line PEO14 determined from three independent experiments by qPCR. 
Larger ERCC1 mRNA and total ERCC1 mRNA levels were each calculated relative to beta-actin.  
***, P < 0.001. 
 
 




To characterise the 5′ end of the larger ERCC1 transcript, 5′ RACE analysis was 
performed on human ovarian cell line PEO14 with cisplatin treatment using 5′ RACE 
kit. The PEO14 cell line was selected for the 5′ RACE study, because the expression 
of the larger ERCC1 transcript in PEO14 cell line showed larger difference between 
cisplatin treatment group and control group compared to other cell lines in the RT-
PCR and qPCR assay.  
 
 
Total RNA was freshly isolated from human ovarian cell line PEO14 with cisplatin 
treatment (6uM) for 48h. The first strand cDNA synthesis was performed using the 
ERCC1 specific reverse primer H exon 2-3 (Fig 5.17A). Then synthesised ERCC1 
cDNA was purified using the high pure PCR product purification kit. A 
homopolymeric A-tail was added to the 3′ end of ERCC1 cDNA and then it was 
amplified using Oligo-DT anchor primer in combination with ERCC1 specific 
reverse primer Hskin 4RT REV (Fig 5.17A). The PCR products were electrophored 
on a 1.5% agarorse gel and visualised by ethidium bromide staining. A single weak 
band was detected at around 400bp (Fig 5.17B). To further amplify PCR products, a 
further round of nested PCR was carried out using internal primers PCR-anchor and 
REV1 (Fig 5.17A). A single clear band was detected at around 400bp (Fig 5.17B). 
This product was slightly shorter than the product in the first round of PCR as 
expected. The 400bp band was then purified and cloned into p-GEM T EASY vector 
by the LacZ blue white screen. 25 positive clones were sequenced and analyzed to 
map the 5′ end of novel larger ERCC1 transcript.  
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A schematic representation of the investigation of the origin of the larger ERCC1 transcripts 
using 5′ RACE. The tailed ERCC1 cDNA was amplified using PCR Oligo dT-anchor forward 
primer and Hskin 4RT REV reverse primer. The PCR product was visualized at the position 
around 400bp in the first lane line from the left on the gel shown. The further round of nested 
PCR was performed using internal PCR anchor forward primer and REV1 reverse primer. The 




The suquencing results showed that ERCC1 5′ RACE endpoints determined on the 
RNA of human ovarian cell line PEO14 with cisplatin treatment were much further 
upstream than the normal transcriptional start site. The endpoints of 23 independent 
5′ RACE clones are shown in the Figure 5.18 aligned alongside the human genomic 
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DNA sequence. The endpoint of the longest clone mapped to -669, around 500bp 
upstream of the normal transcriptional start site (Fig 5.18). 
 
Figure 5.18 Sequence analysis of 5′ RACE results aligned with human genomic 
DNA  
-690 
5′RACE                                CTAATACTA    ACTCATCAGC 
DNA      TACTATCCTT    TCAGGAAGTG    ACTAATACTA    ACTCATCAGC 
-650 
5′RACE   CAGGCCCCTG    CTCAGATGTC    CCTTCCTCCA    GGAAGCCCTT 
DNA      CAGGCCCCTG    CTCAGATGTC    CCTTCCTCCA    GGAAGCCCTT 
-610 
5′RACE   CCGGACTCCG    GGGCTGAGTC    AGGCGCTCCC    CCTGACCCCC 
DNA      CCGGACTCCG    GGGCTGAGTC    AGGCGCTCCC    CCTGACCCCC 
-570 
5′RACE   ATCCCACGGC    TCTACCGGGA    TCTCCCATCC    CAGACCTGCC 
DNA      ATCCCACGGC    TCTCCCGGGA    TCTCCCATCC    CAGACCTGCC 
-530 
5′RACE   CATTCTGGGT    CAGCACTGGG    AACGTGTCTG    TGTCCCTTAC 
DNA      CATTCTGGGT    CAGCACTGGG    AACGTGTCTG    TGTCCCTTAC 
-490 
5′RACE   TGAACCGTAA    GCTCCGGGAG    GACAACACGG    GGCTGTCGTT 
DNA      TGAACCGTAA    GCTCCGGGAG    GACAACACGG    GGCTGTCGTT 
-450 
5′RACE   GGTCACTGCT    GTGTCACCAG    CACGGACTCG    CACAGGACCG 
DNA      GGTCACTGCT    GTGTCACCAG    CACGGACTCG    CACAGGACCG 
-410 
5′RACE   GGAAGAGAGG    AAGCGCGTGG    GGGGAATAGG    TGTGGAATAA 
DNA      GGAAGAGAGG    AAGCGCGTGG    GGGGAATAGG    TGTGGAATAA 
 
-370 
5′RACE   ATGAATGAAT    GAGGAAACTG    AAGCCAAGTC    TATGTCTGAG 
DNA      ATGAATGAAT    GAGGAAACTG    AAGCCAAGTC    AATGTCTGAG 
-330 
5′RACE   TTGGATTCAA    ACTTAAGTCT    CTCCTTACTG    AGAGGAGGGA 
DNA      TTGGATTCAA    ACTTAAGTCT    CTCCTTACTG    AGAGGAGGGA 
-290 
5′RACE   CCAAGTTGGA    TCTCCTGCGA    TCTGTTCTCC    ACTGAGCCCT 
DNA      CCAAGTTGGA    TCTCCTGCGA    TCTGTTCTCC    ACTGAGCCCT 
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-250 
5′RACE   GCCAGGATTC    TGGGCACACA    GAAGCGCTCA    GTAAGGGCTT 
DNA      GCCAGGATTC    TGGGCACACA    GAAGCGCTCA    GTAAGGGCTT 
-210 
5′RACE   TGAAACTTAA    CAGTTTGGGA    GCCAGATCCT    CAGGCCACAT 
DNA      TGAAACTTAA    CAGTTTGGGA    GCCAGATCCT    CAGGCCACAT 
-170 
5′RACE   CTCTCTCCTC    CCACGACCTC    CGCGGTCCTC    CAGAACCATA 
DNA      CTCTCTCCTC    CCACGACCTC    CGCGGTCCTC    CAGAACCATA 
-130
                                     REV 1 
5′RACE   GAGAGTTGTA    CAGAGATCGC    CCTGCTCTAT    GCTCTACTCT   
DNA      GAGAGTTGTA    CAGAGATCGC    CCTGCTCTAT    GCTCTACTCT 
-90                   Hskin 4RT REV 
5′RACE   CCTGGGGAGC    GGGGCCAGAG    AGGCCGGAAG    TGCTGCGAGC 
DNA      CCTGGGGAGC    GGGGCCAGAG    AGGCCGGAAG    TGCTGCGAGC 
-50 
5′RACE   CCTGGGCCAC    GCTGGCCGTG    CTGGCAGTGG    GCCGCCTCGA 
DNA      CCTGGGCCAC    GCTGGCCGTG    CTGGCAGTGG    GCCGCCTCGA 
-10 
5′RACE   TCCGCTCCAG    ATGGACCCTG    GGAAGGACAA    AGAGGGGGTG 
DNA      TCCGCTCCAG    ATGGACCCTG    GGAAGGACAA    AGAGGGGGTG 
31 
5′RACE   CCCCAGCCCT    CAGGGCCGCC    AGCAAGGAAG    AAATTTGTGA 
DNA      CCCCAGCCCT    CAGGGCCGCC    AGCAAGGAAG    AAATTTGTGA 
71 
5′RACE   TACCCCTCGA    CGAGGATGAG    GTCCCTCCTG    GAGTG 
DNA      TACCCCTCGA    CGAGGATGAG    GTCCCTCCTG    GAGTG 
             H Exon 2-3  
 
 
Start points of human ERCC1 larger transcript by 5′ RACE. The sequence of the longest 5′ 
RACE clone determined using human ovarian cell line PEO14 is shown, aligned against the 
human genome DNA sequence. The sequence is numbered from the translational initiation codon 
in orange in exon 2, with intron 1 omitted. The start points of 5′ RACE clones are indicated in 
red. Mismatched sequence is indicated in light blue. The H exon2-3, Hskin 4RT REV and REV1 
primers used in the 5′ RACE assay are indicated in green. TSS, normal transcription start site is 
shown in yellow at -152bp. 
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5.3 Discusssion  
 
 
The MAPK pathway plays a major role in regulation of cell growth and 
differentiation, often induced by growth factors, cytokines and phorbol esters 
(Johnson and Vaillancourt 1994, Niedernhofer et al. 2006). It is also activated by 
some conditions of stress, particularly oxidant injury, and is believed to confer a 
survival advantage to cells (Guyton et al. 1996). Many studies have demonstrated  an 
activation of the MAPK in response to CDDP treatment (Brown et al. 1993, 
Mirmohammadsadegh et al. 2007). However, the role of the MAPK pathway in 
response to cisplatin is complex (Brozovic and Osmak 2007). Although some studies  
showed a role for the MAPK pathway in the induction of apoptosis (Wang et al. 
2000), most reports suggest that activation of the MAPK pathway enhances the 
resistance to cisplatin and plays an important role in enhancing survival of CDDP-
treated cells (Persons et al. 1999, Wang et al. 1998). In melanoma, overexpression of 
activated N-RAS has been reported to protect melanoma cells and induce cisplatin 
resistance (Jansen et al. 1997). In this chapter, we focused on the molecular 
mechanisms underlying activation of the MAPK pathway by CDDP and enhanced 
chemotherapy resistance.   
 
 
The use of cisplatin in cancer chemotherapy is limited by acquired or intrinsic 
resistance of cells to the drug. Acquired resistance developed in patients undergoing 
cisplatin treatment, increasing concentration of cisplatin treatment could reduce 
sensitivity to cisplatin. Resistance was described as intrinsic when patients’ tumours 
were naturally unaffected by cisplatin (Kartalou and Essigmann 2001). Melanoma 
shows intrinsic resistance to cisplatin. The mechanisms involved in cisplatin 
resistance had been proposed in previous studies. Firstly, increased reflux, or 
increased inactivation by sulfhydryl molecules, such as glutathione, could result in 
resistance to cisplatin. Secondly, changes of expression level of regulatory proteins 
involved in signal transduction pathways that control the apoptotic pathway could 
also cause cisplatin resistance. Moreover, an increased level of DNA repair in 
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tumour cells was also suggested to be a cause of cisplatin resistance (Kartalou and 
Essigmann 2001). An improved understanding of the mechanisms of resistance 
contributed to increase the utility of cisplatin for the treatment of cancer. 
 
 
ERCC1 is essential in the NER pathway where it forms a tight heterodimer with XPF 
protein. Its role is to incise DNA on the 5′ side of a lesion such as platinum-DNA 
adducts (Andrieux et al. 2007). In this chapter we assayed mRNA and protein levels 
of two NER proteins, ERCC1 and XPF, in human melanoma cell line A375 
following cisplatin treatment. In our study we noticed that cisplatin induced a time 
dependent increase in both ERCC1 and XPF and that induction by cisplatin occurred 
at both protein and transcriptional levels. Previous studies have shown that higher 
levels of ERCC1 were observed in other cisplatin resistant tumours as well. 
Overexpression of ERCC1 in non small lung tumours are significantly related with 
resistance to cisplatin and cisplatin resistance decreases after antisense RNA 
inhibition of ERCC1 in non small lung tumour cell lines (Rosell et al. 2003). In 
addition, overexpression of ERCC1 in human ovarian cancer cells has been 
associated with repair of cisplatin-induced DNA damage and clinical resistance to 
cisplatin (Li et al. 1998a). Ovarian cell lines that developed resistance in vitro after 
exposure to cisplatin are found to have increased ERCC1 levels (Ferry et al. 2000). 
Furthermore, testicular cancer treatment was one of the most successful cisplatin-
based treatments. About 95 percent of testicular cancer patients were sensitive to 
cisplatin and achieved a cure (Bosl and Motzer 1997). Several reports indicated that 
most testicular cancer cell lines are NER deficient (Koberle et al. 1997, Koberle et al. 
1999). In particular, ERCC1 and XPF DNA repair protein levels decreased in these 
cell lines (Welsh et al. 2004). Our data agreed with these observations and suggested 
that ERCC1 and XPF induction during cisplatin treatment might contribute to 
development of resistance to chemotherapy in melanoma. 
 
 
After the identification of ERCC1 and XPF as cisplatin induced genes, the major 
object of this study was to identify the mechanism of induction of ERCC1 and XPF 
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by cisplatin. Protein kinases regulate signaling pathways for a broad spectrum of 
cellular response including proliferation, differentiation, apoptosis and DNA damage 
(Cantley et al. 1991). It was reasonable to speculate that one or more protein kinases 




ERK1/2 is one of the important kinases in the MAPK pathway that regulates cell 
growth and death. Several studies showed that ERK1/2 was activated in response to 
DNA damage agents, including UV radiation, ionizing radiation, alkylating agents 
and cisplatin (Stecca and Gerber 1998). Our findings indicated that ERK1/2 was 
activated by cisplatin in the human melanoma cell line A375. This data confirmed 
previous results that treatment with cisplatin increased the activation of ERK1/2 in 
melanoma cell lines and induced drug resistance (Mirmohammadsadegh et al. 2007). 
This permitted us to investigate whether ERK1/2 activation was responsible for 
ERCC1 and XPF induction following cisplatin treatment. Indeed, we noticed that 
inactivation of MEK1/2-ERK1/2 by the specific MEK inhibitor PD0325901 
prevented the cisplatin induced increase of ERCC1 protein and mRNA. Previous 
studies have shown that ERCC1 induction by EGF was dependent on the MAPK 
pathway, which was regulated by the activation of the GATA transcription factor 
(Andrieux et al. 2007). Activated H-Ras could up-regulate ERCC1 induction through 
increased transcriptional activity of AP-1 in NIH3T3 and MCF-7 cells (Agar and 
Young 2005). In addition, the ionizing radiation-induced ERCC1 increase also 
depended on ERK1/2 activation in prostate cancer cells (Yacoub et al. 2003). 
Moreover, blocking ERK1/2 activation by the MEK inhibitor U0126 decreased 
cisplatin-induced ERCC1 protein levels in lung cancer cell lines (Ko et al. 2010). In 
a similar way, our data indicated that the MAPK pathway took part in regulation of 
ERCC1 mRNA and protein levels following cisplatin treatment in melanoma cells.      
 
 
We next sought to determine whether cisplatin directly activated the ERK1/2 
signaling cascade or acted indirectly through cellular damage. In contrast to the usual 
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rapid and transient activation of this pathway in response to various other stimuli 
such as growth factors, UV damage, or cytokines (Xia et al. 1995), the time course 
for activation of ERK1/2 following cisplatin treatment showed that activation of 
ERK1/2 was only observed after 24 hour following initiation of cisplatin treatment 
and was then sustained to 72 hours. It suggested that phosphorylation of ERK1/2 
might occur indirectly through cisplatin induced cellular damage. ERK1/2 activation 
may result from activation of upstream members of the MAPK pathway. An 
important role for RAS activation in accumulation of ERCC1 mRNA by insulin had 
been described (Lee-Kwon et al. 1998). However, another cause seemed to be 
inhibition of ERK1/2 phosphatases. ERK1/2 activation was opposed by ERK1/2 
phosphatases like DUSP6 (Kondoh and Nishida 2007). Both mathematical models 
and experimental data showed that DUSP6 was the principal time regulator of the 
ERK1/2 signaling (Ekerot et al. 2008). It was tempting to speculate that cisplatin 
mediated delayed and long lasting activation of ERK1/2 was, at least in part, due to 
inhibition of the ERK1/2-specific phosphatase DUSP6.  
 
 
In this study we found that the DUSP6 protein levels showed a time dependent 
decrease following cisplatin treatment. In addition, overexpression of DUSP6 in 
human melanoma cells could reduce the basal mRNA levels of ERCC1, but did not 
affect the basal mRNA levels of XPF, suggesting that expression of DUSP6 is 
involved in ERCC1 basal expression, but does not regulate XPF basal expression. 
Furthermore, the induction of ERCC1 and XPF mRNA by cisplatin was inhibited by 
introduction of DUSP6 to melanoma cells. It suggests that cisplatin mediated DUSP6 
inhibition could upregulate phosphorylation of ERK1/2 which may induce ERCC1 
and XPF expression. In the SRB assay for detecting cisplatin cytotoxity and 
resistance, the DUSP6 overexpression transfection pools were more sensitive to 
cisplatin compared with non-tranfected cells. Either the ERCC1 basal expression 
decrease or the cisplatin-induced ERCC1 and XPF expression decrease by 
overexpression of DUSP6 could increase the sensitivity to cisplatin. DUSP6 appears 
to play a crucial role in resistance of melanoma to cisplatin. Overexpression of 
DUSP6 has previously been found to reduce ERK activity and sensitize ovarian 
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cancer cells to cisplatin induced cell death (Chan et al. 2008). On the contrary, 
knockdown of DUSP6 by siRNA increased ovarian cancer cells resistance to 
cisplatin (Chan et al. 2008).  
 
 
An increase in ERCC1 expression can only boost repair if there is a corresponding 
increase in expression of its partner XPF. We found XPF protein and mRNA levels 
were also increased by cisplatin treatment. However, unlike ERCC1, this XPF 
increase was not inhibited by the MEK specific inhibitor PD0325901, but was by 
DUSP6 overexpression. Our observations agreed with another report which showed 
that DUSP6 overexpression enhanced sensitivity of ovarian cancer cells to cisplatin 
more strongly than the MEK inhibitor treatment. Overexpression of DUSP6 had a 
stronger influence on the suppression of ERK1/2 activity and cisplatin resistance 
(Chan et al. 2008). It was possible that DUSP6 overexpression in melanoma cells 
could not only block the MAPK pathway but also inhibit other pathways which may 
regulate XPF induction, so that XPF mRNA and protein induction following 
cisplatin was reduced by DUSP6 overexpression but not by the MEK inhibitor.  
 
 
Previous study in our lab showed a novel Ercc1 mRNA in mouse skin that originated 
from an alternative upstream promoter (Song et al. 2011). Levels of this skin-specific 
transcript were low in embryonic skin and increased rapidly after birth, but there was 
no induction by UV radiation (Song et al. 2011). In this study, RT-PCR results 
showed that larger ERCC1 transcript also existed in a series of human cells (human 
melanoma cell line, ovarian cancer cell lines, keratinocyte cell line and human 
fibroblast cell line). Moreover, larger ERCC1 transcripts could be induced by 
cisplatin and inhibited by inactivation of ERK1/2. It suggested that larger ERCC1 
transcripts are regulated by the MAPK pathway. These results were confirmed by the 
qPCR assay. Furthermore, the qPCR assay results revealed that the ratios of larger 
ERCC1 relative to total ERCC1 mRNA increased following cisplatin treatment and 
this increase could be abrogated by the MEK inhibitor. It implied cisplatin may 
preferentially induce larger ERCC1 transcripts rather than normal ERCC1 transcripts 
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through the MAPK pathway or that induction of normal transcripts is less affected by 
the MEK inhibitor. The function of novel ERCC1 transcripts is possibly related to 
cisplatin resistance and contributes to protect cells. Finally, the origin of the larger 
ERCC1 transcript was investigated by 5′ RACE assay. The ERCC1 5′ RACE 
endpoints determined on the RNA of human ovarian cell line PEO14 with cisplatin 
treatment were mapped to around 500bp upstream of the normal transcriptional start 
site. This novel transcript in human cell lines is similar to the novel transcript of 
Ercc1 in mouse skin which mapped to 400bp upstream of the normal transcriptional 
start point (Song et al. 2011). We concluded that there is another ERCC1 promoter 
upstream of the mormal promoter and additional upstream elements to regulate the 
expression of larger ERCC1 transcripts following cisplatin treatment.   
 
 
Although cisplatin increased total ERCC1 mRNA and larger ERCC1 mRNA levels in 
all assayed cell lines, there were still some differences in expression of ERCC1 
between melanoma cell line and ovarian cancer cell lines. Firstly, the cisplatin 
induced total ERCC1 mRNA increase was completely inhibited by the MEK 
inhibitor in the human melanoma cell line, but was not significantly reduced by the 
MEK inhibitor in ovarian cancer cell lines. We can not rule out the possibility that 
beside the MAPK pathway, other pathways may also regulate expression of ERCC1 
in ovarian cancer cell lines. Some studies have demonstrated that the activation of c-
Jun-NH2-kinase(JNK)/stress-activated protein kinase (SAPK) pathway was related 
to regulation of ERCC1 expression in ovarian cancer cells (Altaha et al. 2004, Li et 
al. 1998a). Secondly, the melanoma cell line had both higher total ERCC1 mRNA 
and larger ERCC1 mRNA basal levels than ovarian cell lines. Finally, the cisplatin 
induced larger ERCC1/total ERCC1 mRNA ratio increase was more obvious in 
ovarian cancer cell lines than in the melanoma cell line. These findings may explain 
why melanoma patients are naturally unaffected by cisplatin while ovarian cancer 
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We also noticed that there was another smaller band showing in both normal ERCC1 
transcript detection and larger ERCC1 transcript detection. Previous studies showed 
that the ERCC1 exon 1 region contains a 42bp sequence which is often lost during 
splicing (Yu et al. 2001). Loss of this sequence produced a shorter transcript that was 
reported to be correlated with higher levels of ERCC1 mRNA in ovarian cancer 
speciments (Yu et al. 2001). In this study, the ratio of the alternatively spliced 
product relative to normal product in upstream ERCC1 transcripts was higher than in 
all ERCC1 transcripts. The previous study in our group indicated that the lack of the 
42bp sequence in exon 1 transcripts was not correlated with high levels of ERCC1 
expression and had limited significance in ovarian cancer and melanoma cells 
(Winter et al. 2005). We have no evidence to support the suggestion that this 
alternatively spliced transcript contributes to expression of ERCC1.  
 
 
Clinical failure of chemotherapy is mainly due to drug resistance in cancer cells. 
Thus, it is very important to understand the molecular mechanisms underlying 
resistance to chemotherapy. This was the first time that cisplatin induced expression 
of two NER proteins, ERCC1 and XPF, to repair DNA damage had been 
demonstrated in melanoma cells. These inductions contribute to increase drug 
resistance which is one of the major obstacles to melanoma treatment. This showed 
us a hint that ERCC1 or XPF inhibitors could be used to enhance the effectiveness of 
cisplatin treatment. Furthermore, our observations revealed a new molecular 
mechanism that ERCC1 induction by cisplatin was regulated by activation of 
ERK1/2 in melanoma cells. We also provided the first direct evidence for DUSP6 
reduction following cisplatin treatment and showed that its disruption was involved 
in ERCC1 induction by cisplatin. The understanding of this molecular mechanism 
may assist the development of new therapeutic interventions for melanoma. 
Simultaneous treatment with cisplatin and MEK inhibitor may result in synergistic 
therapeutic effects at tolerable doses of cisplatin. In addition, a novel larger ERCC1 
transcript was found in human cell lines and was upregulated by cisplatin. The 
functions of this larger ERCC1 transcript on cisplatin resistance deserve further study. 
 







































General conclusion   
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Malignant melanoma is notorious for therapeutic resistance. There are no FDA-
approved agents so far that can alter the natural history of metastatic melanoma in 
large randomized clinical trails. Therefore, one of the major goals of the work in this 
thesis was to increase our understanding of melanoma biology and discover new 
targets for therapeutic intervention. The work in Chapter 3 identified and 
characterised a molecularly distinct subtype of melanoma, Chapter 4 explored the 
role of DUSP6 and p-ERK in melanoma progression and Chapter 5 studied the 
mechanisms underlying cisplatin resistance in melanoma cell lines.   
 
 
Due to the limitation of using human subjects for disease pathogenesis studies, we 
used a mouse xenograft model to investigate molecular pathology of melanoma. Our 
immortal mouse melanocyte cell lines were derived from primary melanocyte cell 
culture of epidermis of newborn mice by infection with a retrovirus expressing SV40 
T antigen. SV40 T antigen promotes cell growth and renders these cells immortal 
and susceptible to the additional genetic changes necessary for full expression of the 
malignant phenotype. Some of these cell lines were xenografted to mice. Cells from 
some 5-1 and 3-1-1 xenografts were reisolated into cell culture. When these cells 
were xenografted into mice again, they formed large tumours much more quickly 
than their parental cells. That provides a good platform to investigate genetic changes 
in melanoma progression through comparison of 5-1 and 3-1-1 Tumour cell lines 
with their parental cell lines.  
 
 
The MAPK and the PI3K-AKT signalling pathways modulate the function of 
numerous substrates involved in the regulation of cell survival, proliferation and 
invasion. In melanoma, both the MAPK and PI3K-AKT pathways play important 
roles in melanoma development and progression. It is worth noting that DUSP6 acts 
as a phosphatase which can inactivate ERK1/2 through a feedback loop. 
Overexpression of DUSP6 has been reported in melanoma cell lines. We 
hypothesised that some molecular changes in the MAPK pathway and PI3K-AKT 
pathway may contribute to melanoma formation in our mouse xenograft model. 
Therefore, we decided to examine p-ERK, p-MEK, DUSP6 and BRAF in the MAPK 
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pathway and p-AKT, PTEN in the PI3K-AKT pathway in our mouse melanocyte cell 
line panel.  
 
 
Interestingly, we found that our mouse tumour cell lines have lower expression of 
ERK and MEK but higher expression of DUSP6 than their parental cell lines. 
Meanwhile, we did not find any BRAF activating mutations associated with 
melanoma in our immortal mouse cell lines. All these data suggest that our tumour 
cell lines have shut down the MAPK pathway. As previous study showed that 
phosphorylation of RAF by AKT can inhibit activation of the MAPK pathway, we 
suspected that the inactivation of the MAPK may come from hyperactivation of the 
PI3K-AKT pathway. However, our mouse tumour cell lines also have decreased 
levels of p-AKT compare to their parental cell lines. In addition, there was no 
evidence for any PTEN loss in our tumour cell lines. Therefore, the PI3K-AKT 
pathway was not activated in our tumour cell lines and the inactivation of the MAPK 
pathway was not because of activation of the PI3K-AKT pathway. The MAPK 
pathway inactivation and the PI3K-AKT pathway inactivation observed in our mouse 
tumourigenic cell lines are uncommon in classic melanoma. These tumour cell lines 
represent a molecularly distinct and unappreciated subtype of melanoma.  
 
 
Through analysis of our immortal mouse cell lines, we raised the questions: is higher 
expression of DUSP6 and lower level of p-ERK in our mouse tumour cell lines 
related to melanoma progression in the xenograft mouse model? Our results showed 
that overexpression of DUSP6 inactivated ERK1/2 in our immortal mouse 
melanocytes. Moreover, enforced expression of DUSP6 indeed increased anchorage 
independent-growth ability and invasive ability of our immortal mouse melanocytes. 
It suggests that DUSP6 may indeed be involved in melanoma progression in the 
xenograft assay and contributes to transform our immortal mouse melanocytes to 
melanoma cells. Our data also indicated that increasing phosphorylation of ERK1/2 
suppressed invasion of our mouse tumour cell lines in the transwell migration assay. 
However, introduction of constitutively active MEK1 and MEK2 into mouse tumour 
Genetic changes in melanoma progression  
192 
cells only slightly reduced anchorage independent growth ability. The differences 
between the MEK1 and MEK2 transfected and non-transfected cells were not 
significant in the methylcellulose assay. As DUSP6 is regulated by the MAPK 
pathway, exogenous expression of constitutively active MEK1 and MEK2 can 
induce DUSP6 expression which in turn impairs colony formation caused by the 
MAPK pathway activation. We can not rule out the possibility that DUSP6 can 
interact with other uncharacterized targets and pathways to control colony formation 
in the methylcellulose assay.  
 
 
In contrast, although overexpression of DUSP6 also results in dephosphorylation of 
ERK1/2 in human melanoma cell line A375, enforced expression of DUSP6 
decreased anchorage independent-growth ability and invasive ability. It is possible 
that mice and human have slightly different mechanisms involved in melanoma 
development and progression. We also consider that our mouse tumour cell lines are 
identified as a molecularly distinct subtype of melanoma. DUSP6 may play different 
roles in our distinct subtype of melanoma compared to classic melanoma exemplified 
by A375. In addition, there is BRAF V600E mutation in A375 human melanoma 
cells but not in our mouse tumour cells. The mechanisms underlying melanoma 
progression are possibly different in A375 human melanoma cell line with BRAF 
mutations and our mouse tumour cell lines without BRAF mutations.  
 
 
Recent study showed that treatment of melanoma cell lines with cisplatin increased 
the phosphorylation of ERK1/2. The MAPK pathway activation was reported to play 
an important role in the regulation of ERCC1 gene expression by insulin and EGF. 
Overexpression of ERCC1 has been associated with repair of cisplatin-induced DNA 
damage and clinical resistance to cisplatin in NSCLC, ovarian, colorectal and gastric 
cancers. Therefore, cisplatin is able to activate ERK1/2 and induce ERCC1 and XPF 
overexpression which can protect tumour cells from DNA damage and enhance 
resistance to cisplatin. In Chapter 5, we explored the phosphorylation level of 
ERK1/2 and the mRNA and protein level of ERCC1 and its partner XPF following 
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cisplatin treatment. The results provide evidence that cisplatin induced a time 
dependent increase in expression of p-ERK, ERCC1 and XPF. Moreover, use of a 
MEK inhibitor showed ERCC1 induction by cisplatin was dependent on the MAPK 
pathway, while cisplatin induced XPF expression through not only the MAPK 
pathway but also other pathways. We also found that the DUSP6 level decreased 
after cisplatin treatment and overexpression of DUSP6 inhibited ERCC1 and XPF 
induction by cisplatin and reduced resistance to cisplatin. DUSP6 appears to play a 
crucial role in resistance of melanoma to cisplatin. 
 
 
Previous study in our lab showed a novel Ercc1 mRNA in mouse skin that originated 
from an alternative upstream promoter (Song et al. 2011). In this study, our findings 
showed that the larger ERCC1 transcripts also existed in a series of human cells and 
originated from around 500bp upstream of the normal ERCC1 transcriptional start 
site. In addition, both larger ERCC1 and total ERCC1 basal mRNA expression levels 
are higher in melanoma cells than in ovarian cancer cells. That may contribute to the 
greater cisplatin resistance of melanoma compared to ovarian cancer. Moreover, 
larger ERCC1 transcripts could be induced by cisplatin and regulated by the MAPK 
pathway. Furthermore, the ratios of larger ERCC1 relative to total ERCC1 mRNA 
increase following cisplatin treatment through activation of the MAPK pathway. It 
implied cisplatin may preferentially induce larger ERCC1 transcripts rather than 
normal ERCC1 transcripts through the MAPK pathway. The function of novel 
ERCC1 transcripts is possibly related to cisplatin resistance and contributes to protect 
cells. To investigate this, functional analysis of the role of the larger ERCC1 
transcript should be carried out.  
 
 
In conclusion, the present study described in this thesis revealed the roles of the 
MAPK pathway and DUSP6 in melanoma progression and cisplatin resistance. It is 
hoped that our work can contribute to improve understanding of molecular 
mechanisms underlying melanoma development and chemotherapy resistance. There 
is great hope that the understanding of these molecular mechanisms may assist the 
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